var title_f5_39_5744="Schneider silicone stent";
var content_f5_39_5744=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70395&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70395&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Schneider covered metal stent",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 200px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schneider silicone-covered self-expanding metal stent. Note the nonsilicone covered ends of the stent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_39_5744=[""].join("\n");
var outline_f5_39_5744=null;
var title_f5_39_5745="Midshaft fracture 4";
var content_f5_39_5745=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F64466&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F64466&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Midshaft forearm fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 399px; height: 489px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Radius and ulna fractures with minimal posterior angulation and no displacement in a 1-year-old child.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paula Schweich, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_39_5745=[""].join("\n");
var outline_f5_39_5745=null;
var title_f5_39_5746="Calculator: Friedewald Equation for Low Density Lipoprotein (LDL-C, SI units)";
var content_f5_39_5746=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"Friedewald_SI_form\" name=\"Friedewald_SI_form\" onkeydown=\"clrResults();\" onkeyup=\"Friedewald_SI_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Friedewald Equation for Low Density Lipoprotein (LDL-C, SI units)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"      <tr>",
"       <td align=\"left\" bgcolor=\"#6c9a9c\">",
"        <span class=\"medCalcFontFormuli\">",
"         LDL = TotalChol - (Triglyceride / 2.2) - HDL",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"      <tr>",
"       <td align=\"right\" width=\"50%\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Input:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Total Chol",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Total_Chol_param\" onblur=\"Friedewald_SI_fx(); minMaxCheck();\" onchange=\"Friedewald_SI_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Total_Chol_unit\" onchange=\"Friedewald_SI_fx();\" style=\"width:105px;\">",
"             <option selected=\"selected\" value=\"1|0|mmol/L\">",
"              mmol/L",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             HDL",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"HDL_param\" onblur=\"Friedewald_SI_fx(); minMaxCheck();\" onchange=\"Friedewald_SI_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"HDL_unit\" onchange=\"Friedewald_SI_fx();\" style=\"width:105px;\">",
"             <option selected=\"selected\" value=\"1|0|mmol/L\">",
"              mmol/L",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Triglyceride",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Triglyceride_param\" onblur=\"Friedewald_SI_fx(); minMaxCheck();\" onchange=\"Friedewald_SI_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Triglyceride_unit\" onchange=\"Friedewald_SI_fx();\" style=\"width:105px;\">",
"             <option selected=\"selected\" value=\"1|0|mmol/L\">",
"              mmol/L",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"       <td align=\"left\" bgcolor=\"#eeeeee\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Result:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             LDL",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"LDL_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td valign=\"top\">",
"            <span class=\"medCalcFontOne\">",
"             <select class=\"medCalcFontSelect\" name=\"LDL_unit\" onchange=\"Friedewald_SI_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|mmol/L\">",
"               mmol/L",
"              </option>",
"             </select>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"3\">",
"            &nbsp;",
"            <br/>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"center\" colspan=\"3\">",
"            <span class=\"medCalcFontOneBold\">",
"             Decimal Precision:",
"            </span>",
"            <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"Friedewald_SI_fx();\">",
"             <option>",
"              0",
"             </option>",
"             <option>",
"              1",
"             </option>",
"             <option selected=\"selected\">",
"              2",
"             </option>",
"             <option>",
"              3",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"    <div class=\"notes\">",
"     <span class=\"medCalcFontOneBold\">",
"      Notes",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       In the formula above",
"       <b>",
"        LDL",
"       </b>",
"       represents LDL-C and",
"       <b>",
"        HDL",
"       </b>",
"       represents HDL-C.",
"      </li>",
"      <li>",
"       This calculation is not valid when the",
"       <b>",
"        Triglyceride",
"       </b>",
"       level is &gt;= 4.5 mmol/L.",
"      </li>",
"     </ul>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div class=\"references\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.",
"        <i>",
"         Clin Chem",
"        </i>",
"        . 1972, 18;499-502.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_39_5746=[" /* <![CDATA[ */",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function Friedewald_SI_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.Friedewald_SI_form){",
"",
"",
"doCalc = true;",
"if (Total_Chol_param.value.indexOf(',') >= 0){ Total_Chol_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Total_Chol_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Total_Chol_unit.options[Total_Chol_unit.selectedIndex].value.split('|');",
"Total_Chol = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (HDL_param.value.indexOf(',') >= 0){ HDL_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(HDL_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = HDL_unit.options[HDL_unit.selectedIndex].value.split('|');",
"HDL = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Triglyceride_param.value.indexOf(',') >= 0){ Triglyceride_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Triglyceride_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Triglyceride_unit.options[Triglyceride_unit.selectedIndex].value.split('|');",
"Triglyceride = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = decpts.options[decpts.selectedIndex].text;",
"LDL =  Total_Chol - (Triglyceride / 2.2) - HDL;",
"",
"unit_parts = LDL_unit.options[LDL_unit.selectedIndex].value.split('|');",
"if (doCalc) LDL_param.value = fixDP((LDL - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.Friedewald_SI_form){",
"",
"if (Triglyceride_param.value && Triglyceride < 0) {",
"Triglyceride = 0;",
"Triglyceride_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Triglyceride is 0 mmol/L.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Triglyceride_param.value && Triglyceride > 4.499) {",
"Triglyceride_param.value = \"\";",
"clrResults();",
"Triglyceride = 0;",
"doCalc = false;",
"alert(\"The maximum value for Triglyceride is 4.499 mmol/L.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.Friedewald_SI_form){",
"",
"LDL_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"/* ]]> */"].join("\n");
var outline_f5_39_5746=null;
var title_f5_39_5747="Coronal axial MRI Sturge-Weber";
var content_f5_39_5747=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63073&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63073&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sturge-Weber syndrome coronal and axial MRI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 402px; height: 216px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal and axial brain MRI of a child with Sturge-Weber syndrome showing the extent of atrophy resulting from a large left hemisphere meningeal capillary-venous malformation (angioma). The left hemisphere is indicated by a white arrow in both images.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John Bodensteiner, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_39_5747=[""].join("\n");
var outline_f5_39_5747=null;
var title_f5_39_5748="Activated prothrombin complex concentrates (factor VIII inhibitor bypassing activity): Pediatric drug information";
var content_f5_39_5748=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Activated prothrombin complex concentrates (factor VIII inhibitor bypassing activity): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?36/61/37844?source=see_link\">",
"    see \"Activated prothrombin complex concentrates (factor VIII inhibitor bypassing activity): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?28/51/29492?source=see_link\">",
"    see \"Activated prothrombin complex concentrates (factor VIII inhibitor bypassing activity): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F10514505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F135834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Feiba NF",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F135835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Feiba NF",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F2528322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihemophilic Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Blood Product Derivative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F2528329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/61/37844?source=see_link\">",
"      see \"Activated prothrombin complex concentrates (factor VIII inhibitor bypassing activity): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage is dependent upon the severity and location of bleeding, type and level of inhibitors, and whether the patient has a history of an anamnestic increase in antihemophilic inhibitor levels following use of preparations containing antihemophilic factor. Maximum dose should only be exceeded if bleeding severity warrants; monitor closely for DIC and/or coronary ischemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adults: I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Considered a first-line treatment when factor VIII inhibitor titer is &gt;5 Bethesda units (BU) (antihemophilic factor may be preferred when titer &lt;5 BU)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      General dosing:",
"     </b>",
"     50-100 units/kg (maximum: 200 units/kg/",
"     <b>",
"      day",
"     </b>",
"     ); dosage may vary with the bleeding site and severity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Joint hemorrhage:",
"     </b>",
"     50 units/kg every 12 hours; may increase to 100 units/kg every 12 hours; (maximum: 200 units/kg/",
"     <b>",
"      day",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Mucous membrane bleeding",
"     </b>",
"     : 50 units/kg every 6 hours; may increase to 100 units/kg every 6 hours for  up to two doses (maximum: 200 units/kg/",
"     <b>",
"      day",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Soft tissue hemorrhage:",
"     </b>",
"     100 units/kg every 12 hours (maximum: 200 units/kg/",
"     <b>",
"      day",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Other severe hemorrhages:",
"     </b>",
"     100 units/kg every 12 hours; may be given every 6 hours if needed (maximum: 200 units/kg/",
"     <b>",
"      day",
"     </b>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F135824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Feiba NF: ~500 units, ~1000 units, ~2500 units [heparin free; contains natural rubber/natural latex in packaging; exact potency labeled on each vial]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F135810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2528330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Reconstitute with provided diluent; swirl gently; do not shake; do",
"     <b>",
"      not",
"     </b>",
"     refrigerate after reconstitution; use within 3 hours of reconstitution; administer without further dilution. Maximum rate of infusion: 2 units/kg/minute",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F2528328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prior to reconstitution, store at room temperature [maximum of 25��C (77��F)]; store in original package to protect from light. Do",
"     <b>",
"      not",
"     </b>",
"     refrigerate after reconstitution.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2528323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Control of spontaneous bleeding episodes or to cover surgical interventions in hemophilia A and hemophilia B patients [FDA approved in infants (&gt;28 days of life), children, and adults]",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F135855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Blood pressure decreased, MI, thromboembolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Hypoesthesia (including facial)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: DIC",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction (including anaphylaxis), anamnestic response, hypersensitivity",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2528325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to anti-inhibitor coagulant complex or any component; patients with a normal coagulation mechanism; significant signs of disseminated intravascular coagulation (DIC); treatment of bleeding due to coagulation factor deficiencies in the absence of inhibitors to coagulation factors VIII or IX; acute thromboembolism (including myocardial infarction)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F2528394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with extreme caution in patients with thrombotic risk factors (eg, history of CHD, liver disease, DIC, postoperative immobilization, neonates, elderly patients); systemic antifibrinolytics (eg, tranexamic acid, aminocaproic acid) should not be used within 12 hours of Feiba NF dose; if signs of DIC occur (eg, chest pain, heart rate changes, blood pressure changes, or cough), discontinue infusion and initiate appropriate therapeutic measures",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2528326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not for use in patients with bleeding episodes resulting from coagulation factor deficiencies without circulating inhibitors. Product is prepared from pooled human plasma; may contain infectious agents that can transmit disease; screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk (rare).  WBCT, aPTT, and TEG tests do not correlate with clinical efficacy; dosing to normalize these values may result in DIC. Discontinue immediately if symptoms of DIC occur. Thrombotic and thromboembolic events (including venous thrombosis, pulmonary embolism, DIC, MI, and stroke) may occur, particularly following administration of high doses and/or in patients with thrombotic risk factors",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Single doses of 100 units/kg or a daily dose of 200 units/kg should not be exceeded; patients receiving maximum single or daily doses must be monitored for the development of DIC and/or symptoms of acute coronary ischemia. High doses should be used for the shortest time necessary to control bleeding. Thromboembolic events may be increased with concurrent use of an antifibrinolytic (tranexamic acid, aminocaproic acid); avoid or delay use of antifibrinolytic for at least 12 hours. Anamnestic rises in inhibitor (antibody) levels have been observed in 20% of the patients which may result in prolonged refractoriness to subsequent therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Allergic reactions (including severe anaphylactoid reactions) have been observed following administration. Discontinue immediately with signs/symptoms of hypersensitivity. Appropriate medication including epinephrine should be readily available.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F2869874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifibrinolytic Agents: May enhance the thrombogenic effect of Anti-inhibitor Coagulant Complex.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F135820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2869871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Reproduction studies have not been conducted. Administer to pregnant women only if clearly indicated.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2528331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for control of bleeding; signs and symptoms of DIC (blood pressure changes, pulse rate changes, chest pain/cough, fibrinogen decreased, platelet count decreased, fibrin-fibrinogen degradation products, significantly-prolonged thrombin time, PT, or partial thromboplastin time); hemoglobin and hematocrit; hypotension; have epinephrine ready to treat hypersensitivity reactions.",
"     <b>",
"      Note:",
"     </b>",
"     Tests used to control efficacy such as aPTT, WBCT, and TEG do not correlate with clinical improvement. Dosing to normalize these values may result in DIC.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2528396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anti-inhibitor coagulant complex contains factors II (prothrombin), IX (Christmas factor or plasma thromboplastin component), and X (Stuart-Prower factor), mainly nonactivated, and factor VII (proconvertin or serum prothrombin conversion accelerator), mainly in the activated form. The exact mechanism of action is not completely known but has been described as \"inhibitor bypassing activity\".",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F2528333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/51/29492?source=see_link\">",
"      see \"Activated prothrombin complex concentrates (factor VIII inhibitor bypassing activity): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Report sudden onset headache, rash, chest or back pain, wheezing or respiratory difficulties, hives, itching, or acute feelings of anxiety. Wear identification indicating that you have a hemophilic condition.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F13335240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosage is expressed in units of factor VIII inhibitor bypassing activity. One unit of activity is defined as that amount of anti-inhibitor coagulant complex that shortens the activated partial thromboplastin time (aPTT) of a high titer factor VIII inhibitor reference plasma to 50% of the blank value.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12912 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-14B9D587E9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_39_5748=[""].join("\n");
var outline_f5_39_5748=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10514505\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135834\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135835\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528322\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528329\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135824\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135810\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528330\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528328\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528323\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135855\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528325\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528394\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528326\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298760\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869874\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135820\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869871\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528331\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528396\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528333\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13335240\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12912\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12912|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/61/37844?source=related_link\">",
"      Activated prothrombin complex concentrates (factor VIII inhibitor bypassing activity): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/51/29492?source=related_link\">",
"      Activated prothrombin complex concentrates (factor VIII inhibitor bypassing activity): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_39_5749="Laparoscopic/robotic-assisted radical cystectomy";
var content_f5_39_5749=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Laparoscopic/robotic-assisted radical cystectomy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/39/5749/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/39/5749/contributors\">",
"     Monish Aron, MD, MCh, FRCS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/39/5749/contributors\">",
"     Inderbir S Gill, MD, MCh",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/39/5749/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/39/5749/contributors\">",
"     Seth P Lerner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/39/5749/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/39/5749/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/39/5749/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical spectrum of bladder cancer ranges from superficial to metastatic disease at presentation. The most important treatment-related issues include the identification of those who can be adequately managed without total cystectomy, those who need radical cystectomy, and those who require a combined modality approach that includes chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy (RT).",
"   </p>",
"   <p>",
"    Radical cystectomy is the treatment of choice for high-risk superficial disease as well as localized but muscle-invasive bladder cancer. Traditionally, radical cystectomy has been performed using an open approach that allows wide excision of the bladder, extended lymph node dissection, and a full range of urinary diversion procedures.",
"   </p>",
"   <p>",
"    The goal of minimally invasive radical cystectomy (with or without robotic assistance) is to reproduce the oncologic results of an open procedure, while decreasing the surgical complications and postoperative recovery time. Laparoscopy was first used for removal of the urinary bladder in 1992 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/39/5749/abstract/1\">",
"     1",
"    </a>",
"    ], and subsequent advances have evolved towards a robotic-assisted intracorporeal approach to include extended lymph node dissection and totally intracorporeal urinary diversion.",
"   </p>",
"   <p>",
"    The technical aspects of",
"    <span class=\"nowrap\">",
"     laparoscopic/robotic",
"    </span>",
"    radical cystectomy and the early results with this approach are reviewed here. The role of open radical cystectomy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/39/634?source=see_link\">",
"     \"Radical cystectomy and bladder-sparing treatments for urothelial (transitional cell) bladder cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of minimally-invasive radical cystectomy (with or without robotic assistance) is to reproduce the oncologic results of an open procedure, while minimizing surgical complications and postoperative recovery time. The technique continues to evolve.",
"   </p>",
"   <p>",
"    Our technique uses a transperitoneal approach (",
"    <a class=\"graphic graphic_figure graphicRef55963 \" href=\"UTD.htm?39/19/40241\">",
"     figure 1",
"    </a>",
"    ). The ureters are identified and divided, and a terminal ureteral biopsy is sent for frozen section analysis. The bladder is then progressively freed from surrounding structures, beginning posteriorly, proceeding laterally, and then anteriorly, including transection of the urethra. In selected men, the cystectomy may be modified to include a nerve sparing approach as with open cystectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/39/634?source=see_link&amp;anchor=H6#H6\">",
"     \"Radical cystectomy and bladder-sparing treatments for urothelial (transitional cell) bladder cancer\", section on 'Nerve-sparing procedures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    High-extended bilateral pelvic and retroperitoneal lymph node dissection is performed, typically up to the origin of the inferior mesenteric artery in a manner similar with open cystectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/39/5749/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/39/634?source=see_link&amp;anchor=H5#H5\">",
"     \"Radical cystectomy and bladder-sparing treatments for urothelial (transitional cell) bladder cancer\", section on 'Pelvic lymph node dissection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After completion of the cystectomy and lymphadenectomy, urinary diversion is performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/34/32298?source=see_link\">",
"     \"Urinary diversion and reconstruction following cystectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1456375\">",
"    <span class=\"h2\">",
"     Robotic-assisted",
"    </span>",
"    &nbsp;&mdash;&nbsp;Robot-assisted radical cystectomy has evolved from a purely laparoscopic approach and has steadily increased in popularity amongst urologists who are familiar with robotic techniques. Robotic technology aids complex laparoscopic surgery due to three-dimensional visualization and wristed, articulating instruments, which facilitate intracorporeal suturing.",
"   </p>",
"   <p>",
"    Between 1999 and 2006, we performed laparoscopic radical cystectomy in 54 patients for bladder cancer at the Cleveland Clinic [",
"    <a class=\"abstract\" href=\"UTD.htm?5/39/5749/abstract/3\">",
"     3",
"    </a>",
"    ]. Of these, 17 underwent a totally laparoscopic approach for the cystectomy and urinary diversion, while 37 underwent laparoscopic cystectomy, followed by the urinary diversion procedure (ileal conduit or orthotopic neobladder) through a mini-laparotomy open incision. The lower rate of perioperative complications in the open-assisted group led us to discontinue a totally laparoscopic technique. Major complications associated with a totally laparoscopic approach were bowel leak",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    urine extravasation and sepsis.",
"   </p>",
"   <p>",
"    Our experience with",
"    <span class=\"nowrap\">",
"     laparoscopic/robotic-assisted",
"    </span>",
"    radical cystectomy exceeds 150 cases, with the most recent 50 cases being performed with robotic assistance. Following robotic-assisted radical cystectomy and high-extended bilateral lymphadenectomy, we now perform completely intra-corporeal urinary diversion (instead of using a mini-laparotomy). Complications rates with a robotic-assisted approach are similar to that of open techniques. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Outcomes'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcomes of",
"    <span class=\"nowrap\">",
"     laparoscopic/robotic",
"    </span>",
"    assisted radical cystectomy come primarily from retrospective case series. One small randomized trial has been performed and compared robotic cystectomy with open cystectomy with lymph node yield as the primary endpoint [",
"    <a class=\"abstract\" href=\"UTD.htm?5/39/5749/abstract/4\">",
"     4",
"    </a>",
"    ]. There were no significant differences in the numbers of lymph nodes obtained (19 robotic, 18 open), overall complication rate, or length of hospital stay. Other randomized trials are underway.",
"   </p>",
"   <p>",
"    Retrospective reviews have also shown that the perioperative and oncologic outcomes of",
"    <span class=\"nowrap\">",
"     laparoscopic/robotic-assisted",
"    </span>",
"    cystectomy appear to be at least equivalent to open surgery. However, long-term oncologic survival data are limited due to the short follow-up in most reports. Procedural costs are higher for the robotic approach, but there is some suggestion that lower hospital costs associated with shorter length of stay and fewer complications may compensate [",
"    <a class=\"abstract\" href=\"UTD.htm?5/39/5749/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Perioperative",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial studies evaluating laparoscopic cystectomy reported long operative times, but the procedure was associated with less blood loss compared with open cystectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/39/5749/abstract/8-14\">",
"     8-14",
"    </a>",
"    ]. Robotic-assisted techniques have improved many of the technical aspects of the procedure and have made a minimally invasive approach competitive with the open approach [",
"    <a class=\"abstract\" href=\"UTD.htm?5/39/5749/abstract/4,15-19\">",
"     4,15-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a cohort study, 45 patients who underwent robotic-assisted radical cystectomy were stratified into three groups of 15 [",
"      <a class=\"abstract\" href=\"UTD.htm?5/39/5749/abstract/17\">",
"       17",
"      </a>",
"      ]. The mean operating time decreased (532, 462, 434 minutes), and the average hospital length of stay shortened (12, 8, 8) over time.",
"     </li>",
"     <li>",
"      One of the largest retrospective reviews evaluated outcomes of 100 consecutive patients undergoing",
"      <span class=\"nowrap\">",
"       laparoscopic/robotic-assisted",
"      </span>",
"      cystectomy and urinary diversion [",
"      <a class=\"abstract\" href=\"UTD.htm?5/39/5749/abstract/15\">",
"       15",
"      </a>",
"      ]. Among the patients, 61 underwent diversion using an ileal conduit, 38 received a neobladder, and one had no ureterostomy. The mean operating time, blood loss, and time to discharge were 4.6 hours, 271 mL, and 4.9 days, respectively.",
"     </li>",
"     <li>",
"      A prospective study that compared 83",
"      <span class=\"nowrap\">",
"       laparoscopic/robotic-assisted",
"      </span>",
"      to 104 open cystectomy procedures found lower perioperative complications rates for the robotic-assisted approach [",
"      <a class=\"abstract\" href=\"UTD.htm?5/39/5749/abstract/19\">",
"       19",
"      </a>",
"      ]. At 30 days, the overall complication rate was 59 percent in the open group and 51 percent in the robotic-assisted group. At 90 days, the complication rates were 62 and 48 percent, respectively. Major complications occurred in 10 versus 30 percent of patients at 30 days in the robotic-assisted compared with open groups, respectively. The amount of blood loss, need for transfusion, and units of blood transfused were significantly less in the robotic-assisted group. There were no significant differences in the duration of the operation between the groups (5.25 hours open versus 6.24 hours robotic).",
"     </li>",
"     <li>",
"      A review of data obtained from the nationwide inpatient sample (NIS) compared 1444 open and 224 robotic-assisted cystectomies. Fewer inpatient complications (49.1 versus 63.8 percent), fewer deaths (0 versus 2.5 percent), and lower parenteral nutrition use (6.4 versus 13.3 percent) were found for robotic-assisted compared with open cystectomy. The length of stay was not different between the groups. The robotic-assisted technique, however, was more costly compared with open cystectomy (+$3797) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/39/5749/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Oncologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited survival data are available for oncologic outcomes following",
"    <span class=\"nowrap\">",
"     laparoscopic/robotic-assisted",
"    </span>",
"    cystectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/39/5749/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. However, there appear to be no significant differences for a",
"    <span class=\"nowrap\">",
"     laparoscopic/robotic-assisted",
"    </span>",
"    approach compared with the open approach.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective review compared early oncologic outcomes after 36 laparoscopic robotic-assisted and 29 open radical cystectomies for bladder cancer with a median follow-up of 12.2 months [",
"      <a class=\"abstract\" href=\"UTD.htm?5/39/5749/abstract/21\">",
"       21",
"      </a>",
"      ]. There were no differences in tumor stage, margins, or mean node count (17 robotic versus 15.5 open) between the groups. No significant differences were found in overall survival (68 versus 63 percent), disease-specific (75 versus 63 percent), and recurrence-free (67 versus 58 percent) survival for",
"      <span class=\"nowrap\">",
"       laparoscopic/robotic-assisted",
"      </span>",
"      versus open cystectomy, respectively.",
"     </li>",
"     <li>",
"      Similar outcomes were reported for another study that reported overall survival rates for a robotic approach at 82 percent at 12 months and 69 percent at 36 months [",
"      <a class=\"abstract\" href=\"UTD.htm?5/39/5749/abstract/22\">",
"       22",
"      </a>",
"      ]. Disease-specific survival was 82 percent at 12 months and 72 percent at 36 months. Patients with lymph node-positive disease and extravesical node-negative disease had worse outcomes.",
"     </li>",
"     <li>",
"      Another series of 85 consecutive patients found overall, disease-specific, and recurrence-free, survival rates at two years follow-up of 79, 85, and 74 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?5/39/5749/abstract/23\">",
"       23",
"      </a>",
"      ]. On multivariate analysis, stage was the most important predictor of survival. At a mean postoperative interval of 18 months, 24 percent of patients had recurrent disease, with 4 percent having local recurrence. The positive margin rate was 6 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radical cystectomy is the treatment of choice in selected patients with bladder cancer. Open radical cystectomy has traditionally been performed and allows wide excision of the bladder, extended lymph node dissection, and a full range of urinary diversion procedures. A minimally-invasive approach is being performed in many centers worldwide. Reports from these sites have demonstrated the technical feasibility and safety of",
"      <span class=\"nowrap\">",
"       laparoscopic/robotic-assisted",
"      </span>",
"      cystectomy and urinary diversion. However, there is a steep learning curve. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goal of minimally-invasive radical cystectomy (with or without robotic assistance) is to reproduce the oncologic results of an open procedure, while minimizing surgical complications and postoperative recovery time. The initial purely laparoscopic approach has evolved to include robotic technology which facilitates intracorporeal suturing and has allowed for completely intracorporeal urinary diversion. (See",
"      <a class=\"local\" href=\"#H1456375\">",
"       'Robotic-assisted'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial studies evaluating purely laparoscopic cystectomy reported long operative times, but the procedure was associated with less blood loss compared with open cystectomy. Robotic-assisted techniques have improved many of the technical aspects of the procedure such that the minimally invasive approach is competitive with the open approach.",
"      <span class=\"nowrap\">",
"       Laparoscopic/robotic-assisted",
"      </span>",
"      technique cystectomy is associated with less bleeding, fewer perioperative surgical complications, and shorter length of hospital stay. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Perioperative'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Retrospective reviews have also shown that short and intermediate oncologic outcomes of",
"      <span class=\"nowrap\">",
"       laparoscopic/robotic-assisted",
"      </span>",
"      cystectomy appear to be similar to open surgery. However, long-term oncologic survival data are limited. Larger numbers of patients and longer follow-up will be needed to establish therapeutic equivalence. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Oncologic'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/39/5749/abstract/1\">",
"      Parra RO, Andrus CH, Jones JP, Boullier JA. Laparoscopic cystectomy: initial report on a new treatment for the retained bladder. J Urol 1992; 148:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/39/5749/abstract/2\">",
"      Desai MM, Berger AK, Brandina RR, et al. Robotic and laparoscopic high extended pelvic lymph node dissection during radical cystectomy: technique and outcomes. Eur Urol 2012; 61:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/39/5749/abstract/3\">",
"      Haber GP, Campbell SC, Colombo JR Jr, et al. Perioperative outcomes with laparoscopic radical cystectomy: \"pure laparoscopic\" and \"open-assisted laparoscopic\" approaches. Urology 2007; 70:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/39/5749/abstract/4\">",
"      Nix J, Smith A, Kurpad R, et al. Prospective randomized controlled trial of robotic versus open radical cystectomy for bladder cancer: perioperative and pathologic results. Eur Urol 2010; 57:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/39/5749/abstract/5\">",
"      Yu HY, Hevelone ND, Lipsitz SR, et al. Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample. Eur Urol 2012; 61:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/39/5749/abstract/6\">",
"      Martin AD, Nunez RN, Castle EP. Robot-assisted radical cystectomy versus open radical cystectomy: a complete cost analysis. Urology 2011; 77:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/39/5749/abstract/7\">",
"      Lee R, Ng CK, Shariat SF, et al. The economics of robotic cystectomy: cost comparison of open versus robotic cystectomy. BJU Int 2011; 108:1886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/39/5749/abstract/8\">",
"      Simonato A, Gregori A, Lissiani A, et al. Laparoscopic radical cystoprostatectomy: our experience in a consecutive series of 10 patients with a 3 years follow-up. Eur Urol 2005; 47:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/39/5749/abstract/9\">",
"      Guillotreau J, Gam&eacute; X, Mouzin M, et al. Radical cystectomy for bladder cancer: morbidity of laparoscopic versus open surgery. J Urol 2009; 181:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/39/5749/abstract/10\">",
"      DeGer S, Peters R, Roigas J, et al. Laparoscopic radical cystectomy with continent urinary diversion (rectosigmoid pouch) performed completely intracorporeally: an intermediate functional and oncologic analysis. Urology 2004; 64:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/39/5749/abstract/11\">",
"      Tanaka K, Hara I, Takenaka A, et al. Incidence of local and port site recurrence of urologic cancer after laparoscopic surgery. Urology 2008; 71:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/39/5749/abstract/12\">",
"      Haber GP, Gill IS. Laparoscopic radical cystectomy for cancer: oncological outcomes at up to 5 years. BJU Int 2007; 100:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/39/5749/abstract/13\">",
"      Cathelineau X, Arroyo C, Rozet F, et al. Laparoscopic assisted radical cystectomy: the montsouris experience after 84 cases. Eur Urol 2005; 47:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/39/5749/abstract/14\">",
"      El-Tabey NA, Shoma AM. Port site metastases after robot-assisted laparoscopic radical cystectomy. Urology 2005; 66:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/39/5749/abstract/15\">",
"      Pruthi RS, Nielsen ME, Nix J, et al. Robotic radical cystectomy for bladder cancer: surgical and pathological outcomes in 100 consecutive cases. J Urol 2010; 183:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/39/5749/abstract/16\">",
"      Smith AB, Raynor M, Amling CL, et al. Multi-institutional analysis of robotic radical cystectomy for bladder cancer: perioperative outcomes and complications in 227 patients. J Laparoendosc Adv Surg Tech A 2012; 22:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/39/5749/abstract/17\">",
"      Schumacher MC, Jonsson MN, Hosseini A, et al. Surgery-related complications of robot-assisted radical cystectomy with intracorporeal urinary diversion. Urology 2011; 77:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/39/5749/abstract/18\">",
"      Wang GJ, Barocas DA, Raman JD, Scherr DS. Robotic vs open radical cystectomy: prospective comparison of perioperative outcomes and pathological measures of early oncological efficacy. BJU Int 2008; 101:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/39/5749/abstract/19\">",
"      Ng CK, Kauffman EC, Lee MM, et al. A comparison of postoperative complications in open versus robotic cystectomy. Eur Urol 2010; 57:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/39/5749/abstract/20\">",
"      Chade DC, Laudone VP, Bochner BH, Parra RO. Oncological outcomes after radical cystectomy for bladder cancer: open versus minimally invasive approaches. J Urol 2010; 183:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/39/5749/abstract/21\">",
"      Nepple KG, Strope SA, Grubb RL 3rd, Kibel AS. Early oncologic outcomes of robotic vs. open radical cystectomy for urothelial cancer. Urol Oncol 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/39/5749/abstract/22\">",
"      Martin AD, Nunez RN, Pacelli A, et al. Robot-assisted radical cystectomy: intermediate survival results at a mean follow-up of 25 months. BJU Int 2010; 105:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/39/5749/abstract/23\">",
"      Kauffman EC, Ng CK, Lee MM, et al. Early oncological outcomes for bladder urothelial carcinoma patients treated with robotic-assisted radical cystectomy. BJU Int 2011; 107:628.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2974 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-5115C1355F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_39_5749=[""].join("\n");
var outline_f5_39_5749=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1456375\">",
"      Robotic-assisted",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Perioperative",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Oncologic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/2974\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/2974|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/19/40241\" title=\"figure 1\">",
"      Port placement for laparoscopic radical cystectomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/39/634?source=related_link\">",
"      Radical cystectomy and bladder-sparing treatments for urothelial (transitional cell) bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/34/32298?source=related_link\">",
"      Urinary diversion and reconstruction following cystectomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_39_5750="Kudo Pit Pattern Classification";
var content_f5_39_5750=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F69425&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F69425&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 538px\">",
"   <div class=\"ttl\">",
"    Kudo Pit Pattern Classification of colonic mucosal lesions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 373px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pit pattern classification for colonic mucosal lesions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_39_5750=[""].join("\n");
var outline_f5_39_5750=null;
var title_f5_39_5751="Gottrons sign 1 PI";
var content_f5_39_5751=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F77884%7EPI%2F57889&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F77884%7EPI%2F57889&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gottron's sign in dermatomyositis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 229px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An erythematous, scaly eruption over the extensor surfaces of the metacarpophalangeal joints and digits in a patient with dermatomyositis. These lesions, called Gottron's sign, can mimic psoriasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marc Miller, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Gottron's sign in dermatomyositis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 367px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFvAfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6HUBt3anHhcgZ+pqBWXbzUysOeas5Cb6Cjk4wMYpEYHqePSnjluuQe9IaArgimSWyTxtHKpZD2zipl6dTTwcA88VN2Fjz7xn4Zk+zNLAGMaN5kbr1ib0I7rXHWVxd2HiKz1WK3ZY5gqy7PuOOjZ9690DZ68gjBFcnr+mRWJ8+CIfY3P7yIDhD6j2qHFPdHXSxM4R5E/67G1DOJLfdGwZWGVPtXh3imwNp4t1G55An2mvWdGBijMasGgPKg9V/+tXC/ECHbcFwByetc1NWlY1jvcxdNYnHUc10tpIGKmuY04/KAOhrfsZBwuOQeTmiZ6ENjfhYYJ6e1XIZfu8nnt6VmQuCBj9KtwvyO5PvWLNkjZhfhcHmrHmcZI4rNWQZy/I9fSrQkACg9M0ENF2JyQMdO1WQ+FOAWrPhcdP6Vbj+71oIkiXvk9BQr4zuAJPpTNwPfnPNIxOST69u9MmwkzflVR35wSfpUrNvLE5Pt6VWnXaeW59cUmaRK87beRyQcGs+Rsjrj6VdmAIwRjvntVFyQTjr16VLNYlWT/aHbIqnJwc4/GrU3ALdveqch5xSNEVp8BmIPSsq6IKHjA9q0JSDkbunr61mXLADaOV61URtaHP6gvLDvXJ6xGAXrsL05BzXL6t909BWsdzGexxl0qKjFiMBxXYfDue+vtQj0nQ2MBuWxLOTjavrXL3VsbiHYnJaQV6D4D0/+wyl8W2yAfIvqa6ox5mjz6suU97gkk0ASB5jJFFEWLZ+V8Dk/nXBW87TO80hO+Rt5J966PUonh+Hcs8k7TTTTBizcAbyMge3FczaKBtB6jvXPiI8srG+B96LkzSVvmzjj0NTQ/fzjmoUHBGMn1qWIgOAD9cVzncXom4wO9WImPBC84qojZA2qN3cHrVqDGz5iQO1IC9HtC9eeo5qwGOAAMjqapqw2dMj2qWNj5Q+verRm0WN2OMEt1yKXcSue5/Sm7gowM5pN/y8df0qkSI5bbyQRj86z55Dk8ce1WZNwJA4GMnvVG56envQXFEKyq2OQD1zVKa53s+CTk4zUjhh8oBYdTjt9ag8v5M4xz+dN7GlkhpJK4qJ2Prx3qYHjtUEuaaM2V5SdxJzjGaqux2+ntVmQ49z1rPnlwzcc1oZMguJecDmqMzDJ5qeQjcSapStkk5pollWVjlsGs+fkH2q5MccdKoTtgGrRjIptktjNcZ4ymMuqiMfdjG3FdpEAHLN0Ubq8+1BjcX00h5y1WjGRHaZBGa+j/ghpfl6Z9okUAt0Jr590m2NxewxAZLsBX154G05dP0G3QDBKgmuimrJs467u1E6JFAGTz7VOhGOOBUI6YB+X+dSr7fnSZjYZMBktj6VlyJh2Yjr61ruMg1QuEHYZqosTKroXQ4+mKKljXj2oqySYLxxk0q8cimI+O/5VKrdPWshCrJtFTJKBznrURXnGeaTYQeKRRbVwRxn2NPDAnA4ql8wIPORUiSDOT1+lS0BdBzjn8qGRXVldQysMEHoahjcEYzzUyn6mlYDl3gbSr/yclrd/mhY+ndfqKwvGtn9q0+SVOqgtXf31ml7AYpPlOdyP3VvWuYubeSSK4s512zBSrADrkcEVjUjZ8yOilO+h5XYN8owfcCtu0YqVOeeufasC1ypKEDcp289sVs2/DDJBHfjrWdRWZ61F3RuW8hZcdB9a0LYgYJbr0FZFu3TknHetO2lUgr1x2HTFYHSaMZB6cfWrVqpJyTx6VQjdvl2/KtXoW9OD3pEMuxHnjt3qc/MhwcccVWTLLx35xU+AQeCG9f8KCGIjYxk+1TKwOMY57VEOQScZHTPSgkncSMe9MVriuCOeODiq1w2Qck59OtSM3IweeuMVXmYKygcikNIrOACVL9/wqjKeRzz/Orc3JyCRmqMjkEA84NSzaKKs7E59uh9KozHJ2+nfNXZiM8Gqc68k4FBokUbhwDkrkgZrLuGB3k9exFaEwGWxwf5Vlzn04Aqoop7GXdj5T7etczqo64wa6S84U9cYrmtSPzjoK1SMJlLRkjEkjyAYU5/GtSfU2kmRFbjIHFYrv8AZ7MsOrsaTRw1xqlsnJ3SDiuuLsjzKsbyZ9C687L8OdNRs5kuIx+QJrn7TGAc89DXUePYxa+EtDt04PmhsfRTXJ2vLLj17Vz4l3mdeAVqXzNVGA6cYHHvUsPOccGoUHOCeMfnViJiV+XHvXMdiJ4uCD+FWUHAAycVFAh+uauRICcnp60hthETgZ/OrcRyvAGcVAhXJ3cYqYMCuBkZPcVSJkOVwpGSQffmpMAg81AoLHtj3pxztHA9c1SIaGyuojAHX+VZ05LnIHFXpVJPzDIqpIQrHGcnn2oLjoVwHELB/kPdTVKZiST6dqvXAbfk8k/rVWXAQk5pt32ArM45PWopGwM9vansGJ/wqCYnOB17mmiWQzSAgge4rMk+UkKwx15q1L8p6ZHaqUhI3dMHjmrTIasVpic4qnIcnPpVuVuvrVKdjgntWiMmVLnGM96zp24PrVydjiqEwBOM1RkylqEnkabcSHjK7R+NcQqbjnvXUeKJtllDADkuSxrAgXNaRRhJnUfDXSzf+JbZduVUg19Y2kPlwIgGFUAAV4b8C9K3Xr3TLwOhxXvQ6cVvtFI4Ju82xcBQBmhm4/pTWJxwc0gGSM/WlYQ7cSOcCopEYsAMBAO/WpcYGDSt9MetAigI2XJJyc9hRU8nLe5NFWTYorkflUqtgdM0pTkU7Genryagkej5Iz1qeNsjj8Krbe3WnoCBgcc/lSsVct7VcnHWhoc5xxUUbnPPFTo//wCulawEDRsmcZxSpMyEZGcVaBB4OM+lL5SkZA/+vSv3GEM8bn09qbqFnFfRr83lzp/q5R1X2PqPamNajqpIOexqNlmiPDNilZME7bHh+q276frl9azgB4pmBx0554/OrEEmdmeF6YHrV/4lwGPxWZ85FzEknpkj5T/Kse3yQD3Fc9aNmexhZXgmdDaucc8Dj6mr9s646e1Y1q5ONxz3Oa07d1LAEcdetcrO1GhE3I5JHqa0YHIVcZ+p71lxEmUdh71pQHpvBIxjcD3qRsuxu23P8Poe9WeqjA5qshxhjyvTHrTzvx1wRxx2oJtcsIxyR1XHJoYHPJyOopqSYPo3TPapMgkbgc0E7EUi9GzkH07VVlHy8e/Tqaty7fmG7j0xVCTcoJxgDFBUVchfcGB247571TkA/iPNXGPVSCDnnNU58AEgHBqTRalGfALYbIz6VTnOQcEn0qzMSTgk5HTFVJfUHnGMD0pmljOuCQ3Q/SqM2DjJXHbFaE+3OMHd2zWdc8pnAyKuImZF8Dgj9O9c5fx7mPPIrpbzJyf6Vz2oLgP15rVGMzA1P5LW2Ud2Y1ufDnTJ9S8VWFvbRGSQvuIHQAdSfasXVxgWY/2WP1Oa93/Z10ZINMv9UkQGeUiJT3VRzgV0xPMrO1zpfiZbeVommoWDP9pALY/2DxXFW6bWGM/WvQPimB/Ylk2ORdD/ANBauDi7cnHSuau7yOzA/wAMuKN2CRj0qxCOgH145qCPJ7nFW4OOe2ccVznYXIhwMDqOfrVpOmaqQqC31OAKtI3G0/T8aQh2c54BOenrT0IJJxkHqPSoHOSMYAB5qdCqrkjmmhsnXaAeeT7dqbkeYPbk+1MDBuOc0qnBIB+lWjNoSUhtwOfy61UnjA6c47VcwN2QeMce9V7g8Hjk88UMa0KDB2buT71WnXrnGAO1XpBhSRy3vVKUs3GOOpoKuUGbknsP1qvK/H6VZlGGHaqc4Gec4znFNMGQyMOOce3rVCcDnBzn9KsyMd2Mc1RuWIbHY9xWiMpFe4AVs9apTEMvpViQkkkniqs545JrRGMijcNk4HQVTkyXx61ZuCBmqYcBmc8BAWP4VaMZHK+JZRLqpjXpGNtRafGWZVAySapvIZ7qSU87mNdL4Qsje6xbQgZywrWKu0jnnKybPoP4U6ULDQo3ZfmfBrvM+vJ9KpaRbi1sYIlz8qgVfUHPNbzd2cK2GgHcBjg+lPwFyT+dOX6UHGOlQAnDLkfhTXwe1KTuFMIABzTQiJv69qKD68kUVQiPoMdaco546U1V9TxUmQozUCBk4Bpduef6VIhDDgDFKBk9ARRcZGF9uKeAR9O1Ox045pcAUXAVTge1SL3wc00cY4p3PTPAqQHgnpxTyRUOCBntTh8vHakBwHxhtM2ul3qIPkd4GP1GQPzBrz+GTcCCdpr134j232vwbf4Ul4Cs6gf7J5/QmvHoB684FZ1VomejgpaWNa0fgEZ+o6VrWpGAe/pWFAxU47+wrYtZCyglsZ744rikepE0omG7qSO/9K04JNpHPHpWXFhuGGRxzWlB0HynI/WoLZoRS5UDK4HWrUSAKT1U847VQjILDaPl7Z4q4S6AMRjFIlomUqehxxg0ZwcAYI4ApI8Dbnv0zTnIAGBnHpxTII5u2Ac9eO9QEA4zzu6VJKSDnIx0wah3gnBH8NK5SRVnGCWDZUHnNU5TknOQScZNXJx27EZ/GqcoOeQOefwpM0iUbgbufyFU5yBwQeOCO1W7gjJ25PGOOlU5v3keVGOM0GhQlIZflGCOcGqNz1O7GD29DV2YhfmA6iqcpypGQGJxitEQ2Yt0frzWHqJ4I79q6C8Azjn8BXP34wzcZHT/AOvWqMp6mdcW4kuLUtg7I+B7k19F/BWIR+DlAHLSEmvBYYgzw8cBen419A/CAAeGMDs5610Q6s8vEbFj4pL/AMU9bHGcXafyauAix93OR0xXonxSGPDCf9fMf9a86t+AM/nXNX3O3A/wzRgHfOcnBGO9W41KtnsO1UojjuM9atRyZ5JHr9awZ2otqdo6jJ6+1PR8nqc59KrKcgEngnINSZA3bc+9K4WLKkM3HFPB3Ekc47VBGQVHXBOc4qymDxjn1NMHoKD6Zz0NKg+RsZ68igsF6DBNKpwAentTTJEdznjH4iq8jqy9e/PHSpnYHdkjpVOdgQQMAUwIZ5NucHI9T3qqX+Q+/vT2K5H55NVZR34wf0oRWhHKwZs+1UpSpB2qTz61NK+Ccjj1qhNId21RxiqRLIZDkkjgCqM5wxz1qzO/QDjFUJ2HJ75rVGT1IXbk5PFVpjweaklbnI9Kpu3H0q0YyKtwQCfpWRrc/wBm0e5k6M/yCtGc5J5rl/G0+2O1tVODje1aROebMWw5xXr/AMFNK+16157LlY+eleR6aOBX0r8D9N8jR2uCPmeuiktb9jkrPSx6ki4UU/pzQB2zxR/Og5wzwOKDz14NGaG460ANJA6Y9zUbE59acfm/Dmkx3x0poQ3GOPWipNvPPWincTSK4PB6H6UoY/UmmIwzTge5P5VIkSDIxk04Z4Iz+dRh+On4VIpbBxgfSkMlHsKcF57Z61GCxwCakBHc/jSEO5/+vSrjPNKOeKUfjSuADoeKULz0/GlXNPXg8UrjILy1+12d1bN0miaP8xivnWNGiYxOMOhKn6g4P8q+lV4IPvXgvjSzNj4u1WFcAGUyqB6MA39TUy1idWFdp2K0DnfnqCK04CS6Acdqx7djxz+AHata3PzYBB+tccz2YM2rXOwD8q0ITuAAYDPT/Csm3fGFGSSa0oDvUDpg56cVjc1aNKEN8oBG7tV5FLKNxyetUIMk8gYA4x61oQuCoHtn3+lBEh0bENyT9TTpOVPFNJG0nnbnkUx5A2ece4oZO5G7nB6fU/0qqSylj/DnJHcipXbI4PT1qsxOT27YFTc0SEZ8HPA+tVJtxI24qSR9uRkep9qryYJyHznvQVYpz8PhfzzVC4lAbcuWAGeBxV+Vh83OfwxWfOMd8A9h0FNFFKYZG5gfU1SlYbiT68VcmfBc5ByBmqEo+Q5P0J9K1RmUrtuvXdWDfDO70PBPtW7e8dSPzrFvR1HP/wBetERJaC242qjY/gFe8/BvLeEhIeS0jfzrwK4fbHEoP8Ar374RMLf4f28hGfmYgZ6nPArpieXXLHxQJfw5JtJ2QTxFuOpyf8RXnlu3yjB/+vXpXj6Bv+EKujJ/rA0bvz33ivNLfnA79K5q+52YD4H6lyIkHngnoaux5xwO3SqkYGOecDFXY85JJ7YrmO65Mo+XnH0qVE53HOB6npUfIwQcD0pRLxjHGePrSDUnyChIOMelPjYjPPaq6kkkjBX+tTxZ6HgH9fai4Eit8vGM560DcAMkc9aGCqAc801+v3j9RVXAYxwQOfxqpMzEE8ACrErgZIIArOnfe3yjii40rkBmJcr6VBNLuOF49KgmmO7PGM44qB5ecZGOwpopodMeMMfyrNuHcMec/TtVuSXdzwT7dqozHnBwK0iZNleR88D/APXVWQnkDPSp2I7ciq0px3z3rQxZWlJ3EnNVLh8cHr61akxknNUbhhg4/wD1VaMZMrHLSBe5NcH4ouDca1Ng/Kh2j8K7d3EayTHpGhavN5GMk7ueSzE1rE5ps1tFjMs8aDqWAr688A2X2Lw7aoBg7ASO9fLHgS2+0a5ZxnnLivsPTI9lpEg+6FFdEdIXOOq7ysWxnPse1HTp3p2M0HHbipMhBkUjDP8AWnHHuaRvWmBGRj39KAMN0yTTm5pQOevSmAh7Y/Oin5FFFyTLVuakD84zUSgjHSnjPTGKZBKGU8cZxmpV2nkdarDI5NSK3o2DSHcsA+uDUgJ/KoA2cdKlXB78VLQ7kytgHJpytgDioxS4J4H51NgJlcZIqQOOe1VdrAnDfhS4K4AYmlYZaDcda8l+MFr5PiG0ugPluLfDY7lG/wAGFeobTn7xzXC/F+2LaRpt1yfKuDGSfRl/xFFtGa0pWmjzuB+E6cd60bWXaQeDk8nHSsmPG1c4P16Vdtz8uCcHrmuOaPbps3rV9z/KOnete3YHGcZ64rn7UkNtHB9c8VsWo5Dbj+PaudnTbQ2InxjAzng//qqzGzIw5GBVK3f7p3AkdQauxkZxwx6g4oTJZPK25cjAY4/CqxkIIycDvUzglRjqMHGMZqvcfdKg9M59hSbJj2GyED5enHeq7Sc4Y8k85psrnrkAHoPSqjuAAdwyO2Oam5qkTzjqT9MdqrSjjkjt+FK0qkY5wOo7Go53BGRj0GD0oAqTv2JOPpnNZ1zLtQnJ9Mj1q1dMAgAbjPQVm3JHDfePXB7fhVxGys7Z3cDGPujvUDnaoxyM+tPY7j1y3oKr7iRncDk1qiGQ3QBUA9B7Vi3a8nGa2rjHrWTcD5uDirRnLYzdRfbOqAniNT+Yr6G+EytJ4P01D/q0Bkb3JPA/rXzhqwd9cSGPJd44wB6k9K+tfCelLovh2wsBgtFEoc+rY5/WuiJ5mIKvj9d3g/Ux6ID+TA15NAcjnua9f8ZJ5nhXVVz/AMu7H8ua8ct2wo9T+tYV90dWAfutGpFjI7mrcTZHsaoREhfQ/WrMbFSADg4wRXMd9i2zcgKenQ03d8y55UfpUJfHBHJH1xSRnduHBPXrUlrYvxsGIAGDT9+D34HOOcVXR1iwTnngVKoMgGeD/WgkkY5GSaHlwpz2ppGGGTx3FQTtuTHLY6c00MjuZxgj16AVnTyHB+9u6fSnXGQc7iPUVRmkbORyB3plbEN2+Acnr6VTLllBzyOKLmQ4+bp2qmJSrevf6VokS2XHJ2jPUVWkPy9dy85pPOJY5+tIzfLg445qkZSZA547Z6mq0xy2ec4qSViM5PNVp2zg+3erRnIrTsQCcnFUpW65/KrMxOST1/lVKcnPWrRhMytem8nRZsHBkIQVxCDkYrqfFkhFvawj3c1zaL81bLY5Jbnofwds/tXieI4yEwa+rLYbYwBXzt8ArLdfTXJ6D2r6JgPye+K6XpBI4pO8myfjFA6c0g6UvXrzWYhM0mMnPenkAcU3p0zTEIcZpFzmlx707jPBoAUYAoocHbx+dFFiTMHQfzpwH50gHvxT8DA/WmQA456Cnrz2B9eKTbwRk/SpFXjHcUDBO3GalXtxzTUUY+tPXA6dzUsZJyVz0PrQODzSA8804EDHekA4Lkj1+tOwBxTB6GhSOOSMUgJl6cfnXL/E6HzfBd6x6wyRS/kw/wAa6RGG4+lYvjtRJ4M1dewty35EGhblRdmjxCMYJUkDI7mrMTfvOc5xxVVcbuQcZ/MVagl2SI2O3Oa5JHu02bNoxODzkD8q1rdgOejemKwreYAHJ47D1rWs5fkDEAf59a5pI61sbMBGR8uF6YBzzV+JhwCQAeOvFZtvh+g28dMfpV1cEjoB9alCZfLDaQG7Z9qpTyAhsduxqTzMggZP+NVbk8ZHJwTjFDFGJSnkyWXPPUH+tVpGJ4Oc9h6VYlwyHAx0wapyqVGAcNj06VBsiEnqCefSmyMSmQQQPbpUbMqvghQTxj1/GopH2Ngcj2pgxLhsr3A/WqEjFhjOMdfepndZGx14zx1NVZOB0IyTgYzWkUQyFyccgHAx7VFjaCf4qnK87gOpHU0xkABA9M5P9a0RJSlLANnp2Pr+FZ8g3EYxzWjJk5HTPrVKZQMdcjvVozkP8Kaet/8AEvS0lGY0eEMCOuBmvqU9favnn4exB/iRp3HI+c/glfQxrojseViPiM7xEgfQNTVhkG2k/wDQTXh1uxCqcn7ox69K931cbtHvge8Dj/x014NZkMiH/YGeaxrdDqwD0ZqQNkIMAe1WN22T5uQvrVK3IPUdB09Knk9MjJ5zjrXKz0kPLGRiV9evpU4wnC459B0FVIRtAwOD3qznC7vfGe5qSl2LMY4GX6dPU1ZXpjd05HrVCGQKc9c1aiyxzzn0NJA0PHzMctxjrTLj92jZ6n2qwqKik46/pVG9YYO05btVIFqyhNKuRk81nXTjbhSAv0qec7uAdo6kms26yGIOcHqeuKtIckQXJwMJ25HNZ79cg5NSXTc8jj27VU3nkAZPatNjImRyOvJ9akV8jPTmqokxgHrQDnqeOopkMfK2cjr/AFqCUHGOtPkbKEnjHU1Xc5U56iqRlIqTfexVN8kk1auDjOOneqwGSM9+K0iYTZzHitt2oInGEQCsVV5rV8QfNq0+T0OKoxpucAdzit1scstz3/4G2Zg0cSnguc9Otey2+QuK89+Gtp9m0S2XbtO0GvQouFzg9K6KnY4lrqTik9qT3JzTiRz7VkMOuKQ+n86KDzwaYg47CndOaBj0ppPykGgQFucUU0kDk9KKdhFUY4/WlyMZx+dIF7YpQCBk9KCBwI6Z4zT16dOlJGDkcDHUknmpFxxjoe9AwXHH86eME00e3SnYzjBxUgO7+1KRjH6Yo69RzSjpjPFIBAef88U5etKF6fWnhcUhjQCc5zms3xYufCur5yf9Ffp9K1gOASKyvGbBPCOrt0/0Zh+fFOO6GkeERH5Pl6dqU5Dr0+hpsA+U9OuMikmwkigg++K5Wj3I6Glpql2LE7R27iugso1zgDPtWFpmGX5gAO/H866K0jVkDKR6Zz+lc09zrhsacCD5flwAAcdcVbhA3fMdwGcgdQKrogO0HqAMg96sIGCkA8HnHrUDsTKoLHJXnoD9KhlQHIGPqak29AF+b9aUhiMuD06VLBaGdIqqDgnnufWqFxuDcjPGDWpPld/fjFUZ1IJLZA9PSkaIwrnjrkkdM1Sabcu053A9u/8A9er+ocEkgYPQjjmsOWTD4Jx7jtWkVcJF0NggNnbn060xyTIOCevQc5qIShtpBA/z1qePGz5hk/XJ61VrGZGB5jAEYz0JFI6hlIxhh0xVhVDdQV9CTSTx4XdjAP6+lO4rGZMgwCODVOVQckD8q0pQd/PQc4qjN97nmtImcjo/hnHu+JFpntCx/wDHK98xzXhPw1AT4i2pHe3bIP8AuV7sBXTDY8nEfGV9SAOm3YOcGJ+n0NeA2n+qjGB90c+2K+gb3/jzn/65t/Kvn62YrGuM/cFZV+h1YD7RciY8beMnp3p7OWJwc5OPp7VE3CBQAB9aSJvkGefqK5Gj0kX1G0gr1I+lPUghSD34HY1XVyTnOe30qaHLNuVTt/nUtFouQxhRz1qZGYKcD5vem2w3OMjBHrVk5LHGPQ0JDb1Im3Mvde+apXZCjGOPYdKuy8H5iemRWfK5LjPAHbHSqSGtSlccIS/XOcVlXbHyyD+AHetW+3bSEOf5Vk3xcHbgAAYFWhtaGZc5HXoRyKzpPlYn6d6uXZKgnP4E1nySd849KsxkrDi3P04qXOV5btVRW3YPNTq3AFOxix5bKnODioJPXOf6U5+Tmmbge30BqkZsqTHJxmoYl+Zd3TdViboc9aZEMOvGOa0juYT2OL1g7tUuT/tml0eETanbJzy4qPVj/wATS6yf4zWp4Jh87xDaAjo2ea3hq0jkqaJs+oPC8AjsLbPGFFdSvCcen51j6LFttIs+grYH3fWtp6s5UtCQHgfnSggUg4HHWg8DkVABnA9/ejoTnrSZPbFJ060WEOJ9PxpmcHrSFvTOKZIeQO9UkIHcZJNFMY+g/GiqES7MH8KVkznB/SgH8eaduxg4rMQgXvzmnqMD2pB06/hmncZ560CDHOeuadjHtQW6UbucUhj+QcUoA5Iyec4NM3A0bvXoD1pAS9sdqXOO/FQ7x0oD+9KwyYEKuD2rA+IMqp4K1QkkblVOO+WFbG7k5Ncr8T5gvhQoSMyXMS/lk/0ppFQV5I8mgILngYplzky7Tk06P7xPf3pWXLgsM8dK5We5FGlpcZMOBu5+bOPauj0xAkK5IBPA96yNNUbOmew/rWzaKVJK4GOw757Yrnk7nbFaGvAoIIO4g9z2q1k5OMDPOT61XtpF2YYdOmecVOzgqRkAg44H+c1JFh5YEHBz/tE1E5YnOOoyQOlKSOQQMnrnIBpkmQQAML3IPWkxpEEpBbBABGMj0qC44Ugg59x61ZdcYJGM/jUMnCsMgY5yaixaMHUUKjOcgdjyK5bURsJZegPPHSuzu1AUh+V9a5jWFVWJAxzWkNxy2KFs5wCv3vzz9a2rdAqehI6Z6Vj2i/3RlenB7+9bduMEHBJqpELUc0QIUnjB4HXFJKoZfXB5zUzYIGep9O5ppYBSpHPrSQ2jIu1I/ujGeD2/GqUn3uCRzmtG5ILEDoR37VSIAY5/StomMkdJ8Ozt+IVicZ3QH/0E17rXhfgABfHunnr+6wD/AMANe6E4BJ6CumGx5GJ+MiuRmGUDuhz+VfPcOBEgxwOa+hXB8l89SD/KvntT8gHHLfhWNbodOA+18i2PmAGMjrSOxRGwc8fQU+MYTJIPHSqF7KdwTA+Y4C5rmSuz02X7UGUjsOmO1bUSHYM9PQ9qzNNULgEZK1q7+AD16mk0UWY0+Xn+XapRtycD5gOuahUgdTg/WlLKvLAZ7e1JIVitcktIMgFR2zUDIFjAYDIOM4zmnTtliGzntmq7l9mGHAHY46fzraK0NUmVbhMRhgflB2gZ/Wsi6JV2RnDHoD0rX3qqtnBHddvT8ax7xA42gbWOcseT7U7FqN9zDv2w7H7o6EdRWUXJLDsKv3+DIRg59ulZqtvJLDp0zQZVY2RJGSOKlBPQioYgd5Pt0qwcBeOnvTORoCxIPoKjJIGeCaecYAHAqJz7dKaJaI2Gc88jtRGP3ink8ilI4HJ55oX749K0juY1FocFrZxq90B/fNdV8K7f7R4mhBGcVyviIFdbugBj569A+Btv53iMnHCiuih8SOGsrRZ9K2ShY1A6Yq4OoyM1DEm1RgVIWXg9K0Zz2JQcnjrTQT07UisPWl/lSEGcdetMySaVgxJKnB7bhTcnJ7Y7+tNCFZgD14qJyMHNK2PqabnbjuaaEJwepopOtFUKw7PI5PrT1J6cVWWTPepVfng/WosRcl3EAZ60bz2NMzkZyeaXqRjvSsMeZDjr0pd5wKj7ZFL3+tFhjyx9qC59efemngdeaOo7/T0pAKXJPTNCyZGQeDSbRuPP/wCqpAuV7nNA7jRvbjtXE/FmQx6TpsWR89wzH14X/wCvXd7RxjHvXnHxjmAm0iDnhJJCfTJAob0ZdLWaOFjzjB4br9KlQhpR9c88VViYlQCeD+tWoUDsuBgAZPvXFJnuUzatTsVcHGRzgc//AK61YGAC9k6jB6VlKAFycZ9R3q9auPly2DjkGuVnZHY1YZiCAM5PY1ZFx8u0j5vyxVMlgoIGM85zTid6FmOD3yOD7mqQrl+ORc5YBc98dT6e1J5yYwpO7+6OxrMknAXJzzx905H4ihJwDkKSfu7h3Hahodi48gwQpA4zn0NVJJfnK5wp5I96rSTEFl42+o/x9KyvtEzSbcfKT0J5qUi4xLt5IzrgdOmO2a5bUJWIIk5IJ5HtW5K7OTuPzkZ59f8A9VY97Bxk4JPJx3q4ik7FeyLZXpkjsc1sxy4xgHnpx3rHjXaRjJYnpWhC4ZVGc5pyIRoBsoc9O4AyTUMrEnOeRxyKRWCgEcH+Lnmo5HzkAkHGCPWkkDkUpmKu3QHPr0quzZA574BNSzkbyoxu/n71CSS4z3/KtoowlI6HwM+fHmmIvYDIx0whr3dzlwo+prwH4dSrJ8R7fP8AAZOewASvfIlLDe24MTnHt6V0R2PJxDvMkbkHFfPMagzsnIwzZyOvNfQufmr55YiPUblSfuyuOf8AeNZVdUdGAesi1yE5P3eBj0rImLPejkY64PetV87SMqdwrGndknznAJxyKwjuem2dHZyYXpuyMgVcFwdgJK84OB1FZGnzZQK55H8J61fC/ugUJOf4T696HZGsWupejlyOoJOcZFPlnyhLfQCs/wAw4VUXPOee1P8Alc5JB7YJqC0kI2FIJbPXg9/wpmVAYEAnr8wFLIhZWx8o+nNMZFIwW7fTr9KpMvQjdyVGCfoOAayppPn+btk5NarWzyZICgY5G2su7tm3rnqDzntTuF0YWoAvyepz2rPCYDZz/jWxdqGypZhn9aoujbfQD2pmNSV1YpsPLGRjmgyEcYFSsn5Y9ahmOSB3pnOwJ4zTDyQT37U9QD14NNP3ifzpkNgW4Ax+NMYkOD708cU1sZ459R2rSJlPY4bxSCuv3Ge5Br074AIDrUp54AFeceMVA1skdGQV6H8BrgQ61KueSBXTQ+I4K/wn0gSB1/Kmn5hxUZl3EMOnalUk9DgVZzgrkHbyalBz9KrsOc96kViRyMUATduajY4o3dyelNbPbimhAxwM0w5znoKU4A9TQDlcmqEN2sQOcCil3Ac9PrRTFZGXHLuGMgGrAkYDk1UlgKZK9qfDIPut/wDroaOYtrN71J5nXPNVWTAyvHtSK3HvU2GXhL0H61KHFZ+4A55AqaN+nX8KTQ7l0EemTnpTgenNV0fpUitnjPNKxRP94e3rUgGKqK+cjgGrK5I7cYqWgJMgYP515N8Y5Q3iO0iU/wCrtBkehZif6V63/kZNeL/Fhw/jKdeGKQRD6cE/1pPZm2H/AIiOWSXgcduK1dPOWXB5IyB3FYqkjHTI9+1a+ngZQ46VxzPaps29rLgAqRjANWbONTw2COcevSorQl8HdkgZI9PSrcLMCDgDv+P9K5mjqT0Le5FUAHgjv61FJKXlKrwQMkDp9afD82VPy4PHPWnmPB4GfU4/pTWgJq5GY0mjJy7SE4JPTH9PwqB0CxNuJbjjHPfp9KuhsZBQdOvaq8nzM+MgHkqOtO5SZUdAW2oTtJ9OtNNqC5MZG0D1qZwokHXGOnp71X88eap2nuAO/wCApWNCK4QKSVG0Z6/pWNcyqpGOoPf1rfuthjBJDZ6elcxfsGZsDawyB2qoondEURYyYwSemBVwNsi7hjycCs+MFX68Z5HTNPnlATO75j/OrtczbNKOXcQFzgDHX+VRvNg8AdeMdaowXIVQC2W9acjbmJ9T2oUTNsc/VsZ5ogHmTqpPy7h+FRu3yj070jTC2srmc4HlxMw574wP51pEzmzqPgdpbah4i1HV5f8Aj3tiyL/tOx/oB+te5k4HNcd8I9J/sjwDpquu2e4U3MueuX5H6Yrr2OeK2Wmh49SXNK4q/erwDWY/J1y/jzgpdSgD/gRNe/x9sV4X42iEHi3VVIxmbf8AUMoNRNaHTgpWkyj5m6PIb+H8qyZhvVT1I9TV5GJAA5zx9arMoV2GAADjHpWC0PUbLFhJumTI2kfLz3rdjkJQheWPOO1YVuOODz69f8mtCKRCgwxGKmRcWXAu4rtU46CpdhwCuBx061HHcKxCRsCfU9KkQjuAfp3+tQzRSGMCxwCDkc5FPtrZIwQyr6kVIXVAT8pHXpwKeOQNueOw4/nTKc9CRtkQK4OO3asfUHHOAMD9atzuRG3JPPQ9qx7uVirAA4HTHGKNzNaamTcrgk4GOwFVGVgWOcr2H860FLSFjgHHeopI/m4PPqatClLoZ0o+U4HB7+tUZRt4zgA1rzR4BAHFZlyQvQYAHWmjJsrBvWnrnP4VAuAezduKmB646d6ozbBuMY49/WmE+1OZv5d6jJywq4mU2cv4xTGpQP2MYrZ+Fl79l8Rpk4DD1rN8aIc2jnupFVvC8pt9WtnXPDDJrqo6TTOCu7xaPryxm86CNhyCPyq2nPTJrC8LzCbTYm6jbW8vToK2mrM5kxSORmlQgfSmk+/FKD7cdM1I7j+KQn0pvI47etB7E0xXG55yOlIGwTzlqHOCeaYPbvVIVx2FZlLLll6E9qKcBRQK4joMYwM1WeAHJ4xVw4zzwKiOOeKhMwKygocHkfWnNEMl1yc9qfgf40seAcc07gV8bakTGcHip5oQAGQdetQY5I4zRcZYXiph2B/+tUCDH0/lTugIpDQ9SPMAzj61cjJ2qQfzqgn+syBV1Pu/d4zUsaLC84968Q+JZz431HgfKIxx/uCvbFz0x0/WvDfiKS3jjVs8kOg/8cFS/hZvh/4hz6nB3ZHHtWnYMAVPGT0GazdoIGePc1ahkAKBuoHXsK5ZI9eDOlgfhW6LnBPsB29604XVgOMtwMVzEM2TlH2HkcnjP+elacNyBHuOVAHp3rBxOpbGwhA4HU9Qee9ToRxuIDDnOc4rEW73ksVG4DGTVhJBMG++CR0B5Of89qFC5aVzQaYNkLIWycfL3zVG4ZoMqc7ur+w9/p6UrMCil42IRSY3zjHPf8agDLwH5HBAA+96/WrUDSKQSBpFVs/MTyGHzZ/wqtdfLyDsYjAxkk89qnmctODknBJy3zEY+ntWdfMj5YeYoIyrdDj1Ge3vRylxepHcagscRDcueMYBz9QKwpZTK771A24B+bgnPH0pZwyhlLyOVyQWx65/EVSmkUKdoAPPzdzn+eKpRsOdlsWvNdT8uCOAc9aZN+8hU45xwSOKpxTAxlSRgjPuPx9amik+Ug/dHQDmg5Jy10Fts7ssR6CtANj5cAbu2Oaz4sCLbyM8+1WN+5SF5H1/SgyuOlmI3gN3AAx0qZ7V9QFjpsXMmoXSRf8AAQQTmqcZ8yXOBkcYrtPhdp39oePxKwDQaTAWz28xuP6n8q0ijGtO0We4QxJbwRwxjEcShFHsBgUZyaVj2NInOa0PJJVrxz4q2/keLDKw+W4t0YY9Rlf6CvYxXnHxlsybbTL5RkI7QsfZhkf+gmk1dHRh5ctRHmqEqwI24/rSSEBwRtJI5zUW7oSR/jQGznIAzWDR6qZItwY+QKsw3KAsmYz0P0/z6Vkzvtb5T9c+tRJcNtChsdwMcUrG0NTciu8SbFbnPf1q9aX6vEysSW74GMCucZo2Q7R83XGePzp1vcsHITgMP4u9Tym3KmdO02IwDhfQsetW4512bt2R68VzEF3H5e0M4IHI6ip47/EoG5BxnaO9LlE4s17p92MMAOvH86y7gKAzMT6+pzTTc5zgqc84HX/9VVLi72r8xBAGcnvQoMmz2IJmVVYg479aiEoc9c8VmXN35z5UAr6c/nRDcBSFK4/2fWqsKcbItXEwxgH61k3Mmc84Pf2qxcyIWyX+XHGKzZZgXOBnkj6U0jnbJ4hxhiBjtShsE4xRH90k/lTuFwT06cUzMM8Z7+tQydjmpnPGfxqN+VP51UTORj+Ll3WNq3cORWJZNsljbONrA1veJctpEbY+7Jiuajc8dq6Ys45q59S/DmfztJjPJyoNdmDwc/oK8x+EN2ZdKhG7jGOtelBiQMV01N7nHDYf/F0py9Ouaap7nqacKgoU8009qcSBk9Kj3AAihCYjdeo+lNyOgPNDnPemhsEBFz6mqJZMvGMjr09TRRGDnnOaKAJW+YHp0qDOTz6VLuxkYJ4qNuSD7VmZkTHB9DRu+ankZGSeaicZ6NTFYs28u5drYNNliCMfQ/pVTcQQRwfSriSho+e3FAxFHtSnjj8qbx95c4pN2eMGgCRB8/GavRcAZ4z2JqnEDu981aBxggAc/WpZSRMOf4uR2rwrx583jbWOvEwGc/7Ir2wzFCcDAzxXhvjJvN8Zaq4G0mfv16ClJWizfDL94ZRJC5x7YHao+NpycE96tOuIycFvTNU+VLdyPUYrlPWSJkkKgqTnpgnp9avQTGONGLDJ6jGfoP61khzvwWyMYX/9dWrOT94A4+YHeQB7fypWOqDujoY+TvSRSrDJwcHHpV1ldtrQxSlgctsOAvsR3rHt5ovI+chSCFIVQQADnjNTNLGFco6BQO6bSM9c564pqxqmaYYRQ4SUNkbyTkZPcHP6YqqbhQGjGcMvGW/Gs55nkjjO87F4jYsULD1OMiopizsMEthcc5x70mO9i2lyqmdg4YgqFQd8/wAWazrq6CybhgDJ+Ut0OePy9KikOGIHysePl4wPUVRnwZQCBxkge/f6ZxRoJVEmOu58nJOSDlmbjJ65xWXc3AdCAMrnjipZJJHLMQOu/aB3zSSRIZWK5O85wDyO9JsiVQhtgXjKsM4OCPTnirsYEYIBHv7UxYguOw7/ANKeV3bjgjnv+hpGLdyQHew9OtWDgR5UfX2qCBSQODnj8KcX3D5Qe/b0pohkkbi1R7hwNsa7iPU/wj8TXsXwQ0o2PhE30wPn6hIZST1KjIH9T+NeNR2Umq6zpeiWvElzIrSH0B6Z+gyfyr6et7eKxs4LW2XbDAgjQY6ADArWKODEz6Erct/SpFGRUUY3HnPTvU61RyIUe9YPjnT/AO0/C1/CF3SInnRj/aXn+mK3ifwppI6Hp0IoKTs7nzGJP7vPegv8+A3PetHxRph0fxBf2eDsjkJTP9w8r+hrHbA5Xr1rKSPWhO6uF03BA5B5IqrG6ggkMQTg5qaTJHPXvn0qlKWXiM//AFxUG0ZWLTzhThSAx4zjpT7chhGCwaTocDr71nCRN44bcenOB+Iq1BcRbirDLZx93OKZ1wmrGoCFJCspJ47ikk+cEExlF7BSMmqwlO35SwDdcnqPcVNFI4zjBzjPpj2qki+Yf5dwYS6r8oAyc/4dTVa4ba/DGQYBHTHvV+VonQoqBnC4AVyMH3//AFis2QhkCoQSpJ24PH9KbRKZnSEggM7MoJIzx+gqEkoCN56ZwRV2YbFbAYd+cAisufJJ2ZI5BPvUMmbuiO4kwHUr8wO761BHgDdgYY9aWR/lO8AtjOR3ptt93pgE4/Cg5Jl6EsMHPGMe1SrkEr0qNMMyhQMDp61ZQbgMj6VJCRCzfeHSoWbJ98VZlXJOQBiqz+oHSrRnIo6+A2iS88hwa44Pzyea7DVsnQ7ojGBjP51wyv8ANW6ZyS3Pof4IT79PQE8j1r13dnJ/WvD/AIDT/wCjlW5AJFe2qecd66pa2OJLcmQ8dPpUg6e1RqPw/Gn5H1FQULzzkZHvTHGeTwKdu9ufWo25J5z7U0IaxBPH6U5fpn6UwHOelSqD3qiSRSTgDp1+tFKuBxRU3HYaeme3emE/SpMce1RsB78VJkIO49ahI29KkPXjr60Fcr/WmIpynGOSKmtJAPTaeuaSZMjH5VUQmOTI6d6rdAaIJjuCM/IwzTtuJMDPXimD/SIeD+8XpT7ZhJlXyrjr7VJRPECR1qbOV7fSmplF7ZxQx3DkgGkNCMo24LEe1eGeLwy+LtWB6/aD17cCvcQcEY59sZrwvxYf+Kq1clix+0MASeSeKU/gOjDfxCK3QMqjJJPHWormDDA8A+9WbHGACfm9PT2qzcRbiASMr6dq4Wz2EjFEGTljjHPH+etWAFXoeTgkKKsbOcH7uSfWpmhXbhyPn4+XrT5iloZ0hdFBByuMBR2H+FSSqUg+Zsbjx6n3qR49u0bSM8Z/wqvPuUuWBDgdDTNk7hFPPOXhhiK/xgdAfXip1kyjYzkLzg9D6VXtBN5rGOXYQD1Yr19PeqO/ypTH5pIHQ45zQ9hydy+HzCSTlvrVYsFO7aGJHf1psbb+FBz2+vrTzHuZjnnOB2xU3MWyF23Bh3YgE47UxVAm3MBg/rV4QgDkkEcCo/K2rxjOaLk2G+XyueT6Y6VMsXy89cnig7VwRye+KiuJMgqvDUkDFBCocE7iOaYhBY7idpBLn0UDJqIMdpHb1FVdUm8rTioJDXDeWMdSo5b+grRGUnZHonwH046lruoeILhPlhUJFkdHb0+igfnXtkjZPQnPGK5j4a6R/YngjT7dl2zSr9om/wB5uf5Yro4wXbH41ulY8qpLmkWYgcVKOKZGABmnGoJQGmMecd6VuDzwPr3qKU844poGeY/GLTSs9hqiL/rAbeQgfxDJX9Nw/CvMpDzwpBr6D8X6WNY8LX9mqgy+X5kXs68j+WK+fByctnJ6ZqJnoYWV427EH3HySSv1qC4j4LIcAjv/ACq/5GVJY4wegpkiA8bT069M1nc67GNKjqGZe3X6+tIJGjXII6Y5rSkh8tyRxnsKozxDcxGMnoKDSErOzJYZy7p1IIxk9QatRyABgxHbHA5/OsWECIbQWB3ep61c+cfOr8E5HH86aZ0p3NRR5kTJI0mxeQ2SV/EL1p0dqYMGRgQSNu4YB/DqRUEDOh37Aw7huRj6VZGFwpkB2jcCcfMPQf8A16vzBvoV7tI1OYyWJOM45H0Has5lRUkXGAT3PXHer97iQkjhd2QSfvenSqUgHTnjrxWbepMnoZUqjzNwBK/1oTIIzjtzVmbaFZThdvT2Jqa0gDMS3QjpSuc8tQhQsvuPbtVxCe44FPWLYfvc49adINgHAANSKxUucFQOnNUZTwc9fWrkzckHOR0qjO3Uds9K0iYzKt4C2i3iYydhNefKelejqC8FxEerxtgY9q86IxIwxg5rY5JHs3wIlw7qeAGr39emTzmvnb4FSEX0i5ONwPFfRKDoQK638KOLqyZCAM+nYU7jHT8qjXdkjipcZI9vSoGMbH4HrUZ5JA4xUrDkjNRN19/amhAvykd6nUepOfeoV6g+1WEGME9adxDselFPUE5GOaKVwK8MwdAe/pTnAwMc1iafd5C8/nW3G4YA9qTVjIjOR2/CkHJzjipSOOO3rUajBpARyjPvVKVeTxz6Zq+4GQTyOlVWHPPf9KpCIrWRo3yvBXqPWtLYGKyp361kspSYMPu9fpWnYuAuM5Q05DRZSQ7cEDjmlZsjjb9aQxjgggCmsCpwSCfT0qCh6sQysehPbrXz5qcv2rWb+cEHfcOQfUbjXumq3X2TS7q4wD5UTsM+oFfP0RYlScZPzH8eamo/dOrCq87mtYnjHQ9zjtWiq4UqflH+NZVqp69VH5VqwYZT/P1rhkevEb5fzDAwOlPRRuADcgZORxj0pzoQ/JyopxGfu8g8H2FQWOaMMNw9enp7Vnzwh0XcuCOcZ4q/v2nBxkeg6VTnO5jnj17VSYWMyQAp8wz6kcVV8lS2do74z6VoyxAIRxk802OBT90AmncZDFAucKDkgY9qtRwqpywBXP51IiBd2exwSKlZQGJyCuOOf1pXFYrbBsLHknt6VWl4z3bpirDucZBIPb3qnI2Xyc470AV5JgpIx05qJ3DHAOc0XByzEDHNV1boO/eqRmyxGCzYXOWIWpNDsx4g8baVp0XzRK6o2fQHc/8AKmQbQwZidi5ZvoBnFdb8A7AXmuanq0y/6mPapI6M5/oBWsFdnJXlaJ7pKVXCoMKBgD0xT7Y88nmq7cnru/DrVuIAY4561szzixnHApu76D3ppbng00H1qLDHlsDPbvVUtmUj3qSVwFNQRc85PBz9faqQFtHIK8e9eA+NdOGk+Jr+1QERF/Oi9Nj8j+o/Cvet3yglvxrzr4x6b5lnYasinMLfZ5T/ALJ5U/gcj8amSujbDT5Z27nmaj5QGB4/Wh1PBPPYe1EZBHP5+lSggKfrXOz14sryxhl2tn1/CqM8eTgjnOPcVrMgKY6c5+tU5osZYn8aVx2MiSPkgAHPTnFNhl8qLPJOeVNX5Yt69iB3PFVQqbguAQM9sU7mkJEsTqpB3Yz90+n4VJchXIkXcRxuz/PFLHbqwUnBCkVpmAKN20bMflRctzM5EyzMQQg49MVXntjndgBO/Na42jK/w9Qf61UlYMCMDrzSJ1ZnrahyCRk/SrEcYMZOAMelOiA3FecdjU6pwcDgjmkQyEqeMdPWo5iAvXnHX0qyU4OMkD9Koyt82TnFCQmVpuHXPAxyapyDaxJHHOD71bn6/TiqM5IAycjPPtWkTCauLbk+crN1ziuC1WH7PqU8eOjmu8j7bhgD0PeuZ8aQeVqolA+WZQ4rU5pI7P4GyBdZkUnuDX0qnTg9f1r5b+DUoTxFtPQgGvqOHHlr9K6/sROFq0mDZ3AipYzgYHXvSEfnT1wMVIDJMnnqKauG5/Pmg9wTkUsY7jr7UySRQeOnH61KnHX/APXSehAFKB1z1pCH56YGM0Umcj0xRQBwdrOUb5eo610dhdblA7H3rm7m3MTnGR6VNY3JjcAnitpRuYJnYhhkc/h60jjPI4PtVK0ulbapJyRnmtAYI9ax2GQdCf51DKDxkAZq1KmR8tQH5lyck9zTQFI8NjtVm2GOhqLjIz0qeEhQM8ZpsEXUbjjOPen4zjiooz1BHFO3cdCRmoLRy3xLuWtfCV4EIBuGWHOccMeR+hrxyMZfJyBXonxgvQU02xUg8vcOoPXHyrn8zXn0YDsMnr1rKs9kd2Ejpcv25O35SCRWlE2SCOuKzoAd4GMKOo9K0IRzgDg9ciuRnpRLEalgVH3RwR3NTLGxGCMEf5/KkQ4Gep6DPH41YxhflOenQfnUGiKhRnYkYzjofX2qCSI8BhtJ5PrWgQASeTgcVXmUB2LZz0Ge1BVjNeHoSMZ5zTVUqCMfXmrREYZ225L43NnrjpUbZwxP3SOaAsQliW47+1NkAIPJJHIzT2YDhRzUTYUDccjqcVSQmRMMHnAGPyqlOx+YdAe9TySZyTwD6VRmkwrkt8vrTIZXuX+Xap5A7VEDls9KXO5hnq3QetKoy+T34zVIzbDUGEWl3LE/M4EQPoSf8Aa9l+CVgLPwWsxGHu5Wk/AcCvFdZUm1togPmkcn8sAfzr6U8M2g07w9p9qoC+XbqDx3xXRTRwYmXQ1owWfBFW84UA4qpB+JBqyeeucelUzjFJ7cUmWBz26U3IBHr601m4/rSsMjmYlguP1qRB8oyMCoUAZjnOOlSZ4zjtxkVQDweOMHv7VS1nT01fR73TpMj7RGUVj/AAv1U/nirBPHLEnrwKAM9Gbn3osK9tT5xUPFK8cyFZY2KOPQjgirCkMc5/E10nxV0r+zvEgvI1xBfjzeOgkHDD+R/GuTSUKFYfqK5pxsz2KVTmSZdJCp7jr9KrykZA+638qlRsn2xzVabIk3NyOhFZM6EweMMFAxt7e1ReUUGAOPU1ZCkAEccUpG7OeP8aQ0RIqh8jj39Ktq6h8E4XoTntVJ9wYYI2jr7VJHCzfM2WP86C7Fm7j+Vdh4PQ1nmFwSEAz3J71qwuNuyQkLnOcZ/CmyxID8hBA6e9MLmckYXrk1KRhc9MdqkOADxg+lQyMSenJ/LFAmV5n5ODzVSXjhiDzyatuoxzkZ6VSlx0H3aERIgI+bdiqc4DFuMEVd25OQD+FRTryMckirRkysq4YdB3zWZ4xt/O0qKfq8LbSR6GtgqD8wzxwRSzW63djcWzc704+vatUc8zB+GU5g8UW2WwG4r61tG3W8Z7EV8ceHC1nrduTwUkwa+vPD0wuNKt2PAKCuqGsDhqK0zSHTAA+maJeRnoPelShRlqCGMCEmpVXB609VGD6UvGKLisIB1xSg8ev1oyMkU0nHOc4oEKx4z3oqB5O360UWEZV/ablIGfasCaLy2KkYIPWuwlUMMEGsjUbQOCRjPatYy6M59inp1ztYBjyPeugs7gYAJ49a5BgY3+la1hd5GCckUSiUmdL196rXMZXMiD6j1FFtPuAUn6VZyCo46VlsMzcg4IOQalQEYIGfxpLmBky8fQ9RUcMgfgHBqgLyE7euPp3qTDFenX36VXQkAYGPWpTOsUbO+CI1LkH0AzU2KueL/ES7+2+LrwK2Ut1WBPw5P6msWIfd2jPv2qNpzd3M9w/LSyNIT1zk5qzbgnaeMd+1ctV3kevh48sUi5AMyhV/M1fwNpVTgE5yzc5qrCuSo5x+VX4VG8ZAyT1rBnWizbRktnIyvc1ZUDcBjj+v1qFAM7WGP61ZTJAUjIA71JaGZzyBg9fbPtVaZCTkkDB5Gc1a3jaT1z0x61XlbYpyeKGikzNmXY3y989arM7AEYzwc89KtXLjcdowc4qm7ZHB+UU0O4xSQwGTuHWoZ5ASMDgU+RkA+Ukk8/hVd2yhZjxmmS9Suz5yCO3TNU5TuyW6H9att3xx7VWlwT7gdTTRlJkLDOfbt2FPVQM47nj3pQCGAHfmpI1HHTGeDVGYtrbG+8W6HbEblZ13KPdv/rV9L7QoCcEAba+fvBcAl+JekBhlY4t/HsDXv4J4x1Pc10U9jz8R8RPG2RwD+fAp+ePmP4VEoIHTP8vyp5GCe4x3qmc49iAuQcdvqagZskjoM8880krnbg8+lRIMnt6UIZZUY579qdkYyScdeKhYkdME9KhZj0GfXg0WEWyVAwTz6UmAe+f6VRJkzjaVHoDkmmFZfoPQU7AUPH+kLrHha6SJQ91an7TCPUqOR+K5rwmJssfmDA19Cqk/GOF7g9x3zXh3iXTDpGv3lpjCxvuT3U8j+dZ1I9Trw07e6VIWJ+Un8alJB/3vftVWMng1OjZ2jvnIrmZ6MSdFIXGef5U1lwWPehGx157U88nOMZ4z6VDNUQKuecZA7Vct0wmRgY6e1NiQEY2j61YRd3HJPXHQmpuUBUevHr61JtUodiFnPXnpUgwYzlQCeDk9DTAuGBHrz70JiKMyMHKkdOeKgddyjA5HStPA3OXygJ4BHJqrIm3JC8Z/KmJszmA4xg5PJqtKhyenPBAq86Acdveq0gJc4GQaaJZTkQgfKOOx9KrzqcKR0I4PrV2QD5gN1VpgduM5welWjJlXP3vcdKfA/wA6sBjb1prgkYxjng0iZ+8MD69q0izCaOZ1eA2etuQMIzCRfpX0x8Ob0Xnh23OclVAr588Vw77S3uB1U7TXqXwN1MT6e9sx5TjFdVHZxOKt0Z64CM4FSjA7VADgZXGfSkL8ZPWqMizuGaaWxnJqv5ueO9QtMQeQaLCLZde1QTTIh+du9VZpzn5eB61Vkmx0AJ9zVKIrlx5jk4zg+9FZzzgHAwc0VSiSbuR7c1HLGCCMcelCHoamHIrMxOb1K0x8wAH071lxuYXyp5HUV111FvUjAzXO31sUPAz+FbRdxLQv2N2JEHtWvDPuUZxxXIWkpiYf3fSt+0mDDgg4qZRKNcHIqpPAR80fBqWFwepqbGRxWadhlOGXnbICG96o+M7v7F4Q1SZThjD5an3Y4rUmjVuoBPauK+Kk7xeGYLcHia4UN7hQTT8yoq7SPL7cAduB6VqWpwRuyR2rKgGCD1rVtAHJBPHU+9cMj3Ka0NGFAW3ZwTwSen4Vct9yOQowaghxjABPoBVyKLcMAc9STWTNokwweSAewA71KAMDBIb0FLGhO1QMAfkaEG18Ae4pFodKCqdscc9MYqjMAwJY5yOK0HyxwOmOtZ07bWY4OT6ckUMpFC5yOFBwemTx+NUpF6cgDpVqbk/e6+9U5GBJ6cU0xNFeQ/MfXHWq7NkHI4xyDT5Qc5zz2FRSYIAPFNEtjJJADkDOKhA3ZLY/Knr82Bx7Z7UAZZR/DVIzkNUEE9BmpVA4PAPf3oGMg0KBn9aCTe+Hw/4uZZ5yB9mPP4Gvc0yTyPxNeF/D44+Jmnk87rVgv1wa9yVW4yTjPP0rphsebiPiLJYDAHzH19KHbjJOMUi88j/9VNlO1CG9MY9qZhYikYlhjGKfHkADAz1+lVkAbBPbpVgdBnIFMbJCwJ9vUUu5Rkgf/XqNuOh/SkOcHGBQKxKWUdRS7h6Ae9QZwMdT60o5AJOAO1AWJt/90fia8u+L1oF1GwvgD++hMbHHXaeP0NembyPuD3ya4r4rxiXw9byDJaK5HPT7ykY/Splsa0NJo8oQfLkD6j3qWM4JI5FREsqH07U4f7J5Fcsj14ExJOOf/rVJG5PysvI4PH61GiqdvUkc1LEOcgkE9Kg1Ret2zJ0HTjjpVlAF52jLd+9VEOxdwB/D0q7EpY5HPHTNQxgyKzDPGOx70OFyAucj9KmkQdVx7806VElQOG2kHG0ChAZlw7BiGyMngnmqshwWBwfxzV+VMn5OGHOT6VXlhPmfd4PtVIRTwf4hwKgkGRnjGMcnpVp4v4s9qglH7spjHemSyi5wBxndwKrSlQSDVmdcDnpVWROc8k9apGbRUkPQ9DTEGGIPQ80+T7wx06GonPznnj0q4mMkOv4/O0+5hOCduQD7VJ8INV+w+IfKYkB+2ajgbEgV+Q3B+lctZzNo/ihCCQI5evtmuinK0kzjqq8Wj7BWQNGGAHIzUTTL2rG0K/F5pkEgYEMo6djV5mzwB+tdLjZnKSvMCe/p0prPjv8ArUDM3bAqMnt/KnYQ6Vt2QBVcqTjgCn7ckDBqVYiecU9hFfbg8DmitBYhgFhmii4EsMmQMEfjVxHx1xmsK3lIxmtKCUHB6gnrUNGJfIyOoqleW529MirKNnPWpCAw5/I1KdhnI6jb4/eIOnWixnZTxhvQdM1t31tgEgfKeoxXPzxNDLuGMZ4xWyfMgR0cMm4ZHPrVmOXBA7ViWE4YYJwa1kZHHv6Vm0MtgA5HGK80+MUxVtJts4H7yUj8gK7/AHNHwFyK8s+Ldx5viC0QEkR2/P4tUvSLNaSvNHLW5yM4yelalupABxj171k2wzweMVrWr/KNo+YdCa4We1A14CGVVOM+npV+CMbSGJUgdQayoCd2ckEfrWmj5RcjnI4rNmyLMWUXBOO+alQJuHU49P8AGm8EcE5z1zTQWBAUEZPQcHFKwxJ++GHbIBrOuSOdvJznir0rbFJwG6/hWXOSzyM/Tp9aCrlOdwcjsD196pS8ZGTxyc1YlycjjPt2qnMSWJGMdOtOwXGPy2RVV85PB5/nUwzuH+c1DICGJPWgkaxG3oKTB3EE9DxSYyTnvSqpyMnOPyqjMl2/KQelGSO3Pp7UjcAep7UIc8Z70CNXwi/k/EbQGycOrJx3PNfQMa4GWHt+NfOWkT/Z/GXhyQY/15XPrz/9evoncS3vXTD4TzsQveJ+vcZ9KqXT8Dr7mpdwAPXAqq5LSd6tGA+IdzkDsBUwOeCcevFMTgcd6U+nSgTH9uMD3zTDyQaTgYA5pDy3J5oEB6kAcjuOlOLdCSOeKjJ7Ac00cEk/Mf60Bcf97ndgCua+JCB/CM7AEgTRHP410qqXOW59BWJ8SEx4Ku8nBEsXT/epS2NKb99HicmASBmnITgEck0Hl845xzmhMZ4FcjPXiSxtwe+e1TRH5sdz1qqThjxzmpocnBHXvWZtE0YQQRg5Hp3q0Zdijb1/lWdGSGBWrAbjkEn1pWKL6vujABIOeKeocAMcenB7VURixVV4xwRUwXAUE5X2/rRYVyTZ8vAAUdz1qCb58fLtAHHtVkEFD/DxgYqrdA4GT155pk3Ks4AU8jnmqWMZLc5q2zK3Utg9c9c1WlOAeDn3qrCKUyksdvftVOZeeMircmBzzn+VVZzwc4+tNEMoSZU9eTVV8bgc9asynIOR+NU5m4H14qkYzAEBxk+2a5zxhGU1GKZekig5963c8Yxkis3xXHv0qKXHMb4z7Gtkc0kev/CHWReaKsLYJQY59a9GXecHt6V87/BXUzDrDWzNwxBFfSMEZKLwBx1Fdt7xUjg2biQmEnr396abbJGCa0VjHHH50uwfSp5hlGG3IPXn1qcR47VOF4zikale4hoUYwBxRSMSFz270UxGFGoU8HmrsEnPJ4/Kqm3I7U5CMj2q2YGxFIGAweanVxwT+tZUMhGOn41dRiy5zmspIpFxwGXmsbULPKkrWshO0enSkmTeuCBzRGVgaOQV2gmwenvW7YziQKTnNU9StPlLDg+1ULWZoZSCOBwa1autATOqUqy85/rXjXxQJ/4TCROm2GP34Ir121nVxkEDHWvGPiVJv8a3xGfl2LyPRRWM/hZtQ/iIybUjdzWrbH1x/Kse3OdpGea07ZtxGMZzXCz2obGxbkYJGefU81diY7cgn1x6is2IjPy4xnvV6BtygbyMelSa3NS3fdI3BzjIx2qSUEPzuU44JqvbvlwBwcdff0qbOU5PX5st3osFyvKdozkKPfrWbcuQOD8ufxNXLltvG7APJyM5rMuG5OM89fWkUilLkA89Kqbgz49OakmYjIAzzxVQttYeh9utIY/AB46E/jULNj15pzMeSCDmq7MeM0yWOXtxgZqRRgdT71EgyN3HtVgYbaAMd/amQg24IyaB96mynaQKXJz7igRXv5Db3+i3A6x3Q5/KvplNuAwOcjI96+XPErkWNvIp+5cK3P0NfSWmXXmaVZzE/fhQ5PXoK6Kex5+JXvFueTaO2TxTIhgZPXNQKTJJubpVlcjjnH0rU5iQYxQeMdFH86Tk55wDSbgo7k0CBSc/KoA9fWmyHnAPPdjSSMdpLtsA61Efm+6DgdWP9KBDgwzhByT17VMiDGWPXqKji5J2fnip1bA68DvQBMuFHUYFcz8TXA8G3AHUzxDP4k10IcZ5Oe3Ncl8VJSnhRRu+/dIMD2BNTLY0pfGjyOXhiCeTyaavAPrilYg85yfQ01ySPl71yM9hDuSxxwD3NTRNwEPGP1NQqxZOnzLx+FPUAHJGOeCe9J7GsS4jHIwOfXNW0bgnIIUVRjcBTycE9MVKc4BBxnoDU2Hcu2rAnp8wq0SXJYkg+3Aqhbkqp65/rVxSCCCDz1zTsJljadwwSpHXFVbp1yy54HX2qQyMI8DoOQe9U5WJj2twByMmqSJKjNz+PWoJjwe565p8vcA557VWd+MHGelAXI5SN3OeeeO9UJT1wePerT8FjwMd6oy5JOTx1p2M2yrMwxjORVJ+HyeasXGc5qjNJke4qomUhHfDg55puqqLjRLgY5ADY+lQs5//AF1NCwkt7iPrujPBrVbGEtzI+H1ybbxPZsDjcdpr7A09t9pE/qoNfF/h2TyNctG6ASivsTQJlk0m3Ib+EV1Q1p/M4KmkzWJGADTd3X1qJn4Izg1G0gzyaVgJGfA5z+HNRtLjoKieQDPINV3lBOD2qkiSZ5u2cg0VRmlbouM+9FXYQ0Nlc9qQKN2cdTVW3lOfmI9uatblI4OTQYEik/w9u1WoZMkDOM1SDZHX/Cnq+3mk0UjVRuAMmp13DGMCs+KYEAH8Kto4NZNFBPFuWsDUrMqS6gge1dJkYxxxVa4iDocd/WqhKwmc/Y3RjYKxHFeT+O5jN4s1CQnq4/kK9Wv7UxMWQfL16V454tf/AIqC9LEk7/6U63wXNsP8Yy0bIGcVq274281iWpBXgjFa9s3BPJNecz2Ys1EbIxnJ68Vfg3KBtAz2APSsyAjIBx+FaEZI2kLUo1NS0IXaZN2R1xzk1Ydx5ZGD2Ix0JqrbMQhYL+PepmZvKydq460wM+5kAyRySD1NZc7nAI6d6tXT7iRj5lJ6+lZ1w5U7enAyaVikQTtlvl6VWbPIOOfSpZGBPGBjrkVCW56ZqRsjbjIP86hzubI6etPlYFs9O/41GnG7HFMhkwbHC8kdvWp0bC4zmoEGADxntmplORjAyaYDXwfcD1ppZScetErfjUXmYPNMkq+IstpTj0kQ17/oTN/YOlIDyLZCfyFfP+tndpUvoCp/WvoDw2m3RrDjn7PH+Pyit6Jw4nobMS7VIAGQc1L0Gd3J9ahBzjk81IACBnFanGPz2J5prNjBC8dqYzhfugk9OBUZkcsckBfQdRTEPPJLDB7Zb/ClXhu7/oBUSt83zc+lPTnJbhR2WgCcHnHBNOznp+LNTE/2VG3tmpMZ+8Mn2pDEX0AzjvXE/FyTGj6bED9+dmx7Bf8A69dzk4PyjjtXnXxfkIfSY8Y+SRsfiKifwmtBe+jzh/RqAQOhwMfnTX+91/8Ar0ucZ7NXKz1oiK3lsM9DxUytufAGAO3pUUnIBxnvQG+bOAaktF3OU+XgDsKcu5QjZ5XpVdH4PXHGamjYZIPUjgetAzQiZHA3AD19M1YUqNpxnjkKcis2HGOeB6VYjOGGMZzVJXE3YvOMgcgDvntVOUFkkOOnerEjlRuB6jHHNUppCSM5PGKdhXK03yg4IyR271Rc8H+dWZWxuIIGOnFVJWHA744oEyKZiAOQfaqcjjBA47YqS6cDK9SO5qk8nynOM0EMhuGyDgc46VmyNnOKuTtl+oOeOe1Z0xO48Djj61UTORDIdp44/Gp7VyJgPUVSlPP8jS2cn79BnoetaoxkYMT+TqYPTbKD+tfW3gu587QbcqeAvUV8iXx26hN/v19P/DGfzvDUHso/lXTQ1i0cNfSaO3aTaOCPpULyD1xmoy3HNVpHHrmtEiCZ5OOtQSygEc1XduPvEmoJGTI5JNWkImeck8c0VUeT32iinYV7FbT71JlVgRg962EcHBrz6VpNLn3IS1ux7fw10+lags8YO76c1LRitTokYE5yKAyuSeevU8VSR+MKeB2zVhJAevHFIZOsmM5HFXYJcgc4FZrEEd/anwylScnjpUtDNmOQE4qXqDkVnRyn/Jq1DNuBBOD/ADqGhjbmAOPr6V8/ePFEPirUI8cCXp+Ar6H3A9enTivnz4nKYvGmojGMsrfgQKU9YGtDSojNs3yBmtW2fJ5zjpWDbSAY5J+ta1vLyp7gVws9eBswycgA1djk3Lhuc9cmsi3ZiRz3q/BwMDp15pG2hsWzyZKqTz/FU07/ACYz82OveqNrLhuefWieVhkMAfQ+lUhNkUuArE8kdBWZdNuG4jjOcVcuWwg2n7w/KsudhnkYI/WpZSIZOT8vU1GXwegx3p0uFQP69arhsDIHFTYpsdIxYjavTkmo1BYc/nSl8j7x59aYjEKARyetBKLIztGOnpUi9jn86gY9g3btTlbj0780CYsmOfXpVfPze1Pdj6k1Ac5NMi5Fqrj+zLjsAB/MV9BeGJS2h6dtHBgjOT9K+d9XbbpNzjP3QP1Fe/8AhIMPDWk+n2ZP5V00epxYp7HRKwK8nFPLZXC46cfWoYzgEnqe9RvNglVGD1rWxxsldmI+9gHuBUQK5JUAnuT0qNj08xmYnkL05qSNSfv/ACj+7VWsIlUGRcgkL/Op0AGNxyey1EQMZJxjlRmplIBwFGfXNSwRIpJAO38KduPGRjPvTD0ycn8aXjHQ0hj856HOO1eX/GGUf2tp0ZOAtuTx7tXpoc7civJvi3IX8QWq9lthx+JqKnwm+H+M40N6YprtgHk47Zpm7aD15okc7c46frXKz1EO3sBxyT1ppft+tIxyQDUFwjPHiFtjdd2M9O1SXc0VkG30x0FSxjA3NnHSsyJiSCT055rQifKjceFGcDvQh3L8b7enQCp42BAOBkfyrJilYuSMg/zq1BIxOcHjjHrVolmi53kDGTjg1QnJDHPbsKtIxCnJwvTmqcx3E84P86ZN7FaYktyRVOaTOemB3qzJjB3fnVC4zknOO9JhcrXDZwexqlI3yk8VPM557Vnzy43dCB3oJZFJIDkA8VSlbAOeSe9SSOOpGDVGaQADrWiM2MmfI6Ej+VNt3xMD6GoZH9TxSQPlxzWkTORl6mf+JjN/vV9EfCC53+HIVGeFAJr501Js6hKR617z8GZE/sKME5OMYNb4fqcWI+JHp0kig8nJqNpcggelNVvVSM0j8k4z/hW5kQEnOD0qJiB2H41I5Cjk5NV3kUZB9KpCZFM4xg8CioJpQF45op3sKxkB1mjaN+/asRZJNLu9yZMRPT0rau4dp3rWbdEFORn1zSaujCO9zq9M1BLmIEHOa1IpARXnFldNY3OFP7tjwPSutsbsygYPJ71K7Glup0PmE4OeacHwTVKOXKAjvUokHJOSfaiwi7HNj2HXFWYpypyM8Vk+aAQKnWQj5c49qTQ0bgk3AMDXgnxa+XxjcEdGRDz9K9lt7oDajk7SeMeteOfGVNnilZM/6yIH9cVEl7rNKWlRHLwy4x16dK1LRywFYVs+7Pr3rUtmC464rgkj2IbHQW8nyjPWrsMm7g/rWNbyDaOTz3q3BJnqDjvUo0NyCRcgbj16VLcsdpBZT3IHSsyBjySSc8j29qmeVmUbT29KoXUieXAk5PTABrOlOD/jVq4crgE5zzwKoXLcgFsc9allIbI2AMniq8rDIAOM/rTXkyMfr61AXJ5xUg2WXIPA7DFNU4OMnmmoeD+lG/A5GD/OgETKfm9zwRTucAc1GGBHpign9aAFZsZOaidhxt/nUUjHJxUZcn2oRDIdZfOmy9izqp/OvozQYxHpFghONtvGP/HRXzZqhzHawgn97Oq19LWR8u0gQjcFjXB/DFddBaM4MS9i/vGMDPrxUZdpGO0ZIOM9sVE0pfbnCr3oRyxCoPl+tb2OQsRLg5xuY9yelTgA43kHPaokixjeevYVbSMADgdOlSwEALAb8dOmOlSoMYAxSDA/xpR161Ix69MAYz60HI+6M9uTTGcDGc4xzVe4mAwMEknpmnYB0sgzycV5P8UXD+IYegAt1B/M16ZjefmJJPavL/ir8niKH5QP9HXj161FVe6dGG+M5BmIyKTdlMN07VC7/MNxz6U3ed2MkCuNnpomY4wRyab5hG4j04qMt6Uwscj2pFkiyEuF52+561Z81pH5AGDms9WBPtnNWYpOBnPvQhGlEeeDjjODVqKQDPPI9KzVdckZODU0chYEZxnk1SAv+YTuOeD71Xll6D+91qJpm9cenFV5pCDnPPaqJHSvjoenas+eXnrU0zkKT3rMuJOevHepYhs8gVu4I71mzyZOcY/rTriX5hyaqPIM4ppCY2Vs9s1QnYn6VLNJ1wapyvwTVolkTtgdaIGPmLg1A544JxS25w4781aM5FK8bN7IT617p8GZVGjpkA9q8EuGzcyH3Ne5fB1gNGXPOa6MNuzhxG69T1QSHHB69KZI7YALY9T0qs02MknA+lNeUkfNzXSZDnfOcnJPaq8zjA3Ypk1xtBA64qnNcYXknmncVhLqdVJA/Gisa9utrk96KhsaR//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     Pink scaly patches of skin on the front of the knees in a child with dermatomyositis. Doctor&rsquo;s call a rash like this \"Gottron&rsquo;s sign.\"",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; 2012 American College of Rheumatology. Used with permission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_39_5751=[""].join("\n");
var outline_f5_39_5751=null;
var title_f5_39_5752="Acetazolamide: Drug information";
var content_f5_39_5752=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Acetazolamide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?6/25/6549?source=see_link\">",
"    see \"Acetazolamide: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/57/28566?source=see_link\">",
"    see \"Acetazolamide: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F129795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Diamox&reg; Sequels&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F129796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Acetazolam;",
"     </li>",
"     <li>",
"      Diamox&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F129842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticonvulsant, Miscellaneous;",
"     </li>",
"     <li>",
"      Carbonic Anhydrase Inhibitor;",
"     </li>",
"     <li>",
"      Diuretic, Carbonic Anhydrase Inhibitor;",
"     </li>",
"     <li>",
"      Ophthalmic Agent, Antiglaucoma",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F129800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     I.M. administration is not recommended because of pain secondary to the alkaline pH.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Altitude illness:",
"     </b>",
"     Oral: Manufacturer's labeling: 500-1000 mg/day in divided doses every 8-12 hours (immediate release tablets) or divided every 12-24 hours (extended release capsules). These doses are associated with more frequent and/or increased side effects. Alternative dosing has been recommended:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Prevention:",
"     </i>",
"     125 mg twice daily; beginning either the day before (preferred) or on the day of ascent; may be discontinued after staying at the same elevation for 2-3 days or if descent initiated (Basnyat, 2006; Luks, 2010).",
"     <b>",
"      Note:",
"     </b>",
"     In situations of rapid ascent (such as rescue or military operations), 1000 mg/day is recommended by the manufacturer. The Wilderness Medical Society recommends consideration of using dexamethasone in addition to acetazolamide in these situations (Luks, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Treatment:",
"     </i>",
"     250 mg twice daily.",
"     <b>",
"      Note:",
"     </b>",
"     With high altitude cerebral edema, dexamethasone is the primary treatment; however, acetazolamide may be used adjunctively with the same treatment dose (Luks, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Edema:",
"     </b>",
"     Oral, I.V.: 250-375 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Epilepsy:",
"     </b>",
"     Oral: 8-30 mg/kg/day in divided doses. A lower dosing range of 4-16 mg/kg/day in 1-4 divided doses has also been recommended; maximum dose: 30 mg/kg/day or 1 g/day (Oles, 1989; Reiss, 1996).",
"     <b>",
"      Note:",
"     </b>",
"     Minimal additional benefit with doses &gt;16 mg/kg/day.",
"     <b>",
"      Extended release capsule is not recommended for treatment of epilepsy.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Glaucoma:",
"     </b>",
"     Oral, I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Chronic simple (open-angle):",
"     </i>",
"     250 mg 1-4 times/day or 500 mg extended release capsule twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Secondary or acute (closed-angle):",
"     </i>",
"     Initial: 250-500 mg; maintenance: 125-250 mg every 4 hours (250 mg every 12 hours has been effective in short-term treatment of some patients)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Metabolic alkalosis (unlabeled use):",
"     </b>",
"     I.V.: 500 mg as a single dose; reassess need based upon acid-base status (Marik, 1991; Mazur, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Respiratory stimulant in stable hypercapnic COPD (unlabeled use):",
"     </b>",
"     Oral: 250 mg twice daily (Wagenaar, 2003)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F129820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/57/28566?source=see_link\">",
"      see \"Acetazolamide: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     I.M. administration is not recommended because of pain secondary to the alkaline pH.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Epilepsy:",
"     </b>",
"     Oral: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Altitude illness:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Prevention:",
"     </i>",
"     2.5 mg/kg/dose every 12 hours started either the day before (preferred) or on the day of ascent and may be discontinued after staying at the same elevation for 2-3 days or if descent initiated; maximum dose: 125 mg/dose (Luks, 2010).",
"     <b>",
"      Note:",
"     </b>",
"     The International Society for Mountain Medicine does not recommend prophylaxis in children except in the rare circumstance of unavoidable rapid ascent or in children with known previous susceptibility to acute mountain sickness (Pollard, 2001).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Treatment:",
"     </i>",
"     2.5 mg/kg/dose every 8-12 hours; maximum dose: 250 mg/dose.",
"     <b>",
"      Note:",
"     </b>",
"     With high altitude cerebral edema, dexamethasone is the primary treatment; however, acetazolamide may be used adjunctively with the same treatment dose (Luks, 2010; Pollard, 2001).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F129801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Oral: Initial doses should begin at the low end of the dosage range.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F129802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Use is contraindicated in marked renal impairment; creatinine clearance cutoff not specified in manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer every 12 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Avoid use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Moderately dialyzable (20% to 50%).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peritoneal dialysis: Supplemental dose is not necessary (Schwenk, 1994).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15671258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use contraindicated in patients with cirrhosis or marked liver disease or dysfunction.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F129772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, oral: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, sustained release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diamox&reg; Sequels&reg;: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 125 mg, 250 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F129756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F129776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: May be administered with food. May cause an alteration in taste, especially carbonated beverages. Short-acting tablets may be crushed and suspended in cherry or chocolate syrup to disguise the bitter taste of the drug; do not use fruit juices. Alternatively, submerge tablet in 10 mL of hot water and add 10 mL honey or syrup.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.M.: I.M. administration is painful because of the alkaline pH of the drug; use by this route is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: No specific guidance given by manufacturer, but I.V. push at a rate of up to 500 mg over 3 minutes has been reported in a clinical trial (Mazur, 1999); a study to assess cerebrovascular reserve has used rapid I.V. push of up to 1 g over &le;1 minute (Piepgras, 1990)",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F129848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     R, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR, NS,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, R, SL.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration:",
"     </b>",
"     <b>",
"      Compatible:",
"     </b>",
"     Pantoprazole.",
"     <b>",
"      Incompatible:",
"     </b>",
"     TrophAmine&reg;.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Diltiazem.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Pantoprazole",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F129775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of glaucoma (chronic simple open-angle, secondary glaucoma, preoperatively in acute angle-closure); drug-induced edema or edema due to congestive heart failure (adjunctive therapy; I.V. and immediate release dosage forms); centrencephalic epilepsies (I.V. and immediate release dosage forms); prevention or amelioration of symptoms associated with acute mountain sickness (immediate and extended release dosage forms)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F129839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Metabolic alkalosis; respiratory stimulant in stable hypercapnic COPD",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F129850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Diamox [Canada and multiple international markets] may be confused with Diabinese brand name for chlorpropamide [Multiple international markets]; Dobutrex brand name for dobutamine [Multiple international markets]; Trimox brand name for amoxicillin [Brazil]; Zimox brand name for amoxicillin [Italy] and carbidopa/levodopa [Greece]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F129840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Flushing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Ataxia, confusion, convulsions, depression, dizziness, drowsiness, excitement, fatigue, fever, headache, malaise",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Allergic skin reactions, photosensitivity, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Electrolyte imbalance, growth retardation (children), hyperglycemia, hypoglycemia, hypokalemia, hyponatremia, metabolic acidosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Appetite decreased, diarrhea, melena, nausea, taste alteration, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Crystalluria, glycosuria, hematuria, polyuria, renal failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, aplastic anemia, leukopenia, thrombocytopenia, thrombocytopenic purpura",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Cholestatic jaundice, fulminant hepatic necrosis, hepatic insufficiency, liver function tests abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Pain at injection site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Flaccid paralysis, paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Myopia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Hearing disturbance, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F129780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to acetazolamide, sulfonamides, or any component of the formulation; hepatic disease or insufficiency; decreased sodium and/or potassium levels; adrenocortical insufficiency, cirrhosis; hyperchloremic acidosis, severe renal disease or dysfunction; long-term use in noncongestive angle-closure glaucoma",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F129760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: Impairment of mental alertness and/or physical coordination may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfa allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonylurea allergy is specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe. Discontinue if signs of hypersensitivity are noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic dysfunction; in cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory acidosis: Use with caution in patients with respiratory acidosis; may worsen acidosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aspirin (high dose): Use with caution or avoid in patients taking high-dose aspirin concurrently; may lead to severe adverse effects including tachypnea, anorexia, lethargy, coma, and death.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to side effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Increasing the dose does not increase diuresis and may increase the incidence of drowsiness and/or paresthesia; often results in a reduction of diuresis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; I.M. administration: Painful because of the alkaline pH of the drug; use by this route is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F129837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F129765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Carbonic Anhydrase Inhibitors may decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Carbonic Anhydrase Inhibitors may decrease the excretion of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Barbiturate): Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of Anticonvulsants (Barbiturate). Specifically, osteomalacia and rickets.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of Anticonvulsants (Hydantoin). Specifically, osteomalacia and rickets.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Carbonic Anhydrase Inhibitors may increase the serum concentration of CarBAMazepine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of other Carbonic Anhydrase Inhibitors. The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Management: Avoid concurrent use of different carbonic anhydrase inhibitors if possible.  Monitor patients closely for the occurrence of kidney stones and with regards to severity of metabolic acidosis.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): AcetaZOLAMIDE may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flecainide: Carbonic Anhydrase Inhibitors may increase the serum concentration of Flecainide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Carbonic Anhydrase Inhibitors may decrease the serum concentration of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Memantine: Carbonic Anhydrase Inhibitors may decrease the excretion of Memantine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetFORMIN: Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk of developing lactic acidosis may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methenamine: Carbonic Anhydrase Inhibitors may diminish the therapeutic effect of Methenamine.  Management: Consider avoiding this combination. Monitor for decreased therapeutic effects of methenamine if used concomitant with a carbonic anhydrase inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of Primidone. Specifically, osteomalacia and rickets. Carbonic Anhydrase Inhibitors may decrease the serum concentration of Primidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Carbonic Anhydrase Inhibitors may decrease the excretion of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Bicarbonate: AcetaZOLAMIDE may enhance the adverse/toxic effect of Sodium Bicarbonate. Specifically, the risk of renal calculus formation may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Carbonic Anhydrase Inhibitor Diuretics may decrease the serum concentration of Trientine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F129768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F129783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F129805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F10912707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In a case report, low concentrations of acetazolamide were detected in the breast milk and the infant serum following a maternal dose of acetazolamide 500 mg twice daily. Acetazolamide concentrations in the breast milk were 1.3-2.1 mcg/mL, 1-9 hours after the dose. Acetazolamide concentrations in the infant serum were 0.2-0.6 mcg/mL, 2-12 hours after nursing. Maternal plasma concentrations were 5.2-6.4 mcg/mL, 1-7 hours after the dose. All levels were obtained on days 4-5 of therapy, 10 days after delivery. Due to the potential for adverse events in a nursing infant, breast-feeding is not recommended by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F129784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with food to decrease GI upset. May have additive effects with other folic acid antagonists. Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F129782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 12-hour",
"     </b>",
"     (AcetaZOLAMIDE ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $429.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 12-hour",
"     </b>",
"     (Diamox Sequels Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $732.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (AcetaZOLAMIDE Sodium Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (1): $48.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (AcetaZOLAMIDE Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mg (100): $66.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $76.79",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F129770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intraocular pressure; serum electrolytes, periodic CBC with differential; monitor growth in pediatric patients",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F129785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acetadiazol (MX);",
"     </li>",
"     <li>",
"      Acetak (PE);",
"     </li>",
"     <li>",
"      Albox (JP);",
"     </li>",
"     <li>",
"      Apo-Acetazolamide (MY);",
"     </li>",
"     <li>",
"      Azol (TW);",
"     </li>",
"     <li>",
"      Carbinib (PT);",
"     </li>",
"     <li>",
"      Cetamid (PH);",
"     </li>",
"     <li>",
"      Diacarb (RU);",
"     </li>",
"     <li>",
"      Diamox (AE, AR, AT, AU, BD, BE, BG, BH, BR, CH, CL, CO, CY, DK, EE, EG, ES, FI, FR, GB, GR, HK, HR, IE, IN, IQ, IR, IT, JO, JP, KP, KW, LB, LU, LY, MT, MY, NL, NO, NZ, OM, QA, RU, SA, SE, SG, SK, SY, TH, VE, YE, ZA);",
"     </li>",
"     <li>",
"      Diamox Sustets (CO);",
"     </li>",
"     <li>",
"      Diazomid (TR);",
"     </li>",
"     <li>",
"      Diluran (CZ);",
"     </li>",
"     <li>",
"      Diural (UY);",
"     </li>",
"     <li>",
"      Diuramid (PL);",
"     </li>",
"     <li>",
"      Evamox (PK);",
"     </li>",
"     <li>",
"      Fonurit (HU);",
"     </li>",
"     <li>",
"      Glaucomed (CO);",
"     </li>",
"     <li>",
"      Glaumox (AU);",
"     </li>",
"     <li>",
"      Glaupax (CH, DE, HR, JP, TH);",
"     </li>",
"     <li>",
"      Glauseta (ID);",
"     </li>",
"     <li>",
"      Huma-Zolamide (HN, HU);",
"     </li>",
"     <li>",
"      Ledamox (JP);",
"     </li>",
"     <li>",
"      Medene (TH);",
"     </li>",
"     <li>",
"      Oculten (DO, SV);",
"     </li>",
"     <li>",
"      Odemin (FI);",
"     </li>",
"     <li>",
"      Renamid (HR);",
"     </li>",
"     <li>",
"      Stazol (PY);",
"     </li>",
"     <li>",
"      Synomax (IN);",
"     </li>",
"     <li>",
"      Uramox (IL);",
"     </li>",
"     <li>",
"      Zolmide (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F129759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reversible inhibition of the enzyme carbonic anhydrase resulting in reduction of hydrogen ion secretion at renal tubule and an increased renal excretion of sodium, potassium, bicarbonate, and water. Decreases production of aqueous humor and inhibits carbonic anhydrase in central nervous system to retard abnormal and excessive discharge from CNS neurons.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F129779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Capsule (extended release), tablet (immediate release): 2 hours; I.V.: 5-10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: Capsule (extended release): 8-18 hours; I.V.: 15 minutes; Tablet: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Inhibition of aqueous humor secretion: Capsule (extended release): 18-24 hours; I.V.: 4-5 hours; Tablet: 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Erythrocytes, kidneys; blood-brain barrier",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Capsule (extended release): 3-6 hours; Tablet: 1-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (70% to 100% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/39/5752/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 97.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Basnyat B, Gertsch JH,. Holck PS, et al, &ldquo;Acetazolamide 125 mg BD is Not Significantly Different from 375 mg BD in the Prevention of Acute Mountain Sickness: The Prophylactic Acetazolamide Dosage Comparison for Efficacy (PACE) Trial,&rdquo;",
"      <i>",
"       High Alt Med Biol",
"      </i>",
"      , 2006, 7(1):17-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/39/5752/abstract-text/16544963/pubmed\" id=\"16544963\" target=\"_blank\">",
"        16544963",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chapron DJ, Gomolin IH, and Sweeney KR, &ldquo;Acetazolamide Blood Concentrations Are Excessive in the Elderly: Propensity for Acidosis and Relationship to Renal Function,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1989, 29(4):348-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/39/5752/abstract-text/2498399/pubmed\" id=\"2498399\" target=\"_blank\">",
"        2498399",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chapron DJ, Sweeney KR, Feig PU, et al, &ldquo;Influence of Advanced Age on the Disposition of Acetazolamide,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1985, 19:363-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/39/5752/abstract-text/3986087/pubmed\" id=\"3986087\" target=\"_blank\">",
"        3986087",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Corbett JT, &ldquo;Acetazolamide and Purpura,&rdquo;",
"      <i>",
"       Br Med J",
"      </i>",
"      , 1985, 1:1122-3.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hackett PH, Roach RC, \"High-Altitude Illness,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(2):107-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/39/5752/abstract-text/11450659/pubmed\" id=\"11450659\" target=\"_blank\">",
"        11450659",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heller I, Halevy J, Cohen S, et al, &ldquo;Significant Metabolic Acidosis Induced by Acetazolamide,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1985, 145(10):1815-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/39/5752/abstract-text/4037942/pubmed\" id=\"4037942\" target=\"_blank\">",
"        4037942",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Luks AM, McIntosh SE, Grissom CK, et al, &ldquo;Wilderness Medical Society Consensus Guidelines for the Prevention and Treatment of Acute Altitude Illness,&rdquo;",
"      <i>",
"       Wilderness Environ Med",
"      </i>",
"      , 2010, 21(2):146-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/39/5752/abstract-text/20591379/pubmed\" id=\"20591379\" target=\"_blank\">",
"        20591379",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marik PE, Kussman BD, Lipman J, et al, \"Acetazolamide in the Treatment of Metabolic Alkalosis in Critically Ill Patients,\"",
"      <i>",
"       Heart Lung",
"      </i>",
"      , 1991, 20(5 Pt 1):455-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/39/5752/abstract-text/1894525/pubmed\" id=\"1894525\" target=\"_blank\">",
"        1894525",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mazur JE, Devlin JW, Peters MJ, et al, \"Single Versus Multiple Doses of Acetazolamide for Metabolic Alkalosis in Critically Ill Medical Patients: A Randomized, Double-Blind Trial,\"",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1999, 27(7):1257-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/39/5752/abstract-text/10446816/pubmed\" id=\"10446816\" target=\"_blank\">",
"        10446816",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moviat M, Pickkers P, van der Voort PH, et al, &ldquo;Acetazolamide-Mediated Decrease in Strong Ion Difference Accounts for the Correction of Metabolic Alkalosis in Critically Ill Patients,&rdquo;",
"      <i>",
"       Critical Care",
"      </i>",
"      , 2006, 10(1):R14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/39/5752/abstract-text/16420662/pubmed\" id=\"16420662\" target=\"_blank\">",
"        16420662",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Oles KS, Penry JK, Cole DLW, et al, &ldquo;Use of Acetazolamide as an Adjunct to Carbamazepine in Refractory Partial Seizures,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 1989, 30(1):74-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/39/5752/abstract-text/2492225/pubmed\" id=\"2492225\" target=\"_blank\">",
"        2492225",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Parikh JR, Nolan RL, Bannerjee A, et al, &ldquo;Acetazolamide-Associated Nephrocalcinosis in a Transplant Kidney,&rdquo;",
"      <i>",
"       Transplantation",
"      </i>",
"      , 1995, 59(12):1742-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/39/5752/abstract-text/7604446/pubmed\" id=\"7604446\" target=\"_blank\">",
"        7604446",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Piepgras A, Schmiedek P, Leinsinger G, et al, &ldquo;A Simple Test to Assess Cerebrovascular Reserve Capacity Using Transcranial Doppler Sonography and Acetazolamide,&rdquo;",
"      <i>",
"       Stroke",
"      </i>",
"      , 1990, 21(9):1306-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/39/5752/abstract-text/2204147/pubmed\" id=\"2204147\" target=\"_blank\">",
"        2204147",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pollard AJ, Niermeyer S, Barry P, et al, &ldquo;Children at High Altitude: An International Consensus Statement by an Ad Hoc Committee of the International Society for Mountain Medicine, March 12, 2001,&rdquo;",
"      <i>",
"       High Alt Med Biol",
"      </i>",
"      , 2001, 2(3):389-403.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/39/5752/abstract-text/11682018/pubmed\" id=\"11682018\" target=\"_blank\">",
"        11682018",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reiss WG and Oles KS, &ldquo;Acetazolamide in the Treatment of Seizures,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1996, 30(5):514-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/39/5752/abstract-text/8740334/pubmed\" id=\"8740334\" target=\"_blank\">",
"        8740334",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rousseau P and Fuentevilla-Clifton A, &ldquo;Acetazolamide and Salicylate Interaction in the Elderly: A Case Report,&rdquo;",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 1993, 41(8):868-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/39/5752/abstract-text/8340566/pubmed\" id=\"8340566\" target=\"_blank\">",
"        8340566",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schwenk MH, St. Peter WL, Meese MG, et al, &ldquo;Acetazolamide Toxicity and Pharmacokinetics in Patients Receiving Hemodialysis,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1995, 15(4):522-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/39/5752/abstract-text/7479208/pubmed\" id=\"7479208\" target=\"_blank\">",
"        7479208",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shinnar S, Gammon K, Bergman EW Jr, et al, &ldquo;Management of Hydrocephalus in Infancy: Use of Acetazolamide and Furosemide to Avoid Cerebrospinal Fluid Shunts,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1985, 107(1):31-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/39/5752/abstract-text/4009338/pubmed\" id=\"4009338\" target=\"_blank\">",
"        4009338",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      S&ouml;derman P, Hartvig P, and Fagerlund C, \"Acetazolamide Excretion Into Human Breast Milk,\"",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1984, 17(5):599-600.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/39/5752/abstract-text/6733009/pubmed\" id=\"6733009\" target=\"_blank\">",
"        6733009",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vaziri ND, Saiki J, Barton CH, et al, &ldquo;Hemodialyzability of Acetazolamide,&rdquo;",
"      <i>",
"       South Med J",
"      </i>",
"      , 1980, 73(4):422-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/39/5752/abstract-text/7367929/pubmed\" id=\"7367929\" target=\"_blank\">",
"        7367929",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wagenaar M, Vos P, Heijdra Y, et al, &ldquo;Comparison of Acetazolamide and Medroxyprogesterone as Respiratory Stimulants in Hypercapnic Patients With COPD,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(5):1450-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wandstrat TL and Phillips J, &ldquo;Pseudotumor Cerebri Responsive to Acetazolamide,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1995, 29(3):318.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weiss IS, &ldquo;Hirsutism After Chronic Administration of Acetazolamide,&rdquo;",
"      <i>",
"       Am J Ophthalmol",
"      </i>",
"      , 1974, 78(2):327-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/39/5752/abstract-text/4847470/pubmed\" id=\"4847470\" target=\"_blank\">",
"        4847470",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9268 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-08F90C6EF9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_39_5752=[""].join("\n");
var outline_f5_39_5752=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129795\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129796\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129842\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129800\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129820\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129801\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129802\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15671258\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129772\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129756\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129776\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129848\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129775\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129839\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129850\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129840\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129780\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129760\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129837\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129765\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129768\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129783\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129805\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10912707\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129784\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129782\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129770\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129785\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129759\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129779\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9268\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9268|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/25/6549?source=related_link\">",
"      Acetazolamide: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/57/28566?source=related_link\">",
"      Acetazolamide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_39_5753="Sirolimus: Drug information";
var content_f5_39_5753=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sirolimus: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?26/35/27190?source=see_link\">",
"    see \"Sirolimus: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/14/10472?source=see_link\">",
"    see \"Sirolimus: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F221226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Rapamune&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F221227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Rapamune&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F221253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Immunosuppressant Agent;",
"     </li>",
"     <li>",
"      mTOR Kinase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F221230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Low-to-moderate immunologic risk renal transplant patients:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     &lt;40 kg: Loading dose: 3 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1, followed by maintenance dosing of 1 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     &ge;40 kg: Loading dose: 6 mg on day 1; maintenance: 2 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      High immunologic risk renal transplant patients:",
"     </b>",
"     Oral: Loading dose: Up to 15 mg on day 1; maintenance: 5 mg/day; obtain trough concentration between days 5-7 and adjust accordingly. Continue concurrent cyclosporine/sirolimus therapy for 1 year following transplantation. Further adjustment of the regimen must be based on clinical status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage adjustment:",
"      </i>",
"     </b>",
"     Sirolimus dosages should be adjusted to maintain trough concentrations within desired range based on risk and concomitant therapy. Maximum daily dose: 40 mg. Dosage should be adjusted at intervals of 7-14 days to account for the long half-life of sirolimus. In general, dose proportionality may be assumed. New sirolimus dose",
"     <b>",
"      equals",
"     </b>",
"     current dose",
"     <b>",
"      multiplied by",
"     </b>",
"     (target concentration",
"     <b>",
"      divided by",
"     </b>",
"     current concentration).",
"     <b>",
"      Note:",
"     </b>",
"     If large dose increase is required, consider loading dose calculated as:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Loading dose",
"     <b>",
"      equals",
"     </b>",
"     (new maintenance dose",
"     <b>",
"      minus",
"     </b>",
"     current maintenance dose)",
"     <b>",
"      multiplied by",
"     </b>",
"     3",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maximum dose in 1 day: 40 mg; if required dose is &gt;40 mg (due to loading dose), divide loading dose over 2 days. Whole blood concentrations should not be used as the sole basis for dosage adjustment (monitor clinical signs/symptoms, tissue biopsy, and laboratory parameters).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Maintenance therapy after withdrawal of cyclosporine:",
"      </i>",
"     </b>",
"     Cyclosporine withdrawal is not recommended in high immunological risk patients. Following 2-4 months of combined therapy, withdrawal of cyclosporine may be considered in low-to-moderate immunologic risk patients. Cyclosporine should be discontinued over 4-8 weeks, and a necessary increase in the dosage of sirolimus (up to fourfold) should be anticipated due to removal of metabolic inhibition by cyclosporine and to maintain adequate immunosuppressive effects. Dose-adjusted trough target concentrations are typically 16-24 ng/mL for the first year post-transplant and 12-20 ng/mL thereafter (measured by chromatographic methodology).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      GVHD prophylaxis (unlabeled use):",
"     </b>",
"     Oral: 12 mg loading dose on day  -3, followed by 4 mg daily (target trough level: 3-12 ng/mL); taper off after 6-9 months (Armand, 2008; Cutler, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Treatment of refractory acute GVHD (unlabeled use):",
"     </b>",
"     Oral: 4-5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     for 14 days (no loading dose) (Benito, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Treatment of chronic GVHD (unlabeled use):",
"     </b>",
"     Oral: 6 mg loading dose, followed by 2 mg daily (target trough level: 7-12 ng/mL) for 6-9 months (Couriel, 2005)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F221242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/14/10472?source=see_link\">",
"      see \"Sirolimus: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Immunosuppression:",
"     </b>",
"     Children &ge;13 years: Oral: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F221231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F221232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment (in loading or maintenance dose) is necessary in renal impairment. However, adjustment of regimen (including discontinuation of therapy) should be considered when used concurrently with cyclosporine and elevated or increasing serum creatinine is noted.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F221233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Loading dose: No adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maintenance dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild-to-moderate hepatic impairment: reduce maintenance dose by ~33%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe hepatic impairment: reduce maintenance dose by ~50%.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F221201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rapamune&reg;: 1 mg/mL (60 mL) [contains ethanol 1.5%-2.5%, propylene glycol, soy]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rapamune&reg;: 0.5 mg, 1 mg, 2 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F221186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F11310396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM235958.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM235958.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F221204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initial dose should be administered as soon as possible after transplant. Sirolimus should be taken 4 hours after oral cyclosporine (Neoral&reg; or Gengraf&reg;). Should be administered consistently (with or without food).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Solution: Mix (by stirring vigorously) with at least 2 ounces of water or orange juice. No other liquids should be used for dilution. Patient should drink diluted solution immediately. The cup should then be refilled with an additional 4 ounces of water or orange juice, stirred vigorously, and the patient should drink the contents at once.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Tablet: Do not crush, split, or chew.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F221203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylaxis of organ rejection in patients receiving renal transplants",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F221249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylaxis of organ rejection in heart transplant recipients; prevention acute graft-versus-host disease (GVHD) in allogeneic stem cell transplantation; treatment of refractory acute or chronic GVHD; treatment of soft tissue sarcoma (chordoma, angiomyolipoma, or lymphangioleiomyomatosis)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F4288698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Rapamune&reg; may be confused with Rapaflo&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Sirolimus may be confused with everolimus, pimecrolimus, tacrolimus, temsirolimus",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F221251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Incidence of many adverse effects is dose related.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;20%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema (54% to 58%), hypertension (45% to 49%), edema (18% to 20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (34%), pain (29% to 33%), insomnia (13% to 22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Acne (22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypertriglyceridemia (45% to 57%), hypercholesterolemia (43% to 46%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation (36% to 38%), abdominal pain (29% to 36%), diarrhea (25% to 36%), nausea (25% to 31%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (26% to 33%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (23% to 33%), thrombocytopenia (14% to 30%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (25% to 31%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Serum creatinine increased (39% to 40%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     3% to 20%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Atrial fibrillation, CHF, DVT, facial edema, hypervolemia, hypotension, orthostatic hypotension, palpitation, peripheral vascular disorder, syncope, tachycardia, thrombosis, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Anxiety, chills, confusion, depression, dizziness, emotional lability, hypoesthesia, malaise, neuropathy, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (10% to 20%), skin carcinoma (up to 3%; includes basal cell carcinoma, squamous cell carcinoma, melanoma), cellulitis, dermal ulcer, dermatitis (fungal), ecchymosis, hirsutism, pruritus, skin hypertrophy, wound healing abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Acidosis, Cushing's syndrome, dehydration, diabetes mellitus, glycosuria, hypercalcemia, hyperglycemia, hyperphosphatemia, hypocalcemia, hypoglycemia, hypomagnesemia, hyponatremia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdomen enlarged, anorexia, dysphagia, eructation, esophagitis, flatulence, gastritis, gastroenteritis, gingival hyperplasia, gingivitis, ileus, mouth ulceration, oral moniliasis, stomatitis, weight loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Impotence, pelvic pain, scrotal edema, testis disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Hemolytic-uremic syndrome, hemorrhage, leukopenia, leukocytosis, polycythemia, TTP",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Abnormal liver function tests, alkaline phosphatase increased, LDH increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthrosis, bone necrosis, CPK increased, hyper-/hypotonia, leg cramps, myalgia, osteoporosis, paresthesia, tetany",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Abnormal vision, cataract, conjunctivitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Ear pain, otitis media, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Albuminuria, bladder pain, BUN increased, dysuria, hematuria, hydronephrosis, kidney pain, nephropathy (toxic), nocturia, oliguria, pyelonephritis, pyuria, tubular necrosis, urinary frequency, urinary incontinence, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Asthma, atelectasis, bronchitis, cough, epistaxis, hypoxia, lung edema, pleural effusion, pneumonia, pulmonary embolism, rhinitis, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Lymphoproliferative disease/lymphoma (1% to 3%), abscess, diaphoresis, flu-like syndrome, hernia, herpesvirus infection, infection (including opportunistic), lymphadenopathy, lymphocele, peritonitis, sepsis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;3% (Limited to important or life-threatening): ALT increased, alveolar proteinosis, anaphylactoid reaction, anaphylaxis, anastomotic disruption, angioedema, ascites, AST increased, azoospermia,",
"     <i>",
"      Clostridium difficile",
"     </i>",
"     colitis, cytomegalovirus, Epstein-Barr virus, exfoliative dermatitis, fascial dehiscence, focal segmental glomerulosclerosis, hepatic necrosis, hepatotoxicity, hypersensitivity reaction, hypersensitivity vasculitis, hypophosphatemia, incisional hernia; interstitial lung disease (dose-related; includes pneumonitis, pulmonary fibrosis, and bronchiolitis obliterans organizing pneumonia [BOOP] with no identified infectious etiology); joint disorders, lymphedema, myocardial infarction, mycobacterial infection, nephropathy (BK virus-associated), nephrotic syndrome, neutropenia, pancreatitis, pancytopenia, pericardial effusion,",
"     <i>",
"      Pneumocystis",
"     </i>",
"     pneumonia, progressive multifocal leukoencephalopathy (PML), proteinuria, pulmonary hemorrhage, reversible posterior leukoencephalopathy syndrome (RPLS), tamponade, tuberculosis, wound dehiscence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Hepatic artery thrombosis (HAT) and graft failure have been reported in liver transplant patients (not an approved use); bronchial anastomotic dehiscence has been reported in lung transplant patients (not an approved use)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F221207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sirolimus or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F221190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactic/hypersensitivity reactions: Hypersensitivity reactions, including anaphylactic/anaphylactoid reactions, angioedema, exfoliative dermatitis, and hypersensitivity vasculitis have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angioedema: Has been reported; concurrent use with other drugs known to cause angioedema (eg, ACE inhibitors) may increase risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infections:",
"     <b>",
"      [U.S. Boxed Warning]: Immunosuppressive agents, including sirolimus, increase the risk of infection.",
"     </b>",
"     Immune suppression may also increase the risk of opportunistic infections (including activation of latent viral infections including BK virus-associated nephropathy), fatal infections, and sepsis. Prophylactic treatment for",
"     <i>",
"      Pneumocystis jirovecii",
"     </i>",
"     pneumonia (PCP) should be administered for 1 year post-transplant; prophylaxis for cytomegalovirus (CMV) should be taken for 3 months post-transplant in patients at risk for CMV. Progressive multifocal leukoencephalopathy (PML), an opportunistic CNS infection caused by reactivation of the JC virus, has been reported in patients receiving immunosuppressive therapy, including sirolimus. Clinical findings of PML include apathy, ataxia, cognitive deficiency, confusion, and hemiparesis; promptly evaluate any patient presenting with neurological changes; consider decreasing the degree of immunosuppression with consideration to the risk of organ rejection in transplant patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Interstitial lung disease: Cases of interstitial lung disease (eg, pneumonitis, bronchiolitis obliterans organizing pneumonia [BOOP], pulmonary fibrosis) have been observed (some fatal); risk may be increased with higher trough levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperlipidemia: May increase serum lipids (cholesterol and triglycerides). Use with caution in patients with hyperlipidemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lymphocele/fluid accumulation: Use has been associated with an increased risk of fluid accumulation and lymphocele. Peripheral edema, lymphedema, ascites, and pleural and pericardial effusions (including significant effusions and tamponade) were reported; use with caution in patients in whom fluid accumulation may be poorly tolerated, such as in cardiovascular disease (heart failure or hypertension) and pulmonary disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Malignancy:",
"     <b>",
"      [U.S. Boxed Warning]: Immunosuppressive agents, including sirolimus, may be associated with the development of lymphoma and other malignancies,",
"     </b>",
"     including an increased risk of skin cancer; limit sun and ultraviolet light exposure; use appropriate sun protection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Proteinuria: Increased urinary protein excretion has been observed when converting renal transplant patients from calcineurin inhibitors to sirolimus during maintenance therapy. A higher level of proteinuria prior to sirolimus conversion correlates with a higher degree of proteinuria after conversion. In some patients, proteinuria may reach nephrotic levels; nephrotic syndrome (new onset) has been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal effects: May increase serum creatinine and decrease GFR with long-term combination use of sirolimus and cyclosporine. Immunosuppressed patients are at an increased risk of BK viral-associated nephropathy which may impair renal function and cause graft loss; consider decreasing immunosuppressive burden if evidence of deteriorating renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Wound dehiscence/healing: May be associated with wound dehiscence and impaired healing; use caution in the perioperative period. Patients with a body mass index (BMI) &gt;30 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     are at increased risk for abnormal wound healing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; a reduction in the maintenance dose is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Calcineurin inhibitors: Concurrent use with a calcineurin inhibitor (cyclosporine, tacrolimus) may increase the risk of calcineurin inhibitor-induced hemolytic uremic syndrome/thrombotic thrombocytopenic purpura/thrombotic microangiopathy (HUS/TTP/TMA).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cyclosporine: Safety and efficacy of combination therapy with cyclosporine in high immunologic risk patients have not been studied beyond 12 months of treatment. Monitor renal function closely when combined with cyclosporine; consider dosage adjustment or discontinue in patients with increasing serum creatinine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Avoid concurrent use of strong CYP3A4 and/or P-glycoprotein (P-gp) inhibitors (eg, clarithromycin, erythromycin, telithromycin, itraconazole, ketoconazole, voriconazole) and strong CYP3A4 and/or P-gp inducers (eg, rifampin, rifabutin).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nephrotoxic drugs: Use with caution in patients concurrently taking medications which may alter renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Liver transplants:",
"     <b>",
"      [U.S. Boxed Warning]: Sirolimus is not recommended for use in liver transplantation; studies indicate an association with an increase risk of hepatic artery thrombosis (HAT), graft failure, and increased mortality (with evidence of infection) in these patients when sirolimus is used in combination with cyclosporine and/or tacrolimus.",
"     </b>",
"     Most cases of HAT occurred within 30 days of transplant.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lung transplants:",
"     <b>",
"      [U.S. Boxed Warning]: Sirolimus is not recommended for use in lung transplantation. Bronchial anastomotic dehiscence cases have been reported in lung transplant patients when sirolimus was used as part of an immunosuppressive regimen; most of these reactions were fatal.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal transplant: In renal transplant patients,",
"     <i>",
"      de novo",
"     </i>",
"     use without cyclosporine has been associated with higher rates of acute rejection. Sirolimus may delay recovery of renal function in patients with delayed allograft function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Product interchangeability: Sirolimus tablets and oral solution are not bioequivalent, due to differences in absorption. Clinical equivalence was seen using 2 mg tablet and 2 mg solution. It is not known if higher doses are also clinically equivalent. Monitor sirolimus levels if changes in dosage forms are made.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Sirolimus should be used in combination with cyclosporine (and corticosteroids) initially. Cyclosporine may be withdrawn in low-to-moderate immunologic risk patients after 2-4 months, in conjunction with an increase in sirolimus dosage. In high immunologic risk patients, use in combination with cyclosporine and corticosteroids is recommended for the first year. Adjustment of immunosuppressive therapy beyond 12 months should be considered based on clinical judgement.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should only be used by physicians experienced in immunosuppressive therapy and management of transplant patients. Adequate laboratory and supportive medical resources must be readily available.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Laboratory monitoring: Sirolimus concentrations are dependent on the assay method (eg, chromatographic and immunoassay) used; assay methods are not interchangeable. Variations in methods to determine sirolimus whole blood concentrations, as well as interlaboratory variations, may result in improper dosage adjustments, which may lead to subtherapeutic or toxic levels. Determine the assay method used to assure consistency (or accommodations if changes occur), and for monitoring purposes, be aware of alterations to assay method or reference range. The manufacturer recommends high performance liquid chromatography (HPLC) as the reference standard to determine sirolimus trough concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F221246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F221195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Sirolimus may enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Sirolimus. Management: Significant sirolimus dose reductions may be required if used with boceprevir.  Concurrent use should be performed with great caution and close monitoring of both sirolimus concentrations and clinical response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: May increase the serum concentration of Sirolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Sirolimus may enhance the adverse/toxic effect of CycloSPORINE (Systemic). An increased risk of calcineurin inhibitor-induced hemolytic uremic syndrome/thrombotic thrombocytopenic purpura/thrombotic microangiopathy (HUS/TTP/TMA) has been described. CycloSPORINE (Systemic) may increase the serum concentration of Sirolimus. This is of specific concern with cyclosporine [MODIFIED].  Management: Administer oral doses of sirolimus 4 hours after doses of cyclosporine.  Monitor for toxic effects of sirolimus if used with cyclosporine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of Sirolimus. Management: Closely monitor sirolimus serum concentrations when starting, stopping, or changing doses of efavirenz, particularly during the first 2 weeks after any change.  Dose adjustment of sirolimus may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: May decrease the serum concentration of Sirolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Sirolimus. Management: Sirolimus dose adjustments will likely be needed when starting/stopping any azole antifungal.  Clinical data suggest sirolimus (adult) dose reductions of 50-90% will be needed when starting an azole antifungal, but specific guidelines are lacking.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Sirolimus. Management: Monitor for decreased sirolimus concentrations if fosphenytoin/phenytoin is initiated/dose increased. Monitor for increased sirolimus concentrations with phenytoin discontinuation/dose decrease. Sirolimus dose adjustments may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Sirolimus. Management: Sirolimus dose adjustments will likely be needed when starting/stopping any azole antifungal.  Clinical data suggest sirolimus (adult) dose reductions of 50-90% will be needed when starting an azole antifungal, but specific guidelines are lacking.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Sirolimus. Management: Sirolimus dose adjustments will likely be needed when starting/stopping any azole antifungal.  Clinical data suggest sirolimus (adult) dose reductions of 50-90% will be needed when starting an azole antifungal, but specific guidelines are lacking.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Sirolimus.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of Sirolimus. Management: Avoid sirolimus during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Sirolimus. Management: Monitor for decreased sirolimus serum concentrations if phenytoin is initiated/dose increased. Monitor for increased sirolimus concentrations with phenytoin discontinuation/dose decrease. Sirolimus dose adjustments may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May increase the serum concentration of Sirolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Sirolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May increase the metabolism of Sirolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): May enhance the adverse/toxic effect of Sirolimus. Sirolimus may enhance the adverse/toxic effect of Tacrolimus (Systemic). Sirolimus may decrease the serum concentration of Tacrolimus (Systemic). Management: Tacrolimus and sirolimus should only be used concomitantly as part of a protocol with a known risk:benefit profile and an established safety record.  Several regimens combining these agents have been associated with excess morbidity and/or mortality.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Sirolimus. Sirolimus may enhance the adverse/toxic effect of Tacrolimus (Topical).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Sirolimus. Management: Significant sirolimus dose reductions are likely to be required if used with telaprevir.  Concurrent use should be performed with great caution and close monitoring of both sirolimus concentrations and clinical response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Sirolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F221222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Grapefruit juice may decrease clearance of sirolimus. Ingestion with high-fat meals decreases peak concentrations but increases AUC by 23% to 35%. Management: Avoid grapefruit juice. Take consistently (either with or without food) to minimize variability.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease sirolimus levels. Some herbal medications have immunostimulant properties (eg, echinacea). Herbs with hypoglycemic properties may increase the risk of sirolimus-induced hypoglycemia (eg, alfalfa). Management: Avoid St John's wort, cat's claw, and echinacea. Avoid alfalfa, aloe, bilberry, bitter melon, burdock, celery, damiana, fenugreek, garcinia, garlic, ginger, ginseng (American), gymnema, marshmallow, and stinging nettle.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F221197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F221210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have demonstrated embryotoxicity and fetotoxicity, as evidenced by increased mortality, reduced fetal weights and delayed ossification. There are no adequate and well-controlled studies in pregnant women. Effective contraception must be initiated before therapy with sirolimus and continued for 12 weeks after discontinuation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The National Transplantation Pregnancy Registry (NTPR, Temple University) is a registry for pregnant women taking immunosuppressants following any solid organ transplant. The NTPR encourages reporting of all immunosuppressant exposures during pregnancy in transplant recipients at 877-955-6877.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F221237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F4288699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for adverse reactions in the breast-fed infant, including possible immunosuppression, breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F221211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take consistently (with or without food) to minimize variability of absorption.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F221209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Rapamune Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (60 mL): $919.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Rapamune Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (100): $767.05",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (100): $1534.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $3068.22",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F221199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor LFTs and CBC during treatment. Monitor sirolimus levels in all patients (especially in pediatric patients, patients &ge;13 years of age weighing &lt;40 kg, patients with hepatic impairment, or on concurrent potent inhibitors or inducers of CYP3A4 or P-gp, and/or if cyclosporine dosing is markedly reduced or discontinued), and when changing dosage forms of sirolimus. Also monitor serum cholesterol and triglycerides, blood pressure, serum creatinine, and urinary protein. Serum drug concentrations should be determined 3-4 days after loading doses and 7-14 days after dosage adjustments; however, these concentrations should not be used as the sole basis for dosage adjustment, especially during withdrawal of cyclosporine (monitor clinical signs/symptoms, tissue biopsy, and laboratory parameters).",
"     <b>",
"      Note:",
"     </b>",
"     Concentrations and ranges are dependent on and will vary with assay methodology (chromatographic or immunoassay); assay methods are not interchangeable.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F221202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Sirolimus concentrations are dependent on the assay method (eg, chromatographic and immunoassay) used; assay methods are not interchangeable. Determine the assay method used to assure consistency (or accommodations if changes occur) and for monitoring purposes, be aware of alterations to assay method or reference range.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Serum trough concentration goals for renal transplantation (based on HPLC methods):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Concomitant cyclosporine: 4-12 ng/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Low-to-moderate immunologic risk (after cyclosporine withdrawal): 16-24 ng/mL for the first year after transplant; after 1 year: 12-20 ng/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     High immunologic risk (with cyclosporine): 10-15 ng/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Trough concentrations vary based on clinical context and use of additional immunosuppressants. The following represents typical ranges.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     When combined with tacrolimus and mycophenolate mofetil (MMF) without steroids: 6-8 ng/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     As a substitute for tacrolimus (starting 4-8 weeks post-transplant), in combination with MMF and steroids: 8-12 ng/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Following conversion from tacrolimus to sirolimus &gt;6 months post-transplant due to chronic allograft nephropathy: 4-6 ng/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serum trough concentrations for GVHD prophylaxis in allogeneic stem cell transplant: 3-12 ng/mL (Armand, 2008; Cutler, 2007)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F221212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Rapacan (IN);",
"     </li>",
"     <li>",
"      Rapamune (AR, AT, AU, BE, BG, BR, CH, CL, CN, CO, CR, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, GT, HK, HN, IE, IL, IT, KP, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, RU, SE, SG, SK, SV, TH, TR, TW, VE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F221189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sirolimus inhibits T-lymphocyte activation and proliferation in response to antigenic and cytokine stimulation and inhibits antibody production. Its mechanism differs from other immunosuppressants. Sirolimus binds to FKBP-12, an intracellular protein, to form an immunosuppressive complex which inhibits the regulatory kinase, mTOR (mammalian target of rapamycin). This inhibition suppresses cytokine mediated T-cell proliferation, halting progression from the G1 to the S phase of the cell cycle. It inhibits acute rejection of allografts and prolongs graft survival.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F221206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 12 L/kg (range: 4-20 L/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~92%, primarily to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive; in intestinal wall via P-glycoprotein and  hepatic via CYP3A4; to 7 major metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral solution: 14%; Oral tablet: 18%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Mean: 62 hours (range: 46-78 hours); extended in hepatic impairment (Child-Pugh class A or B) to 113 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Oral solution: 1-3 hours; Tablet: 1-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (91% due to P-glycoprotein-mediated efflux into gut lumen); urine (2%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Antin J, Kim H, Cutler C, et al, \"Sirolimus, Tacrolimus, and Low-Dose Methotrexate for Graft-Versus-Host Disease Prophylaxis in Mismatched Related Donor or Unrelated Donor Transplantation,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2003, 102(5):1601-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/39/5753/abstract-text/12730113/pubmed\" id=\"12730113\" target=\"_blank\">",
"        12730113",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Armand P, Gannamaneni S, Kim HT, et al, &ldquo;Improved Survival in Lymphoma Patients Receiving Sirolimus for Graft-Versus-Host Disease Prophylaxis After Allogeneic Hematopoietic Stem-Cell Transplantation With Reduced-Intensity Conditioning,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(35):5767-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/39/5753/abstract-text/19001324/pubmed\" id=\"19001324\" target=\"_blank\">",
"        19001324",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Benito AI, Furlong T, Martin PJ, et al, &ldquo;Sirolimus (Rapamycin) for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease,&rdquo;",
"      <i>",
"       Transplantation",
"      </i>",
"      , 2001, 72(12):1924-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/39/5753/abstract-text/11773890/pubmed\" id=\"11773890\" target=\"_blank\">",
"        11773890",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bissler JJ, McCormack FX, Young LR, et al, &ldquo;Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 358(2):140-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/39/5753/abstract-text/18184959/pubmed\" id=\"18184959\" target=\"_blank\">",
"        18184959",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Couriel DR, Saliba R, Escalon MP, et al, &ldquo;Sirolimus in Combination With Tacrolimus and Corticosteroids for the Treatment of Resistant Chronic Graft-Versus-Host Disease,&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2005, 130(3):409-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/39/5753/abstract-text/16042691/pubmed\" id=\"16042691\" target=\"_blank\">",
"        16042691",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cutler C, Kim H, Hochberg E, et al, \"Sirolimus and Tacrolimus Without Methotrexate as Graft-Versus-Host Disease Prophylaxis After Matched Related Donor Peripheral Blood Stem Cell Transplantation,&rdquo;",
"      <i>",
"       Biol Blood Marrow Transplant",
"      </i>",
"      , 2004, 10(5):328-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/39/5753/abstract-text/15111932/pubmed\" id=\"15111932\" target=\"_blank\">",
"        15111932",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cutler C, Li S, Ho VT, et al, &ldquo;Extended Follow-Up of Methotrexate-Free Immunosuppression Using Sirolimus and Tacrolimus in Related and Unrelated Donor Peripheral Blood Stem Cell Transplantation,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2007, 109(7):3108-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/39/5753/abstract-text/17138818/pubmed\" id=\"17138818\" target=\"_blank\">",
"        17138818",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ettinger RB and Grimm EM, &ldquo;Safety and Efficacy of TOR Inhibitors in Pediatric Renal Transplant Recipients,&rdquo;",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2001, 38(4 Suppl 2):22-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/39/5753/abstract-text/11583941/pubmed\" id=\"11583941\" target=\"_blank\">",
"        11583941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kahan BD, &ldquo;Efficacy of Sirolimus Compared With Azathioprine for Reduction of Acute Renal Allograft Rejection: A Randomised Multicentre Study. The Rapamune US Study Group,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2000, 356(9225):194-202.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/39/5753/abstract-text/10963197/pubmed\" id=\"10963197\" target=\"_blank\">",
"        10963197",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McDonald AS, &ldquo;A Worldwide, Phase III, Randomized, Controlled, Safety and Efficacy Study of a Sirolimus/Cyclosporine Regimen for Prevention of Acute Rejection in Recipients of Primary Mismatched Renal Allografts. RAPAMUNE Global Study Group,&rdquo;",
"      <i>",
"       Transplantation",
"      </i>",
"      , 2001, 71(2):271-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/39/5753/abstract-text/11213073/pubmed\" id=\"11213073\" target=\"_blank\">",
"        11213073",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Soft Tissue Sarcoma,&rdquo; Version 2.2010. Available at file://www.nccn.org/professionals/physician_gls/PDF/sarcoma.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Raichlin E, Bae JH, Khalpey Z, et al, &ldquo;Conversion to Sirolimus as Primary Immunosuppression Attenuates the Progression of Allograft Vasculopathy After Cardiac Transplantation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 116(23):2726-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/39/5753/abstract-text/18025531/pubmed\" id=\"18025531\" target=\"_blank\">",
"        18025531",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sifontis NM, Coscia LA, Constantinescu S, et al, &ldquo;Pregnancy Outcomes in Solid Organ Transplant Recipients With Exposure to Mycophenolate Mofetil or Sirolimus,&rdquo;",
"      <i>",
"       Transplantation",
"      </i>",
"      , 2006, 82(12):1698-1702.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/39/5753/abstract-text/17198262/pubmed\" id=\"17198262\" target=\"_blank\">",
"        17198262",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stacchiotti S, Marrari A, Tamborini E, et al, &ldquo;Response to Imatinib Plus Sirolimus in Advanced Chordoma,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2009, 20(11):1886-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/39/5753/abstract-text/19570961/pubmed\" id=\"19570961\" target=\"_blank\">",
"        19570961",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stenton SB, Partovi N, and Ensom MH, &ldquo;Sirolimus: The Evidence for Clinical Pharmacokinetic Monitoring,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2005, 44(8):769-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/39/5753/abstract-text/16029064/pubmed\" id=\"16029064\" target=\"_blank\">",
"        16029064",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10329 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-D438A33F91-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_39_5753=[""].join("\n");
var outline_f5_39_5753=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709411\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221226\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221227\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221253\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221230\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221242\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221231\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221232\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221233\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221201\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221186\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11310396\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221204\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221203\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221249\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4288698\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221251\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221207\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221190\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221246\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221195\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221222\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221197\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221210\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221237\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4288699\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221211\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221209\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221199\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221202\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221212\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221189\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221206\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10329\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10329|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?26/35/27190?source=related_link\">",
"      Sirolimus: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/14/10472?source=related_link\">",
"      Sirolimus: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_39_5754="Posterior vaginal wall prolapse 6";
var content_f5_39_5754=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52823%7EOBGYN%2F64155%7EOBGYN%2F71853%7EOBGYN%2F64583%7EOBGYN%2F78517&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52823%7EOBGYN%2F64155%7EOBGYN%2F71853%7EOBGYN%2F64583%7EOBGYN%2F78517&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Repair of posterior vaginal wall prolapse",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 349px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Locations of site-specific defects in the posterior vaginal wall. Defects in the fibromuscularis can be found in the lateral sidewalls (L), midline (M), or in a transverse orientation (T) at the apex or distally near the perineal body.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Walters, MD, Karram, MM. Urogynecology and reconstructive pelvic surgery, 3rd ed, Mosby-Elsevier, 2007. Copyright &copy;2007 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Repair of posterior vaginal wall prolapse",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 438px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A longitudinal central defect is seen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Walters, MD, Karram, MM. Urogynecology and reconstructive pelvic surgery, 3rd ed, Mosby-Elsevier, 2007. Copyright &copy;2007 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Repair of posterior vaginal wall prolapse",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 348px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Example of a left lateral defect.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Walters, MD, Karram, MM. Urogynecology and reconstructive pelvic surgery, 3rd ed, Mosby-Elsevier, 2007. Copyright &copy;2007 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Repair of posterior vaginal wall prolapse",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 350px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFeAXQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKgurqK2UGVsZ6DqTQBPRXNyeKbYyMsMNy+DjPlED9afYeKtNuLj7O9ykc39xztP60AdDRSKwZQVIIPcUtAFTVNQttLsZLy9cpBHjcwBOMnHaqV54k0yzgaaedljUZJCE8VX8fRed4O1VcZxDu/Ig/wBK4fxCBL4WeYkjdCP1WgD1SCVJ4Y5YjmORQ6n1BGRUlZHhCQzeGNLcnJNunP4Vr0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFHOfaigBsjBEJJxVPyWzvP3j68mrG4O7En5U/nXP+IPEUOnxuxdVCjkk0Aac9sJVIZq5zVdGtZiPPhjkIOQzLyK466+I1uk+GafZ/fEZK/nXT6L4gi1KJGV0mibowOaAHaLqkug3Qtbxt2nytiJyeYz/AHT7V3kciyIGQ5B6GuM1vTEuLR45F3QyD8R7ineCNQliDabePulg4Vj/ABL2NAGz40/5FTVf+vdv5VwGtt/xRQ7ZhT/0Gu68evs8Has2dv7gjP1IrgfFJ8vwhtH/ADyUD/vmgD0LwR/yKWk/9e61t1jeDV2eFtKXGP8AR04/CtmgAooooAKKKKACiiigAooooAKKKKACiiigAoopAc0ALRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFU9SvY7K2kmkIAQE1alcIhJrhdSum1rWPs8ZzZ2zZkP8Affsv4UAX7S+lj0xmnJ82Ulz7Z6CuI8SxPf3ttbAk7iXceoFdnfxhIxu4zWVZQxSaz5rbSFj2j86AM+LwqZbTc+0f7OK525tJfC97FewD9xvCzxjoQe9eos2RtXpXGeM5IzFNGSNuw7s0Ad3YzRX+mAx8jHQ9RXLauklnNHe2+RLA43Y7rnkVF4M1L7KLaGUr5d1ECpzxnFb2pwK+d6go3WgBPGd/Fe+Ab2WBgyyqq8+pYVxvj1vL8O7OnGP0xVvxEZE+zWKjNreXMeV6YK85qh8Q33w2douC0sqrj6sBQB6t4ej8rQtPQnJW3jH/AI6K0Kjt4xDBFEOiKF/IVJQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABQeKKqahci3hJzzQBi+LNUe3tTFb8zSHYg9zVXw5pwtrZQeSPmZj3Pc1RiDalqvmclI+FPv3rdv7lLSz8tPvY5oAw/EF6gLMxwiVylgZ7O1uNTu7jYxYmONuiqegPqTU17dfabkKDuGa5vxu0tyIIPN8u3jHmOo4ye1AHYWmuu1vubqR07iuJ8bak0sAt9372dxuUdQneqtoGljQwfaoF6bkJJYVZura2+yv8A6LKZMZ86Q5YmgDqJLRZNFtHhODbqrDHpXbadILqxTJ3KyAjua888B3bT2M9pMQzR9Pda7DwtOI5Ws3JBiOYz/sntQBm6kfO8U6dbEZFuj3Df+gisu7X+1fHmk2uMoJw7D/ZQZrbBSXxRq96ceXCq24Pb5Rlv1rF8EXYk+ILXD/6tIimcdGY8fpQB7NRRVe4l2jAoAsZFFU7eUlutXB0oAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAEdtqkmuN8TagWdYIzl3O1QK6TVZvLgODjiuN0+H7ZdyX03CDiPPZR3oA19OiWyswSOcVj6zM7xMTkA/rW3bRPfndysA6f7X/1qyfEipGPKXAxQBy8MYQvK5wqiuQvhJqt87oRsZ8DPTA/pWp4sdmWyto5GQyS87TyRir2iabI5xEiKUGMt2oAls7GNIEWR5nAHb5RVr7PbiIjZCgPdmyaZcW7JKEuJDnPrTzaQvERCxjb+/jOaAMbQ1On62Uj3H5sDIwGQ10d5eppzyXoIAhBP19vzrlZY/sWsQSXLzbx8qktlWHsfWtW+VdS1Wy09DkbvPmI6bF6A/U0AWJpn07wson+W6uiZJPXLHJ/pVfwhGbXw3cagQ3n3M/nJnrtXgY/WqHiyeTVtXg060PzSyCBMe55P5Zr0XxFoMSeH0sbTCCGILEy8YIHWgDq9NvFu9OguFP30BqpczbnODXC+CvEEkOnDT707biE7SDxmuwt288grzmgDTsRnk1fqC1j2IKnoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKiuJlhiLt2oA5vxzeC10/buw0h259B3qh4fs5tQiQzAx2i42pjl/r7Vn30ja/4jw3zWVp19Hf0/Cu50uHy4QcYzQBOkQiiOBjArgPEb5uW3HjNd7qE6QW7M57V5J4i1EXOpNHG2QDzigDI1nEmsWUhUEgMy+w6VqaXIzE7nMUXfb1P41jlXm1ORn5dwFX/YQf410ltok06KykqrDoPSgB02o6fCwxEJSP4m/xq1HrtnNHsEKfhTG8HWsqf6RI7MfRulcxqvh2TTJXktZnRV5yW4oA0PEH2N9MuHkBaILuA7g9se9UNLEmh6I9xeEnUrpQSW6qvZfwFP0OyudViTUtVUQ6dbHeik489h0Y+3pWF4i1JtV1SOGNtglbaD/cXu1ADtAaY6sNXDYW2YiIH+M/xH8q9OTXBfIFDcEVxNzFFFBDa2oCxwLtX396saIHW6UZ+XPI9DQBp6vpknmi7gHzpzwOo9K63wZexXVsjBs54+h7itWysop7EcAnFcvqVnJot415aofKY/vo17/7Q96APRB04orK0TUUvbZWVgcjIPrWrQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVynjO/kSFbS1b/SZzsT29T+FdHe3CW1u8jnCqMmuI08SX17JfzAl5DtjH91f/AK9AGn4a0tLeCOFPmVByx6se5rp5GEMWfQVDp0HlQjjmoNbu1t7V8ntQByHizV3w6hiB/OvOZJvs8rYBe5l59lFaHi3W4xcpCjZmY5wK5cXAnv0XJ3FsE0Adho9uWvooz80srfMT2FejQwKoAx0FeeeGwLbUVMjEtvZcn9K9Ft5A8WRQBk+IfEGmaCim/kClugxzXO/aY/E2y7vkFlo8R3CJjh5z23ei+3evO/jVeyweJrWZgXhj/hPTNZsevzahaLHZl5HI+72T3NAHX+N/Fq3G20shiEfLHEvG4/4Vz2hMUklNzhp5DhmHQegFYi2kiOWO5pW6u3U1q6buW5jjb+Lg0AdRau0pVf4x09625SLCOC5C98OB6ViW8clldRmQcHlW9fauo82G7t5FCjcnzYPcd6AO18KX6zRqoYEEZFbWpWi3ELZGcivM9BujpmoLAT8jHKH29K9TtpBPbqw5yKAOF0SR9M1aazkyF3bo/cdxXewOJIwRXJ+LbMxsl5CPniOeO4rY0C7W4tUYHqM0AbFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUE4FFR3D7IyfagDmfE92ZJorNP4zlvpVvRrMHDEfKOlYduxv9UlnGcFti/7ortLOIRQqKAJHOxD6CvP/GupkK8aHnpXaaxeR2lo7yMAAK8R8aa+sFrcXbMO6xj1Y0Acmpa81K7uSeEby0z39TWrpdkiB5H5cNnNYekeYlpGJSqtIfMZmOMZ5qtf+MrLTx5Vo5vLjJDRx88fXpQB6LMrjZcW+WGAWx2IroNE11FGJD8p6+xryDRviB9mnUXtvPbRN3dcj86627vbbUbNr3TrhUfGTtI5/CgDS8baFaeIbiMSyARMeWB6U/SNA0Lw/ZPFGwlY9zXIDXpI/lnKsB6sFqje+LbaEMJHjHpl80AdBqYt8ySKqqoql4ds/wC0dTMwP7uEfgTXFXnigXimKy8y4J67Bx+da2jeIrzS4Y45LdYom5KqfmP1oA9Uht7a/V7d2AdVG0+mKzAWsrnbIxyp2n3FcxpXia1kuSvmGJpD8rE8H8a7iwMGqQNDc4EoPD9zxQBHqEizafFd2xHmQuGOPQda7vwxriNCiOeCBg153Z2z2F7NaSNuRhlc+hrT0pWto1CkkKxFAHqWoIl3asOCCMVzPh6VrK7ktZOArfL7itDQ7iSSMA5Kmqetj7JfRTY4JwaAOwRgygjvTqo6XOJYRzV6gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKwPGWojTtEupgfmRDgDqT6VoavqMenWjSvy3RV7sfSuNv0k1iVRdE7CdxQdDQBe8EoZNOt5ZU2OyhiD2rqLm8it4izsAAOlc5DI1pCRGMAVyfiTWpWJhiYsx64oAd4w18XDMpkAhXk88V4D4s8Qf2jquHbFlbnKRryZG9a6nx3qMlpp4jxvuJjgRg9BXncGh3V27T3Egt4zzhT29M0AF7fy6gWGqX4htR92CNsfme9QQ3+mWgVdOgkl5+Zdhw341qw6HZxEMsZlb1xmtOPSZXG2O3SNTzkjmgDMTxJbrbiK5sZoIm5bjINQH+wpY2kivpLY9gk2Mn6dK3o/DkjE77cuD0GcZ+tVJ/CtpFlprZIx3zjn6UAYM1noTSKZ9bnkA6nzM801ZvC9soZma6cNnByc10tv4UiktTPHYsV/gUx/eP5UWukQpMsX2FBOf4XUjFAGbD4qsUMgtbfbkfIEiJ/wDrUDW11NCl05tweCMYJH17VuPpqRDMmnqqdARnmqjafYz5E1u0fvjIoAyhpy+YpsrmWRF5ZCQfyNdh4f8AEMlnKqTyMy9FJ4Nc3J4bBBewl2nsUOKqSR39mNt1H9ogHUHrj1BoA9ch1qG71CCVnIZRg7q2orx4dU8piPJlUMPY149o2oeQyCSc+S33DKMr9Ceor0eC5M9nBIxXzImB3A5yp96APZ/CZWW3zjkVa8SWS3VmwPXsa5vwJeFG8pyMHoc13FzH5sRFAHO+E7j/AEdY3J3xnY2fauoHIrgLdpdO8QvEf9TONyZ/vDqK7i0mEsQIoAnooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApGIAJNLVLVpvItHbOMDk0Acprdx9v1pYgcxwDOPc1taTYBlDuPpXNeFoGvHku3zunckZ/u54ru8JBb4PAAoAwfEvlQ2r4O3A5IrzfVZYNO0261G4wsMKk5Pc+ldX4iuzc3GzOI1529q8c8easuvXTaTA+NOtj++ZT99/7tAHMLcy6zeS3LxmSaQ5A7IK1LXSQ7KbiTdjoo6Vb0HSrm8VLbTLcxwj70rcA/jXSvpVhpGxb2Z7q7bhYIhyT6YoAy7KxQviGLft6ACtAROkscQiXexzsA3M34V1OleFtRv41mv3Gk2LAnyYseYw9z2qjrfirwx4MVotJiW6vxjdIz7ufdj/IUAWtL8LapfNvkUWkJ6swwcVbuLXwN4XDy61fQ3N0BkoDvP5CvE/FXxJ1fXJW827kihJ+WGElV/OuKurm5vMqVYA9cd6APZvF3xs0+WOOz8P6X5cMMgdZHAAOOg21V0T4l6R4m1Iw+KNLitkkKrHcQrgKf9qvIrbS8JueKU+1Mm0+WPcEWRUI+4KAPqr/AIQqOe0M2jXsd7bE/LHIRn8DXL3emWUExtdTtmtZwcESLgMfY15b4B+IOp+F5ER5nkhDZKseD9a+hfDXi3RfHVv5N1NEGbAMDYyfzoA8/vfCEcytJYSbM8qoPWuT1PTL60cRXEe5eoyOv4171e+AbcRM2iXs9nJn5UY70P58iuM8QW93p+6DX7YKp6XEQymfX2oA8WubZ4FfahVVOdp/XFdN4WZrm3It2xheUzww/oav6hZiRxwrITgMOQawk+0aJdPNbLiInlfT1/A0Aet+BbwgwsGJ2nawPUGvYbaQPEpznIr588H6zFNe/IpXzV3gDs3evcNBuRc2aEH5gKAKnirTy1v9qhH72BvNXHt1H5U/RrsP5bIf3cgDCtyQCSFgw7ciuL0h2tL+5sn4EUhaPP8AdNAHdA5FFR27bo1PtUlABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRQKKACiiigArmfHVwY9L8mP/W3DiFB9ev6V01clq/8Ap/ieCIf6qyUyN/vnpQBc0C0W3VEUYVFCin+ItQWGIoh+YjFOa7S1t2II3V5t4+8R/wBn2jOG3XUp2xL15oAxfGGvMhls7Il7lh8xX+Ef41ynhrwsYIJLvWnEUPLlWPTPPPvWxoWnLptk+q63ITPId208nJ6ADua63QfDdxqU66x4oC22mRDzYLNzgADnc/8AhQBD4dsdS11BHo8P9n6WOGu3XDOP9gf1q/rmoeG/BEAgtohd6q/Vid8hPqT2rB8e/FWCDTXtNEK21vja103y59kHf614Xe61dX8ri13Ikv35mOXf8e1AHa+MPiJq2oyGD7SU42+VA2Ao9GP9K4b7LPdSbpMyMTxnt+FXtK0+ERq0pOf7oro7VLSIDYmT60AZdh4bLANKFBrag0WKNQF2j8K1rSWF1ACVZ2LjiM0AZX9nJgDPSq9xpCyIRnr7V0AjBx8hH4VOkHy/d4oA841DQFOfL2ZHqOtZNubvR7xZk3I6nIZeK9WuIYQdxhJb/dqjcQRSxs0tpv4xjA4oA1PA/wAY5rYR2upnzUBB3MfmFe0aRrukeKrFkBjmVjzG+MgGvknWdKaK4aWO3KAgjjmm+F/EWr+GdRjmhYvEhBKZ7UAfTfiHwDAlvLLow2HGWtyfkf6ehryrU7CbbKUjJMZKvGw+ZT6EV614H+IGn+KLNvKcR3QUFoW6/hS+PND89Dq+nRhrhE/fRr/y0X/GgDxDw6yp5h27ZoWyFzhh9PavY/h/q5d1XzCVP8Ldq8j1WwivHW80+R0lBIz0x7EVv+DNQ3RrNF8k0TbZoz2NAH0Rwy59q4zxXEbS6hvkGNjbXP8AsmtrQdWju7VCTzipddslvrGeIgEOhx9aAJtIuBLAvPatGuQ8L3DfY4Q2dyfu2z6iuuQ5UGgBaKKKACiiigAooooAKKKKACiiigAooooAKKR2CKWYgAdzXPTeKbaK5aIKsmOMpKn8iaAOiorDXxLaHG6K4x6qm7+VTjxBp2MtMY/99Cv86ANWiqMOr6fMP3V5C30YVZjuIZB8kqN9GFAEtFAIPQg0UAFFFFACMcA1wkNyFutTuD96SYqPoK7S+lENrJIxwFUmvKrnUEtdM8+ZsBi0h98mgDQ1LVIrW3kuLuUJEozk15qZ473UZdd1RilnF/qIyMn249TVyaRvE1zG53fYYjuJPCtj+lb3hXRYNWv01G7X/iW2hIt4z0Zh1fFAGj4U0Vr4rrviOEW8Malra3lOFhX+8f8Aarhvi58TVvHOn6Xl7GP5SVOPOb/4mn/F74gC8ml06wlxp8P+tZf42/u14lZ+brOqh2yUB6DoKAHm2vtXvBcXu1uflTBIX6V0NppLYG4EAdlWui0+0RVACcdBxW3a2OcHbzQBysNl5Z4DflV+C2ZmGFNddPpcLWxd0xIBxiq1naSRkFYz+dAEFnZ7FBEbZrQjiYEfuz+IrdSyzboxQ7yOmelKlhJQBkAFRyhx7CmPcIvBUr9RW99hcev5VG9nKeig/hQBhMFlHyjP4Ypn2cZ5wK2RFIj4Zar3bDdh4jj1AoAy7zRxPFk7Sh71zGq+GothKk8d672B4wmFbg9jVe4hilB5oA8YF1eeH9RSaGR4wrfI6nlf/rV9B/DPx0+vWfl3UsYvIxgp2dfUV5r4j0ETRsyqGFcVb3V3oF/HNbs6MhyCO3/1qAPevFuhOLi41LSbdpFkbMtvGvXA5Ye9cQITFP8A2hpE4WQ8OjD5W9iPWu0+HHj601WJTNOqXEa4dGPU+orV8TeGoL6ZtU0cRx3EnMsZACyj+h96AMXwn4lBu/KZjFKPvRt/MV6hYaiJ4eG5968K1aw86U+UhsL2HkIThs+o9RXQeC/FLXIa0vGEd7Bw3YSD1FAHoWllYNWubc8B28xPx612kR/diuDRmuRHPEP3yHIrtrCTzbZH9RnFAFiiiigAooooAKKKKACiiigAooooAKKKKAIbuJZraSNujDBrxzxT4ftFuGdGKuD124/kRXs8gJjYLjcRxmvNfE2g67O0skVkkq54EUoJP4HFAHlF59tspT9lvGUfU0+18Q69EfllZgPSQ8/zq5q+i6vbyZudMvEB7+USPzFULVNsm2QFGHUMMYoA14fFOt4zJExH+2it/MVPF4u1SH5zp0LD1EOCfxFXNJiBxtOfpXXWFrG4HmRo4/2lBoA4qL4iXED75tNlQeqTOv6HitC2+K1uHBkXUIx7OrD9a7Z9LsShaS2jP6fyrhfE2l6bvYrbqp9v/r0AakfxTs3kBTVJIh6T2u4fmDWpbfEeGRgE1PSJM9nZoz/I15bFodrPNwoAz/dB/pXYaB4K06cr5sat/wBs1/woA6rXvFEmoaBdR25shI0Z+aO6BAHc84ryK51611m8W1uLqKKwgAVjv5lPt7V7baeANAEA8yyQ477FH8hWF4i0jRdNX/Q9NtY3UYDBBmgDhJfEGjywf2dbTrb2SECebozD+4g6kmsnxt44Y2HlWJbTdJiTaF6PJxj8KytZRLrxZMY0CnyQrug5/OvPdYjF5rc8JeSSKBtqh2zQBC7z6zNtiRxEeVU+vqa7HQdHFlCiZUeuO9UNMtBA6+WTnGMV1unQHCkjJoA0bGBVA71uWacjC1BYW7NjIxXQ2dmigFgaAIvJMsYQqTViDT1XBKgGroMMa8jp702S8hCnEX/jxoAlESFBngD2p6LGBxz+FZTXgYYAOB6Gk+2LjG4j8aANyMR98UriIjggfjWEL2PvJn8aX+0YweCPzoA054UfhW/SqFxZMV4b86at/GDneopw1COTgOp/GgDNe3kQ5OD9KYyp3GD34rQlkjbuv4VRdlycUAUbmFSDtbGa4rxLozTqzIORzkV3NzGpU8fkawr+IkEKSPxoA8ga3u9NvgUJRuoIyM13/gz4pahplwttf7rpOBtY4fHse9M1HS3nwXAIXoa4vxFZmB1ljXDxnINAH0JNqfhrxzaxp9qW11AfcD/IyH+tcvrHg/XoXXy4IrmSA7o7iFwu8e9cp4YtbbXrCFkZUmJwR2z/AEroY9d8TeEotsc5uLZicRudwA9s9KAOw8K+MoLWQWutrJaToAGWVT/P0r1jR9YsJ4la3u4HibkbWzXjVpLq+swrcS2sc7yKD5asoZfbmtW3stR04iR9EuAWUcQzeUpPqw6fiKAPafMTGdy4+tQzXtrD/rbiJPqwrxXVPEWuwf6vQogF7y3e/wDTNc3e+M/ERY7bKwgPqqKx/MmgD6Dl17TYvv3cRPopyf0qN/EFmE3IJ5P92I188x6/4sv2CJdlM9owB/IVpw+H/Ft8AZ724Kn/AG2/+tQB7ZJ4khRC3kOPZ2Vf5mqMnjCFATIbWP0DTg/yzXkx8D6qGzdXm4epbkfqarz+GprcEPeMR7df6UAeoTeO4kJJubUL6IrOf6Vk3vxHgRji+Ix/CkQH8zXlV5pgQkPNK492qrBawRSfcz7k0AepD4hyXLr5CX0gz2KqD+lel+HdS/tPT1l2Mh6EMQf5V4t4eaFWUiOPPrtGa9l8MSb7AUAbNFFFABRRRQAVWurC0u1K3VrBMD18yMN/OrNFAHPT+DdDlwUshAw6GBjH/I4qD/hEzAzGy1O4QdllVZAP5H9a6iigDkbrSdaSLahs7keoYxn8uR+tcH4j0jW0YtNpdzt67owJAP8AvnNe1UUAeAaKivOFJw+eVPB/KvT/AA7a4VeK1/E0Okrps93rMELQwqWMjDDD6HqK878J+JNVR7i6is/N0jeTEkzgSInsx+99D+dAHqV3IILU/SvJPG2oqolZm+VQSa7G48Vadq1kxsZx5ijLwtw6/UV4t49vnu72HToT88zZfHZc0AYMMxjsr3UXH7yQls+g7CuC0RfNmeaXczyOXP516P4wiWw0SO2XngBgK4jT22zbVVVA7CgDcs9xbIXiup0YZYbiK5mGToB19q6DSSIyHkoA7ixEYAycfQVprLCvUsfTArlYtViRQAoz9aJ9XO35Nq/jQB0Ul0oyNgz2JNZ9zcOckMgH0rm5tQmcnDE/jVZ7iZu360AbEt0ckbyc9gKhBLc7vzNZqeax5BzU0cc5PANAFst75qNpFU5zThbTsOv6VE9jL3PFAC+cP7y/lSC62nhlqvNauo4ck/Sqbwzj+I/lQBsLf/7efxqSPUiD1yK50mZTyxP4UC5kXqoNAHWNeRuvIrIvGy+UzWcL4D7wIp4vI270ASM5dCjD8RXO6/p6tEQWz3ro0miI5PNUL5AxOTlT6UAcP4Xv5NJ19bYELFI24c969L195r7QHuI1OYxgCvLNeCwataPGuCsgJ9xXtvhSKLUPDsiv0ZhnNAEvw/1IvZ2rNw20Bh6EV7jodwJrUDPavneyjbQ/EctmSfJl+eM+/cV7R4Pvt8agmgDT1+23oxPNeYa/ahXYhR+Vew6oqfZmd2VVAySTgCvLrqaLXtUlsNF23M6DLNnagH1PX8KAOZ0yUxXAGe9ej6JcCSEAms+y+GdyziS91NIuc7II936n/CuosPBWmW0YWV7q5I/56zED8lxQBk6ldWsSt5s8SH0LDNc9cwzXw/0C0urkN0aOI7fz6V6ha6Tp9oc29lbxt/eWMZ/PrV6gDxY+A9evTn7NDbqe80o/kM1ctPhJcPhr3VY4z3EMRb9SRXrtFAHEad8ONLtCDJc3kxHbeFH6DP611emaZa6ZD5dojKvfc5Y/rVyigAooooAZO/lwu+QMDPNcFd+OfIuXj+1WfynGGVga7HXZJotLna3RXkxgKxwK+ftc0/V0uZZ3toSrEnCl/wD4mgD09PH6HrPYn/gTD+lTr48hI/1tkf8Atqf8K8PE11u2m2Ab3fH86nVL1sYswf8Atqn+NAHty+OYT/FZH/tv/wDWpf8AhOIu/wBi/wDAj/61eKLa6i3TT2I9pU/xqxFpWqSdLBlHqXU/yNAHr0nj23X+OyH/AG2J/pVGf4hKM7Li0X6Kzf0FeXz6Tqcf3bdR7sr4/RarPYX29FM0S5PKohJ/8eIoA6/xP4kk8SvFYNeEWhO+VdmwHHQepqrfam89odO8PlJrnAWSXP7qBe5ZugPsOaj0bwNa6ncB7+RpQDgb3OMf7q4H5k163onhnTNJsUFtbqWjHyFlAC/RQAB9cZoA8B8XeHzpNj/akc9wupq6k3BJUkHjAXoF9AaPCunFjJqmrTGa9JHUY4rtPijGJLG7DDI25/I5rhLK5uPswQKQJO+OnFAGT8RrwyWsezDM8mODXOaXC+N2xVFaPjRHBtBgFFf5mHriq+k+W67SxzQBqW0WOWcCr0eDgbiaW2tYyo24P1q9DaKCMkUAMWIlejflTkhcnAz+ArVt7PcB8wrRtbDaR0/GgDGt9OeQjJYD3rUt9Ixznn3FbcFouANgJ+lMu73T9NGL66trZj0DyYoAqQ6ay9QD9BVhLN2OP0rIvPHmh20gWKZrnHXyVJH51nXnxFtI5A9hZS3CH7xJ2kfhQB132SReAM/WlNnIV5Vc1zUfxHsX0W6uxaTLdQkAWzHl89wfSptF+Iem3kMgv4Z7GZV3YI3K3sD60Aas1lJjHliqUtg/PyjP0qXw54ysdXtrh5VNsYTk+YcAr/eqhD8QdAku2jmmkiXO1ZWjPlt+PagBJdOb+ID8qpTaaMHI/Su2s5rLUI99rPDKn95GBFMuLBWBK7ceoNAHnU+nAE8GqUtkQPlzXoFzp3HABrJutOIBIFAHFOJYj3xTw7OuCa2Ly0YA8CsWWFo3J6UAc74ljRdso5aMhsY616v4EuVl0NQp+WQBjjtXmevRloGc4xjmuk8Hah/Zmg/vAWLRggegoA6vxvFDJYJc20ii5jkBiJOM461b8O+OrW2aztrYfaNTusiK2Bx8wHO49hXM2dld61P9on3rbrkqvQCpLGGCL4haRFDEqtDE7ZA5PHWgC74g8Y69LrkFt4pCwWc4/cCBiYdw6qc87h71t6fFJZ39nq2mPumiPzIDw69xXd6n4QsvEmlESxRu7AFkbgMexB/hb3FedReE9Y8M6kX0yf7ZGv8Ay53j+XIB/st91v0oA9j0zxfpF2QklyLabgeXONhz7Z6/hW/HLHIMxurj/ZOa+VtY1vWLK/lFzDdWSs2fIuY8qPpkEH6in2PjK6gyUSJS33jC7xZ/75OP0oA+qaK+c7X4gXSoFEl4v0uc/wAwatr48u25+0Xv/gQP/iaAPoGivAh44u+1xe/+BA/+JqRfHN6Olzef9/1P/stAHvNFeCN411JvuX16v/bVP/iK7f4Zaxf6ncTfbbyadAvAkKnH5AUAeiUUUUAQ3e37O+/G3HOa8l8V3loJJFE8Q9s17BUE9nbXH+vt4ZR/toG/nQB8wX0iNKSrqR7GrOnN8ww3619Ey+HtGmUrJpVgwP8A07p/hWc/gXw0z7/7It1b1Tcv8jQB55orH5eTXZWDHaOTV6TwLorf6lLm3P8A0ynYfzJqWLwpFAm2DUb9fQs6t/NaAOd8ScwGvOX4uz9a9bvPB91c5Da1IUPZrdT/ACIrn7z4Z33mb7XVoGPpLAR/ImgBfCh5WvRY+bQ/SuJ07w3rulqCo0+6I7LIyfzWr174g1fTNMnuLzw9M8UQJf7POjsB64yDQBxPxJUG1uwenlt/Kub8NPFc6XBgAsVUAenGKf4u8STa/p076ZompyJIpUPsBXnryDXKWE+oaLHHK0UixEYVZBtIxQBZ8caTth+TlGJI+orjbJNkhLDJr0TVNSttV0ZVTKyqNxDetee3DiCaQHnaRQB1+krGYQe9a0MIc9Riud0S5JwCnymtbVNTXS9Mmugu9kU7FAzlu2aAN1pre0gElxNFDGP4ncKKzbzxxpNnbyrZSfbLrBCCMHZn3b/CvKNtxqkgur2VpXfnLHO32A7Vu6da2qYUrk+9AGppXjXW0mlN46zJMCFwuPKPYisn7E9xcPPfSNLM7FmYnJNa62vmfcAx2xV6DSmKAkHHrigDDSxgA4jzVqGyjGT5YzjFdFDpIYADr9KtRaI7FgqOSOcYPSgDkhpaMzNtxnrinS6fFgYjPFdb/Z6xnDBhz3FO+wRn1/KgDiXsP3ciR7lWRdrD1FVH0nKbNvy9MV6EumZxtQkZ9Kil01hJt8og9cYoA85fRmU/IpUf7JK/yqF9LuUU7JrgewlYf1r0v+zG8rJiwB1J4qnc6YqoHyhB44YUAcLb6hr2nY+z6hc+Wo+5K29f1rr9B8fw3kkVprdqtvK3yrcRH5GPuO1Vry1RN2cdBWDeWEBkV4xyDn2oA9Nnjt3yIJI5Cf7jg1zuqxJE2GUbq87gjuYdcjOlXDrdNIC2xsAjvkeldxrM0jfM20vjkjpmgDlvEU25GjB4711nhzTheyWwYZhUIPavPb4S3d55Qf77hAK9g8PwRx2ABcIEAH1OKAOguZ44o47a2XJHGBXI6UyP8RHkzl0tz+GWrrbRYrcM7uuVXJZj1Jrg9N1C0tPHF69zMkYZFWMnowzzigD6T8MNutF+lVvE8CTQssiK49CM1V8HapZyWikXMeMY5bFTeJNTsY4yGuEyRwByTQB5rqd1c2bNHDMWh6GKUCRPyNU7Sw0/VsLdaPpjP/eRGiP/AI6asa15lzL/AKLbXM+enlxE1b0LR9ZjZZDpV2Fz/EuKAGy/DjTZ4wyWvk/9cbtx/MGs6fwDZW68vfD6To2P/HRXokb6lGojOkXJH94CqV7Bq8+RHo9x+JAoA80uPDOnw7t17qCY7YQ1nTaXp0Z+XU74e3kof6129/oOvTkhdGufzFYc3g/xJI/y6Nc/iR/jQBl22jWsxHl6nfMfQW6f/FV6j8JrM2NzcRmSSRSvBkCg/oTXI6V4U8QW8gMulTgD0wa9c8LaTHZ26TPbtFckYbcaAN+iiigAooooAKKKKACiiigAooooAa49BVS6HGH2srcEN0YelXabJGkilXUMD2NAHC3ukRaTdS3nh1VQyHdLaE/I/rj+6amivfDevoba7tYUuyNr28q7XX8O/wBa1tR0xon82AnZ3Fcvr+lWl/t+1RFZV+5PH8rr9GFAGH4i+GNoqPJo8jQZyQqHcv4r/hXifi/wprdjezARHJ/hwfnx3WverG61Pw+QQ76nYqcgEfvEH071uSHSfGARGaCV1XLHO1kb27g0AfLmg6zNbMUmU7lO1lPVa7jTdQhu4+FVh7iug8Y/Cu9fzrjT4UuXJPlurbZOOx7EflXkpN9o98Yp4ZbeROCjjFAHbX+nabseaaxzgFj9nO1if5GuHju288/uZIVz8qSfeA966TTfEUUgAkx75o1vTYtY2XGnyRJcqOA5wr+xPb60AQafqDxMrKcGums9euipVp2CN1wBXBym4sSBfweTzjcGDAn6ir9vOdoKv79aAO6i1IrnynxnHPetOy8Q3ltHKscpPmDGSMlfpXni30iVMmsTKaAOwaeSWQM0rs2c5LGrUJwwdiWYevNccmsTEdBUq6xNj7wH40Adi1w6szIzLnsO1Up7t9zMXcsepzXMSanO4/1p/Oqsl7J3cn8aAOimvFUZPJ+tZl7fqFG3g1kNdk53Gs6+vhCjSOc47UAXrq7ZiSTwBzWSZri8lEFkhbPLP2UeuahmN7cSxQrEyQzYJmH8K961Lm6jsoNlsoRANqg9SB60AM0y2t7C4aUEvcsMM3+FUtc1eT5Y1ZVyMnmslrm7ursLEryknkLwPzrX0zwPqutXqkQPIuOkf3fpuPFAEPhy0e+v1uQoWGPJDN0J9q7wXVtCFTc7kenQn0Heuj8P/CzVvLjjm8i0tR8p2jc5+npXpWkeHNA8I24neGL7QBnzZPmc/n0/CgDzXRPBmu+J97TRvp9kx/1k2VJHsvU1u3PhTwx4ShVb5F1G/P3N4y+fYCupvNfvdTJj0nFvbt96Zhk49hVOx0a3ScylWnuGPzSyHcxoAwNE8N/2hfrdXUHlRBt0cAJwPc+pr1Sx0m0WNWa3iZ/UoM1DpdhtAZlwO1bIwBgUAIkaRjCKFHoBilGcc0tFABRRRQAd6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAIyCDWRqGm+YS0YGe4rXooA4i505lJMeVYdq53UtMjkn85SbW9H3Z4xg/j616lcWyTLyMHsRWBqWnjBEqD2IHBoAxNI8VtZSJaa6nlM3yrdr/q3+v90/WtLxN4V0bxVpyrcQoWb/VSoBuHvmscW0cyyIFEifdeJx/jSWMN3pcxl0e4yoGDZzH5f+AnsaAPJvFvw5k8P3LG7R5LInC3MPA+jDt9a5ttKu9Nk8/TpPPTGQjV9OWXiHTr/wD0PUFNvPt+a3uVwXPt2I+lYfiL4dWdzm40Xbaz/eaA/wCqb/4k/SgD5vn1OK9Jh1dOVOSh+X9akTSoLhVbSr3axz+5nOMfRun54rudc0SKC9Nvqlj5UvZJkxn6N0IrCn8J2ySGSyklgz27A0AYkGnaihZ71RBbx/M7lgePYDqao2+rW0m9g20FvlDdQPetm507WLZSqsGHTjoaoJP9nOy80+AkDHzRL/hQAi6lGzBYyGJOBg9akF0jvsBzITgKOpNOtrjSEdXjsoYJVzh1XkVZ0y80rSGkliQySOOXYbj+HpQBmy6jFDkS5V14Ze4qJLq5uCxEDwxBciSQFQ3pjNXf7Wsf7TkurS03XrjGQu4j6DsfepJ9L1PVyJbkrCh6b2y2PpQBirLeXEhitbeSVwMnYMgfU0tnYeZK02rORtOFtlPLn/aPYV2ugeDWeeO2WSe5nk5MMYwMf7Xp+Neo6V8J7aTyzqTiNcf6q3/qx5oA8WFpqV4haFVgh7MwwMeg9a6Hw18OdQ1WUM1vJOCQPOnyka++Opr33S/Ceh6MwlS3TKrw0rbsfnUV34w063DxWSNdTK2AkK5H50AYHhb4VaZpTrLqJF5MoyFZcIv0WuxnvtL0dFAMKYGNq4GK5W+1PV9RYmSVbGAjGxDl8e57ViXMunaUFnmV55nbarsC7FvQCgDrbrxPd3GRp8ACH+N+B+dYNzCZ7gT6jO08naNelQ218946oyy2qt0aeMpu9lz1rqdN0VYVWSUEs3QdSaAKmm2U90VG0Rx9kH9a6P7GmnWU9wyeYYo2faO+BnFRrcWOlSb7+7ggfHCM4GBWjZ39nf27SWtxDPEByysCKAOG+G73vi3wgdb1HULiO5v2kMSwtsW1UMQoA7kY5zmodK1HUtX+I954eub+UWOjWcUjsgCPdyP/ABMR0A9BWroOlaRCmo2XhvWTDayu0klvCysIWb7xQn7ufxqtFZeF7a5ttV0/WUt7u0QWTXPnB/NXOQkmfvc9DQBnfFJ9Q8OaJbz2Gq3xE+q20YQEFkRjhkBxkg+/NdNoCM2vXDRtrEUccYBS8H7p891yM5FZGr+G9F8QvcQXev3EtzDcRX02yVRsMfK8YwFFd3azR3FvHLBIssTqCrqchh60AS0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAHeiiigAooooAKKKKAA010WRSrqCPenUUAY17o6FzNAPnxypPX8ax7uzdPmeM7f73cfWuxqKWIMCRjPv3oA4i5t4buHyb6FLmHqN33l9wexqGxj1LSGd9PupL6zY5a3mbMij2J610N/YRo5MXy56p/hWfJbOvzRHJHpQBPaahp3iMi3uI4PNU/PDMoLD2wazNa+HltOTJpcxtG7xLyh/A5x+FQ6hZ2l+VN9EyzL92aNijqfZhU9vd69pzKbS5i1S2A5hn/AHcuPZuh/HFAHE6l4a1S0jmWa1+0LCfvw9ce69fyzXPS2VrfRsrxAun3lYYIr2GHxnp7+ZBqUMthcM4UR3SbQfo3Q1Ne+H9I15Y5GijcsxPmRttJHsRQB8733hOGRiYpDGW6ECs7/hBrueMk3kYQH7wzn8sV71ffDGxnYCwv7u3BG4Bn38596oJ4G1K08wRXVpeFT05Rif5UAeV2WjRWEaxQKMdzj5m9ya6bwtoOo65cILVPLtd2GuGXj6L6muj03wRd6jqpXVZY7WzjP7yKIhnkP90kdBXe6lrGmeGrFYYgu8ALFBGMsx9MUAP8O+HrHw/ZlYwA55eRz8zn1Jqh4g8ZwWjLb6Wv2u8JxsQZA+tc5fTa34hk3Xsv9n2BORDHzI31PatDTdMhtItttEFHdjyW+poAznttR1VvM1u8Zk6i2iO1APc9TV6KGO3QJaQog9QMVYYEybEVpG9F6VYg0yaU5uWwnZFoAy3XL7QWnf8Aur0H1qSXQ5blY7p0BeBhIiH7vHUY78V0CR29nH/CoFRXl+YbJ7plaO3UhQ3QuScAD0+tAC+GAlwmoRTgXf787A/IVCAQMdB3q+sR0W7gAYvZTt5eGOfJY9MH+6a57QtL1Ww1/U4BfxWlvdKlzEqReYExwV3EjvzUPjX+0EskittYNwVmjMxMAKwrn7zEGgDfv7YaNrVxqv2YT2dyq/aCF3PEy8Bh/s46+lN0/Tm1RrzUWa3hS5gMEK2zbgVzncxHU/yFUGtriaDzx4pS47sQyxIPpjOP1qvoFhcxa3L/AMI7qrtYtGXuVljEkPm/7BG3BPfFAFrwz4WvtOukkujZ7YI3RBGDmUsMfOe4rPg8J6zvku7mPTmvmLoQrkR+Wy7QFG3jaOfeu+sPtQtlF95Pn/xGInafzqxQB5ongDUTamy+3wwwRo6rMFLvMGxlXHGBx612/hnT5tK0GysbmWOWWCMIXjXapx6DtWpRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBSv4PMHKk+4rGmyjcjcR+Brpqz9RsxMuU4b1oAxwYLsbcZccFSMN/8AXqvLp0kWWgOV/u0sokhbE0W9R3A5q5bTW8yACSRfo2f50AZcjeZGYrmJZY+6SKCP1qlFpttbtv0uWfTZc5Hkt8mf9w8flit/UofLhDRETLnkNwR+NZ5BC8px6GgCk3iHW9Jj/wBOt4r21Xj7RbDDqPVk/wAK6DTr+21mzFzbMsynqY+HU+4rMjCuPkOG9DWc2l/ZL1r3TWNrct98KPkk/wB4f1oAzIdSu7DUtZtbY+fcz3BECA8ucd/QDvVyw0tdKjM+oMlxqkvMknUL/sr7Va8NWQsr67vruNGvrg43joq+grf/ALLjuW82QZxzz2oA5+ES3EnyqWPt0rVisXK/vm49BViS5trUeXGMkdlFQMbm74/1cZ7A80ASNNbWq4LLu/uryTUe+6mGcLBGegPLGrdlpiRHChTIOfZa0IbZZDiPp0aU/wAhQBn2el+ZIHcl2/2u34Vtmzhe3aCaNZYnGGVxkEfSpY41jQKgwBT6AMz+w7DyhF5L+X02ec+PyzV22toLaLy7eJI4/wC6owDU1FAFBtH0xmLNp1mWJySYFyT+VXkRUQKihVHAAGAKWigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCvcWqTDkc1i3mjsGLwHa/qO/1roqCM0AcjHLIjGKdcN3B6Go5IBn93LJH7A5FdHqNglxHkDDjoa524jliYqeGHr3oApz+bbsG89cH+8nBqzHeEoNyo/rtPP5VGZDjEqcfTIpESGVsBVB+mKALVpG91L+7jYD34roI4zHAFkdEH1rO0/ToIULOz89gxp13HbxLlYiT6vk/zoAjnt4UcuHDj1zUcTtNIEgHA6v2FVwJJ5MMu2LsB3rcsrRfLAIwnoO9ABBF5qiNMiEHLt3c1oqAqgAYA6ChVCqAowBS0AFFFAoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKgntYph86g1PRQBly6XGOU4HpT7e0WJshA34Vo0UAQ7W6Ku38KilsxKvzsWPqat0UAUorFEOTVxVCgAdBS0UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Example of a transverse defect.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Walters, MD, Karram, MM. Urogynecology and reconstructive pelvic surgery, 3rd ed, Mosby-Elsevier, 2007. Copyright &copy;2007 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Repair of posterior vaginal wall prolapse",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 443px; height: 294px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Example of a transverse defect.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Walters, MD, Karram, MM. Urogynecology and reconstructive pelvic surgery, 3rd ed, Mosby-Elsevier, 2007. Copyright &copy;2007 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_39_5754=[""].join("\n");
var outline_f5_39_5754=null;
var title_f5_39_5755="Treatment for mild pediatric lead poisoning - level 15 to 19";
var content_f5_39_5755=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53709&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53709&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment strategies for patients with venous lead levels 15 mcg/dL (0.72 micromol/L)  to 19 mcg/dL (0.91 micromol/L)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        1.",
"       </td>",
"       <td>",
"        Report to appropriate health authorities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2.",
"       </td>",
"       <td>",
"        Perform history, physical examination, and laboratory examinations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3.",
"       </td>",
"       <td>",
"        Repeat lead level in one month, then every three to four months until &lt;5 mcg/dL (0.24 micromol/L). If the lead level is not &lt;15 mcg/dL (0.72 micromol/L) with the second or third testing, refer for environmental abatement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4.",
"       </td>",
"       <td>",
"        Provide parents with educational and nutritional counseling",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_39_5755=[""].join("\n");
var outline_f5_39_5755=null;
var title_f5_39_5756="Mod approach surg CRC mets";
var content_f5_39_5756=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F52622&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F52622&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Conventional indications versus modern approach to treatment of hepatic colorectal metastases",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Conventional indications",
"       </td>",
"       <td class=\"subtitle1\">",
"        Modern aggressive approach",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;4 metastases, unilobar disease",
"       </td>",
"       <td>",
"        No limits. Multiple/bilobar metastases acceptable,",
"using neoadjuvant chemotherapy, staged resection, and resection/local",
"ablative therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Size &lt;5 cm",
"       </td>",
"       <td>",
"        No limits",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No extrahepatic disease",
"       </td>",
"       <td>",
"        Pulmonary metastases can be resected",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Resection margin &gt;1 cm",
"       </td>",
"       <td>",
"        Resection margin &lt;1 cm managed with ablative",
"treatment of narrow margin (cryosurgery or radiofrequency ablation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adequate remnant liver parenchyma",
"       </td>",
"       <td>",
"        Preoperative portal vein embolization to increase liver",
"remnant volume",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Resection of all macroscopic disease",
"       </td>",
"       <td>",
"        NED can be achieved with combination of resection and",
"local ablative therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No metachronous liver metastases",
"       </td>",
"       <td>",
"        Synchronous and metachronous metastases acceptable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Absence of vena cava and hepatic vein confluence",
"invasion",
"       </td>",
"       <td>",
"        No limits. Caval/hepatic vein resection with",
"reconstruction can be performed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Absence of hepatic pedicle lymph node metastases",
"       </td>",
"       <td>",
"        In absence of celiac axis metastases, hepatic pedicle",
"lymph node metastases may be resected for improved 3-year survival",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NED: No evidence of disease.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Khatri VP, Petrelli NJ, Belghiti J. Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit? J Clin Oncol 2005; 23:8490. Copyright &copy; 2005 American Society of Clinical Oncology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_39_5756=[""].join("\n");
var outline_f5_39_5756=null;
var title_f5_39_5757="NHLBI panel screening guidelines for pediatric dyslipidemia";
var content_f5_39_5757=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76041&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76041&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pediatric dyslipidemia screening guidelines from the 2011 Expert Panel Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Birth-2 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No lipid screening",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        2-8 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Selective screening using fasting lipid profile (FLP) two times*, based on a positive history of one of the following:",
"        <ul>",
"         <li>",
"          Parent, grandparent, aunt/uncle, or sibling with coronary heart disease (ie, myocardial infarction, angina, stroke, coronary artery bypass graft/stent/angioplasty) at &lt;55 years in males, &lt;65 years in females",
"         </li>",
"         <li>",
"          Parent with TC &ge;240 mg/dL or known dyslipidemia",
"         </li>",
"         <li>",
"          Patient&nbsp;has diabetes, hypertension, BMI &ge;95th percentile, or smokes cigarettes or is exposed to second hand smoke",
"         </li>",
"         <li>",
"          Patient has a moderate- or high-risk medical condition associated with cardiovascular disease (ie, chronic kidney disease, recipient of a cardiac transplant, Kawasaki disease with current or regressed coronary artery disease, or chronic inflammatory disease)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        9-11 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Universal screening with a nonfasting lipid screening using non-HDL C levels.",
"        </p>",
"        <p>",
"         Further evaluation based is recommended with measurement of&nbsp;FLP two times* with&nbsp;a positive result of either a nonfasting non-HDL-C level &ge;145 mg/dL, and HDL &lt;40 mg/dL, or a FLP with LDL-C &ge;130 mg/dL, non-HDL-C &ge;145mg/dL, HDL-C &lt;40 mg/dL or TG &ge;130 mg/dL.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        12-16 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Universal screening",
"        <strong>",
"         not",
"        </strong>",
"        recommended because of normal changes in lipid levels during puberty, which decrease the sensitivity and specificity for predicting adult LDL-C levels and increase false-negative results in this age group.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Selective screening using fasting lipid profile (FLP) two times*, if new knowledge of one of the following:",
"        <ul>",
"         <li>",
"          Family history of coronary heart disease (ie, parent, grandparent, or aunt/uncle)",
"         </li>",
"         <li>",
"          Parent with TC &ge;240 mg/dL or known dyslipidemia",
"         </li>",
"         <li>",
"          Patient has diabetes, hypertension, BMI &ge;85th percentile or smokes cigarettes",
"         </li>",
"         <li>",
"          Patient has a moderate- or high-risk medical condition associated with cardiovascular disease (ie, chronic kidney disease, recipient of a cardiac transplant, Kawasaki disease with current or regressed coronary artery disease, or chronic inflammatory disease)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        17-21 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Universal screening once during this time period with a nonfasting lipid screening using non-HDL C levels.",
"        </p>",
"        <p>",
"         Further evaluation based is recommended with measurement of FLP two times* with a positive result of either a nonfasting non-HDL-C level &ge;145 mg/dL, and HDL &lt;40 mg/dL, or a FLP with LDL-C &ge;130 mg/dL, non-HDL-C &ge;145mg/dL, HDL-C &lt;40 mg/dL or TG &ge;130 mg/dL.",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NHLBI: National heart lung, blood institute; BMI: body mass index; TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TG: triglycerides.",
"     <br>",
"      * Interval between FLP measurements: after 2 weeks but within 3 months.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Daniels SR, Benuck I, Christakis DA, et al. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: Full report, 2011. National Heart Lung and Blood Institute. Available at:",
"     <a href=\"file://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf\" target=\"_blank\">",
"      file://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_39_5757=[""].join("\n");
var outline_f5_39_5757=null;
var title_f5_39_5758="Breast cancer surveillance guidelines";
var content_f5_39_5758=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F61501&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F61501&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of 2012 ASCO guideline recommendations for surveillance after breast cancer treatment",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"20%\">",
"     </colgroup>",
"     <colgroup width=\"80%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Mode of surveillance",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommendation*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Recommended",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        History/physical examination",
"       </td>",
"       <td>",
"        <p>",
"         All women should have a careful history and physical examination every&nbsp;three to&nbsp;six months for the first&nbsp;three years after primary therapy, then every 6 to 12 months for the next two years, and then annually.",
"        </p>",
"        The history and physical examination should be performed by a physician",
"        <sup>",
"         &bull;",
"        </sup>",
"        experienced in the surveillance of patients with cancer and in breast examination.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Patient education regarding symptoms of recurrence",
"       </td>",
"       <td>",
"        <p>",
"         Physicians should counsel patients about the symptoms of recurrence including new lumps, bone pain, chest pain, dyspnea, abdominal pain, or persistent headaches.",
"        </p>",
"        Helpful web sites for patient education include&nbsp;",
"        <a href=\"file://www.cancer.net\" target=\"_blank\">",
"         www.cancer.net",
"        </a>",
"        and",
"        <a href=\"file://www.cancer.org.&Delta;\" target=\"_blank\">",
"         www.cancer.org.",
"         <sup>",
"          &Delta;",
"         </sup>",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Referral for genetic counseling",
"       </td>",
"       <td>",
"        Women at high risk for familial breast cancer syndromes should be referred for genetic counseling in accordance with clinical guidelines recommended by the US Preventive Services Task Force.",
"        <sup>",
"        </sup>",
"        Criteria to recommend referral include the following: Ashkenazi Jewish heritage; history of ovarian cancer at any age in the patient or any first- or second-degree relatives; any first-degree relative with a history of breast cancer diagnosed before the age of 50 years; two or more first- or second-degree relatives diagnosed with breast cancer at any age; patient or relative with diagnosis of bilateral breast cancer; and history of breast cancer in a male relative.",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Breast self-examination",
"       </td>",
"       <td>",
"        All women should be counseled to perform monthly breast self-examination.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mammography",
"       </td>",
"       <td>",
"        Women treated with breast-conserving therapy should have their first posttreatment mammogram no earlier than six months after definitive radiation therapy. Subsequent mammograms should be obtained every 6 to 12 months for surveillance of abnormalities. Mammography should be performed yearly if stability of mammographic findings is achieved after completion of locoregional therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pelvic examination",
"       </td>",
"       <td>",
"        Regular gynecologic follow-up is recommended for all women. Patients who receive tamoxifen therapy are at increased risk for developing endometrial cancer and should be advised to report any vaginal bleeding to their physicians. Longer follow-up intervals may be appropriate for women who have had a total hysterectomy and oophorectomy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Coordination of care",
"       </td>",
"       <td>",
"        <p>",
"         The risk of breast cancer recurrence continues through 15 years after primary treatment and beyond. Continuity of care for patients with breast cancer is recommended and should be performed by a physician experienced in the surveillance of patients with cancer and in breast examination, including the examination of irradiated breasts. Follow-up by a PCP seems to lead to the same health outcomes as specialist follow-up with good patient satisfaction.",
"        </p>",
"        If a patient with early-stage breast cancer (tumor &lt;5 cm and &lt;4 positive nodes) desires follow-up exclusively by a PCP, care may be transferred to the PCP approximately one year after diagnosis. If care is transferred to a PCP, both the PCP and the patient should be informed of the appropriate follow-up and management strategy. Re-referral for further oncology assessment may be considered, as needed, especially for patients who are receiving adjuvant endocrine therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Not recommended",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Routine blood tests",
"       </td>",
"       <td>",
"        <p>",
"         CBC testing is not recommended for routine breast cancer surveillance.",
"        </p>",
"        Automated chemistry studies are not recommended for routine breast cancer surveillance.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Imaging studies",
"       </td>",
"       <td>",
"        <p>",
"         Chest x-rays are not recommended for routine breast cancer surveillance.",
"        </p>",
"        <p>",
"         Bone scans are not recommended for routine breast cancer surveillance.",
"        </p>",
"        <p>",
"         Ultrasound of the liver is not recommended for routine breast cancer surveillance.",
"        </p>",
"        <p>",
"         CT scanning is not recommended for routine breast cancer surveillance.",
"        </p>",
"        <p>",
"         FDG-PET scanning is not recommended for routine breast cancer surveillance.",
"        </p>",
"        Breast MRI is not recommended for routine breast cancer surveillance.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Breast cancer tumor marker testing",
"       </td>",
"       <td>",
"        <p>",
"         The use of CA 15-3 or CA 27.29 is not recommended for routine surveillance of patients with breast cancer after primary therapy.",
"        </p>",
"        CEA testing is not recommended for routine surveillance of patients with breast cancer after primary therapy.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CBC: complete blood count; CEA: carcinoembryonic antigen; FDG-PET: [",
"     <sup>",
"      18",
"     </sup>",
"     F] fluorodeoxyglucose-positron emission tomography; MRI: magnetic resonance imaging; PCP: primary care physician.",
"     <br>",
"      * All recommendations remain the same as those published in 2006",
"      <em>",
"       [Khatcheressian JL, Wolff AC, Smith TJ, et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 2006; 24:5091]",
"      </em>",
"      . The Panel concluded that there was no new evidence that warranted changing any of the recommendations. The 2006 guideline provides a detailed discussion and rationale for the recommendations.",
"      <font class=\"bullet\">",
"       <br>",
"        &bull;",
"       </br>",
"      </font>",
"      Although the evidence is lacking, it seems likely that history as well as physical and breast exams may also be conducted by experienced non-physician providers (eg, nurse practitioners, physician assistants) under the supervision of an experienced physician.",
"      <br>",
"       &Delta; UpToDate also offers free patient information content:",
"       <a href=\"file://www.uptodate.com/patients\" style=\"FONT-STYLE: italic\">",
"        www.uptodate.com/patients",
"       </a>",
"       .",
"       <br>",
"        <font class=\"lozenge\">",
"         &loz;",
"        </font>",
"        Expert consensus-based recommendations are available with criteria specific to patients with cancer (eg, from the National Comprehensive Cancer Network [",
"        <a href=\"file:///\" style=\"FONT-STYLE: italic\">",
"         www.nccn.org",
"        </a>",
"        ]). These recommendations include similar criteria as those from the&nbsp;US Preventive Services Task Force as well as other criteria such as diagnosis of triple negative breast cancer, or a combination of breast cancer and other specific cancers.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Khatcheressian JL, Hurley P, Bantug E, et al. Breast Cancer Follow-Up and Management After Primary Treatment: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2012. DOI: 10.1200/JCO.2012.45.9859. Reprinted with permission. Copyright &copy; 2012 American Society of Clinical Oncology. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_39_5758=[""].join("\n");
var outline_f5_39_5758=null;
var title_f5_39_5759="Position of subcarinal nodes";
var content_f5_39_5759=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F54056&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F54056&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Schematic representation of the anatomic relationships of the subcarinal lymph nodes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 245px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Kavuru, MS, Mehta, AC. Applied anatomy of the airways. In: Wang, KP, Mehta, AC (Eds), Flexible Bronchoscopy, Blackwell Science Inc, Cambridge, MA 1995.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_39_5759=[""].join("\n");
var outline_f5_39_5759=null;
